<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Parkinsons Dis</journal-id><journal-id journal-id-type="publisher-id">JPD</journal-id><journal-title-group><journal-title>Journal of Parkinson's Disease</journal-title></journal-title-group><issn pub-type="ppub">1877-7171</issn><issn pub-type="epub">1877-718X</issn><issn-l>1877-7171</issn-l><publisher><publisher-name>IOS Press</publisher-name><publisher-loc>Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7458533</article-id><article-id pub-id-type="publisher-id">JPD201965</article-id><article-id pub-id-type="doi">10.3233/JPD-201965</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Soluble endogenous oligomeric <italic>&#x003b1;</italic>-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk</article-title><alt-title alt-title-type="left-running-head">R. Kayed et al.</alt-title><alt-title alt-title-type="right-running-head">Expression, Spreading, and Cross-Talk</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kayed</surname><given-names>Rakez</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Dettmer</surname><given-names>Ulf</given-names></name><xref ref-type="aff" rid="aff3">c</xref><xref ref-type="aff" rid="aff4">d</xref></contrib><contrib contrib-type="author"><name><surname>Lesn&#x000e9;</surname><given-names>Sylvain E.</given-names></name><xref ref-type="aff" rid="aff5">e</xref><xref ref-type="aff" rid="aff6">f</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="aff1">
<label>a</label>Departments of Neurology &#x00026; Neuroscience &#x00026; Cell Biology &#x00026; Anatomy, <institution>University of Texas Medical Branch Galveston</institution>, Galveston, TX, <country>USA</country>
</aff><aff id="aff2">
<label>b</label>George and Cynthia Mitchell Center for Neurodegenerative Diseases, <institution>University of Texas Medical Branch Galveston</institution>, Galveston, TX, <country>USA</country>
</aff><aff id="aff3">
<label>c</label>Department of Neurology, <institution>Harvard Medical School</institution>, Boston, MA, <country>USA</country>
</aff><aff id="aff4">
<label>d</label>Ann Romney Center for Neurologic Diseases, <institution>Harvard Medical School</institution>, Boston, MA, <country>USA</country>
</aff><aff id="aff5">
<label>e</label>Department of Neuroscience, <institution>University of Minnesota</institution>, Minneapolis, MN, <country>USA</country>
</aff><aff id="aff6">
<label>f</label>Institute of Translational Neuroscience, <institution>University of Minnesota</institution>, Minneapolis, MN, <country>USA</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Sylvain E. Lesn&#x000e9;, PhD, University of Minnesota, Wallin Medical Biosciences Building (Room 4-114), 2101 Sixth Street SE, CDC 2641, Minneapolis, MN 55414, USA. Tel.: +1 612 626 8341; E-mail: <email>lesne002@umn.edu</email>; Website: <ext-link ext-link-type="uri" xlink:href="https://lesnelab.org">https://lesnelab.org</ext-link></corresp></author-notes><pub-date date-type="preprint" publication-format="electronic"><day>30</day><month>5</month><year>2020</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>7</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>10</volume><issue>3</issue><fpage>791</fpage><lpage>818</lpage><history><date date-type="accepted"><day>7</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 &#x02013; IOS Press and the authors. All rights reserved</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License</ext-link>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>There is growing recognition in the field of neurodegenerative diseases that mixed proteinopathies are occurring at greater frequency than originally thought. This is particularly true for three amyloid proteins defining most of these neurological disorders, amyloid-beta (A&#x003b2;), tau, and alpha-synuclein (<italic>&#x003b1;</italic>Syn). The co-existence and often co-localization of aggregated forms of these proteins has led to the emergence of concepts positing molecular interactions and cross-seeding between A&#x003b2;, tau, and <italic>&#x003b1;</italic>Syn aggregates. Amongst this trio, <italic>&#x003b1;</italic>Syn has received particular attention in this context during recent years due to its ability to modulate A&#x003b2; and tau aggregation <italic>in vivo</italic>, to interact at a molecular level with A&#x003b2; and tau <italic>in vivo</italic> and to cross-seed tau in mice. Here we provide a comprehensive, critical, and accessible review about the expression, role and nature of endogenous soluble <italic>&#x003b1;</italic>Syn oligomers because of recent developments in the understanding of <italic>&#x003b1;</italic>Syn multimerization, misfolding, aggregation, cross-talk, spreading and cross-seeding in neurodegenerative disorders, including Parkinson&#x02019;s disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer&#x02019;s disease, and Huntington&#x02019;s disease. We will also discuss our current understanding about the relative toxicity of endogenous <italic>&#x003b1;</italic>Syn oligomers <italic>in vivo</italic> and <italic>in vitro</italic>, and introduce potential opportunities to counter their deleterious effects.</p></abstract><kwd-group><label>Keywords</label><kwd>Amyloid-&#x003b2;</kwd><kwd><italic>&#x003b1;</italic>-synuclein</kwd><kwd>tau</kwd><kwd>neurodegenerative disease</kwd><kwd>oligomer</kwd><kwd>multimer</kwd><kwd>aggregation</kwd><kwd>cross-talk</kwd><kwd>cross-seeding</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>INTRODUCTION</title><p>Neurodegenerative disorders including Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), and Huntington&#x02019;s disease (HD) are characterized by progressive dysfunction and death of neurons. Within each disease type, this degeneration affects specific neural systems implying selective vulnerability and is associated with the abnormal accumulation of distinct proteins, e.g., amyloid-beta (A&#x003b2;), tau, and alpha-synuclein (<italic>&#x003b1;</italic>Syn), in the brain defining each disease neuropathologically [<xref rid="ref001" ref-type="bibr">1, 2</xref>]. Classically, deposition of A&#x003b2; and tau respectively known as A&#x003b2; plaques and neurofibrillary tangles characterize AD, inclusions of <italic>&#x003b1;</italic>Syn as Lewy body (LB) or glial cytoplasmic inclusion (GCI) define PD, DLB, and MSA (collectively known as synucleinopathies), and inclusions of huntingtin (Htt) neuropathologically define HD.</p><p>Recent studies are however providing new evidence for prevalent mixed proteinopathies across these neurodegenerative diseases, with aging and apolipoprotein E (ApoE) <italic>&#x0025b;</italic>4 genotype constituting risk factors [<xref rid="ref003" ref-type="bibr">3</xref>]. While tau pathology proved ubiquitous across the neurodegenerative diseases analyzed, mixed pathologies were observed in 38&#x02013;81% of synucleinopathy cases including neocortical Lewy body disease as a stark example with 80% increases in A&#x003b2; load and 22% increases in TAR DNA-binding protein 43 (TDP-43) burden [<xref rid="ref003" ref-type="bibr">3</xref>]. Although HD cases were not included in the latter study, prior work indicated that <italic>&#x003b1;</italic>Syn pathology is also increased in HD and colocalizes with Htt inclusions [<xref rid="ref004" ref-type="bibr">4&#x02013;6</xref>]. These observations echo prior work showing that mixed neuropathologies are the most common cause of the clinical syndrome of dementia and are also common among persons with mild cognitive impairment or cognitive decline [<xref rid="ref007" ref-type="bibr">7&#x02013;12</xref>]. Furthermore, two recent longitudinal clinical-pathologic studies of aging reported that only 9% presented pure AD pathology and 78% included more than two neuropathologies [<xref rid="ref012" ref-type="bibr">12</xref>]. AD pathology and neocortical intracellular <italic>&#x003b1;</italic>Syn inclusions had the strongest effect accounting for 58 and 46% of cognitive loss, respectively [<xref rid="ref012" ref-type="bibr">12</xref>]. Combined, these findings extend earlier observations indicating that a more rapid rate of cognitive decline is observed in 30&#x02013;40% of AD cases presenting with LB and Lewy neurites (LN) [<xref rid="ref013" ref-type="bibr">13, 14</xref>] compared to subjects with AD free of <italic>&#x003b1;</italic>Syn pathology.</p><p>The co-existence of these proteinopathies provides additional support to accumulating observations documenting molecular interactions and cross-seeding between aggregates of A&#x003b2;, tau, Htt and <italic>&#x003b1;</italic>Syn [<xref rid="ref015" ref-type="bibr">15&#x02013;18</xref>]. In this particular context, <italic>&#x003b1;</italic>Syn, the amyloid protein genetically linked to synucleinopathies, stands out for several reasons. First, synucleinopathies appear to exhibit distinct prevalence of A&#x003b2; burden and Htt compared to other neurodegenerative diseases [<xref rid="ref003" ref-type="bibr">3, 6</xref>]. Second, <italic>&#x003b1;</italic>Syn expression modulates A&#x003b2; aggregation and deposition in mice [<xref rid="ref019" ref-type="bibr">19, 20</xref>]. Third, <italic>&#x003b1;</italic>Syn oligomers can either form hybrid soluble oligomeric aggregates or interact at a molecular level with A&#x003b2; [<xref rid="ref021" ref-type="bibr">21</xref>] and tau [<xref rid="ref022" ref-type="bibr">22, 23</xref>] <italic>in vivo</italic>. Fourth, short preformed fibrils of <italic>&#x003b1;</italic>Syn (<italic>&#x003b1;</italic>Syn PFFs) can cross-seed tau <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="ref024" ref-type="bibr">24</xref>]. Thus, all of these points infer a central role of pathological oligomeric <italic>&#x003b1;</italic>Syn aggregates as key determinants in influencing or controlling aggregation of other amyloid proteins in the brain.</p><p>Beyond a potential contribution of <italic>&#x003b1;</italic>Syn in shaping inter-relationships with other amyloid proteins in neurodegenerative disease, a now large body of evidence from biochemical, biophysical, genetic and functional studies supports the hypothesis that the processes of <italic>&#x003b1;</italic>Syn oligomerization and fibrilization occupy central roles in the pathogenesis of synucleinopathies [<xref rid="ref025" ref-type="bibr">25&#x02013;29</xref>]. Because endogenous aggregated species of amyloid proteins are formed in cells or brain tissues where they are exposed to cell- and environment-specific variables (e.g., post-translational modifications) and because these endogenous species have been consistently reported to be more potent than their recombinant forms [<xref rid="ref030" ref-type="bibr">30&#x02013;34</xref>], a specific focus will be brought in this review on soluble endogenous oligomeric assemblies defined by the following criteria: (i) soluble in aqueous buffers following ultracentrifugation, (ii) SDS-resistant following tissue or cell lysis, (iii) segregated from monomeric species in liquid-phase chromatography, and (iv) immunoreactive to at least two different antibodies for that amyloid molecule and oligomer-selective antibodies. The importance of the endogenous milieu for <italic>&#x003b1;</italic>Syn aggregation was well-illustrated by Stroh&#x000e4;ker and coworkers who rigorously demonstrated that brain-derived <italic>&#x003b1;</italic>Syn fibrillar aggregates were structurally different to all recombinant <italic>&#x003b1;</italic>Syn fibrillar polymorphs tested [<xref rid="ref035" ref-type="bibr">35</xref>]. For these reasons, our review will focus on endogenous brain-derived <italic>&#x003b1;</italic>Syn oligomers (o-<italic>&#x003b1;</italic>Syn).</p><p>Despite this greater understanding, many fundamental questions remain unanswered: 1) which endogenous forms of <italic>&#x003b1;</italic>Syn are toxic to neurons and glial cells, 2) when are <italic>&#x003b1;</italic>Syn species prevalent in the pathophysiology of neurodegenerative diseases, 3) what molecular mechanisms induced by endogenous <italic>&#x003b1;</italic>Syn aggregates (oligomers, protofibrils, fibrils) contribute to neurodegeneration, 4) how are aggregated endogenous <italic>&#x003b1;</italic>Syn species impacting the physiological cellular localization and function of physiological forms of <italic>&#x003b1;</italic>Syn (monomeric and recently proposed native multimeric species), 5) what is the conformation of brain-derived o-<italic>&#x003b1;</italic>Syn? Given the exponential complication of the landscape related to amyloid protein aggregation due to the intrinsic identification of new assemblies and due to the emergence of prion-like propagation of pathological aggregates, we provide an overview of the current state of knowledge regarding the detection and role of physiological and pathological <italic>&#x003b1;</italic>Syn assemblies across neurodegenerative diseases, the spreading of oligomeric <italic>&#x003b1;</italic>Syn species and the molecular interactions between oligomeric <italic>&#x003b1;</italic>Syn and other amyloid proteins. We finally discuss the implications of these findings for potential therapeutic interventions in the contexts of mono- and multi-therapies.</p></sec><sec id="sec0010"><title><italic>&#x003b1;</italic>SYN FUNCTION AND STRUCTURE</title><p>In the past 5&#x02013;7 years, growing evidence indicates that <italic>&#x003b1;</italic>Syn (gene name: <italic>SNCA</italic>), a synaptically-enriched protein traditionally linked to PD, may act as a regulator of synaptic vesicle release. Despite the original observation that <italic>&#x003b1;</italic>Syn knockout (<italic>&#x003b1;</italic>Syn-KO) mice display only subtle &#x02018;functional deficits in the nigrostriatal dopamine system&#x02019; [<xref rid="ref036" ref-type="bibr">36</xref>], many research groups have been seeking to identify the exact physiological function of <italic>&#x003b1;</italic>Syn with a special focus on the pre-synapse (reviewed, e.g., in [<xref rid="ref037" ref-type="bibr">37, 38</xref>]). In a recent study, the gene deletion of <italic>SNCA</italic> (together with its homologs <italic>SNCB</italic> and <italic>SNCG)</italic> promotes the dilation of the exocytotic fusion in cultured rodent neurons [<xref rid="ref039" ref-type="bibr">39</xref>], potentially explaining previous findings related to <italic>&#x003b1;</italic>Syn&#x02019;s role in exocytosis [<xref rid="ref037" ref-type="bibr">37, 38</xref>]. In addition, <italic>&#x003b1;</italic>Syn may also affect endocytosis by promoting clathrin-dependent endocytosis [<xref rid="ref040" ref-type="bibr">40</xref>] and/or by regulating the kinetics of synaptic vesicle endocytosis [<xref rid="ref041" ref-type="bibr">41</xref>]. Synucleins may have multiple effects on presynaptic architecture [<xref rid="ref042" ref-type="bibr">42</xref>], and it was suggested that <italic>&#x003b1;</italic>Syn can &#x02018;cluster&#x02019; vesicles, thereby preventing free dispersal between neighboring en-passant boutons [<xref rid="ref043" ref-type="bibr">43</xref>].</p><p>In search of a mechanism for how exactly <italic>&#x003b1;</italic>Syn may affect vesicle biology, the S&#x000fc;dhof group proposed that <italic>&#x003b1;</italic>Syn acts as a chaperone for Synaptobrevin-2 (VAMP-2) [<xref rid="ref044" ref-type="bibr">44</xref>], thereby increasing the number of assembled soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes. However, it was also shown that <italic>&#x003b1;</italic>Syn can inhibit membrane fusion by directly affecting the lipid bilayer, rather than indirectly via SNARE proteins [<xref rid="ref045" ref-type="bibr">45, 46</xref>].</p><p>Beyond neurons, larger amounts of <italic>&#x003b1;</italic>Syn are also found in red blood cells, and its function there is even more enigmatic [<xref rid="ref037" ref-type="bibr">37</xref>]. Red blood cells, however, must be kept in mind as a relevant source for <italic>&#x003b1;</italic>Syn in body fluids, e.g., as a potential contaminant of cerebrospinal fluid when measuring <italic>&#x003b1;</italic>Syn in longitudinal and cross-sectional studies.</p><sec id="sec0015"><title>Structure-function relationships of <italic>&#x003b1;</italic>Syn</title><sec id="sec0020"><title>Lipid binding</title><p>Consistent with its proposed function(s), <italic>&#x003b1;</italic>Syn is found mostly at presynaptic terminals, both in brain [<xref rid="ref047" ref-type="bibr">47, 48</xref>] and in mature cultured neurons [<xref rid="ref049" ref-type="bibr">49</xref>]. The driver of its localization may be the attraction between <italic>&#x003b1;</italic>Syn and synaptic vesicles as biophysical studies have shown that the relatively small synaptic vesicles may possess the optimal membrane curvature to promote <italic>&#x003b1;</italic>Syn binding [<xref rid="ref050" ref-type="bibr">50</xref>]. Early characterization of <italic>&#x003b1;</italic>Syn already suggested that its membrane binding goes hand in hand with the formation of amphipathic helices (so-called &#x02018;11/3 helices&#x02019;: 11 aa/3 turns) [<xref rid="ref051" ref-type="bibr">51</xref>]. The helix formation is dictated by an 11-aa repeat with the core motif KTKEGV, which appears imperfectly 6&#x02013;9 times in the first two-thirds of <italic>&#x003b1;</italic>Syn [<xref rid="ref048" ref-type="bibr">48</xref>]. Nonpolar aa in the lower half of the helix &#x02018;dip&#x02019; into the membrane bilayer (&#x0223c;1&#x02013;5 &#x0212b; below lipid head groups) [<xref rid="ref052" ref-type="bibr">52&#x02013;55</xref>] while hydrophilic residues in the upper half interact with the cytoplasm. In addition, positively-charged lysine residues (K) in the KTKEGV motifs interact with negatively-charged membrane lipid head groups [<xref rid="ref056" ref-type="bibr">56</xref>]. Yet, the helix formation is imperfect and only transient because, e.g., polar threonine (T) residues are located in the hydrophobic half of the helix [<xref rid="ref057" ref-type="bibr">57&#x02013;59</xref>]. A recent <italic>in vitro</italic> study suggests that <italic>&#x003b1;</italic>Syn coming off the membrane may retain its fold and assemble into helical multimers [<xref rid="ref060" ref-type="bibr">60</xref>] (see next chapter). This notion is in contrast to the classical view of soluble <italic>&#x003b1;</italic>Syn as an unfolded monomer [<xref rid="ref061" ref-type="bibr">61</xref>]. A model has been proposed in which <italic>&#x003b1;</italic>Syn constantly cycles through at least three different states: unfolded cytosolic monomer, folded monomer at membranes, and (soluble?) folded multimer [<xref rid="ref062" ref-type="bibr">62</xref>].</p></sec><sec id="sec0025"><title>Multimeric vs. oligomeric <italic>&#x003b1;</italic>Syn</title><p><italic>Definitions.</italic> &#x02018;Oligo-&#x02019; (ancient Greek) and &#x02018;multi-&#x02019; (Latin) both mean &#x02018;several&#x02019; or &#x02018;a few&#x02019;, and &#x02018;meros&#x02019; is ancient Greek for &#x02018;part&#x02019; or &#x02018;unit&#x02019;. Thus, multimer and oligomer could be used interchangeably to describe small assemblies. In the case of <italic>&#x003b1;</italic>Syn, however, the term oligomer is mostly used to describe abnormal assemblies (aggregates), while several studies have now established the term multimer for the new concept of native <italic>&#x003b1;</italic>Syn assembly [<xref rid="ref043" ref-type="bibr">43, 62&#x02013;67</xref>]. In the following two paragraphs we will briefly contrast <italic>&#x003b1;</italic>Syn oligomers vs. multimers and focus on the evidence for the (putatively) physiological <italic>&#x003b1;</italic>Syn multimers, while the rest of our review will be dedicated to the pathological oligomers.</p><p><italic>Shared properties and differences</italic>. Endogenous <italic>&#x003b1;</italic>Syn multimers and oligomers have in common that two or more synuclein molecules are directly interacting. Multimeric, native <italic>&#x003b1;</italic>Syn is typically described as tetrameric [<xref rid="ref068" ref-type="bibr">68&#x02013;73</xref>], sometimes octameric [<xref rid="ref067" ref-type="bibr">67</xref>]. Oligomeric <italic>&#x003b1;</italic>Syn aggregates in contrast seems to exist in a wide variety of different conformations (reviewed below). Multimeric <italic>&#x003b1;</italic>Syn is considered to be helical [<xref rid="ref063" ref-type="bibr">63, 68, 69</xref>] and aggregation-resistant [<xref rid="ref068" ref-type="bibr">68</xref>], while <italic>&#x003b1;</italic>Syn aggregates would traditionally be expected to be rich in &#x003b2;-sheet (new insight that indicates bigger complexity is emerging, see below). Multimeric <italic>&#x003b1;</italic>Syn has been proposed to have functional roles in the cells, but there is no consensus yet on the details: multimers may cluster vesicles [<xref rid="ref043" ref-type="bibr">43</xref>], promote SNARE assembly [<xref rid="ref067" ref-type="bibr">67</xref>] or be a passive storage form [<xref rid="ref074" ref-type="bibr">74</xref>]. Multimeric <italic>&#x003b1;</italic>Syn species were shown to be sensitive to temperature and heat denaturation, to cell lysis and to the presence of the anionic detergent sodium dodecyl sulfate (SDS) [<xref rid="ref075" ref-type="bibr">75</xref>] while oligomeric <italic>&#x003b1;</italic>Syn aggregates are typically, but maybe not in all cases, more stable (see below).</p><p><italic>Evidence for native <italic>&#x003b1;</italic>Syn assembly (multimers)</italic>. Bartels, Choi and Selkoe proposed in 2011 that <italic>&#x003b1;</italic>Syn assembles naturally inside cells and occurs as a helical tetramer that resists aggregation [<xref rid="ref068" ref-type="bibr">68</xref>]. <italic>&#x003b1;</italic>Syn was purified from various human sources, including red blood cells, under non-denaturing conditions. Several methods, most prominently analytical ultracentrifugation, sized the purified multimers as principally tetramers while circular dichroism characterized them as helical. Around the same time, tetrameric <italic>&#x003b1;</italic>Syn was purified from bacteria under non-denaturing conditions [<xref rid="ref069" ref-type="bibr">69</xref>]. <italic>&#x003b1;</italic>Syn N-acetylation may be critical for the successful purification of helical <italic>&#x003b1;</italic>Syn multimers from bacteria [<xref rid="ref076" ref-type="bibr">76</xref>]. Subsequent attempts of purifying helical <italic>&#x003b1;</italic>Syn assemblies led to different results: unsuccessful in red blood cells [<xref rid="ref077" ref-type="bibr">77</xref>], successful in red blood cells [<xref rid="ref074" ref-type="bibr">74</xref>], largely unsuccessful in human brain (only evidence for small amounts of multimer) [<xref rid="ref078" ref-type="bibr">78</xref>], partially successful in human brain (multimeric <italic>&#x003b1;</italic>Syn in fractions of lower purity, but not in the highly pure material) [<xref rid="ref066" ref-type="bibr">66</xref>]. Another study probed the native state of <italic>&#x003b1;</italic>Syn from human brain by gel filtration coupled with native gradient gel separation, an array of antibodies with non-overlapping epitopes, and mass spectrometry. The authors concluded that metastable higher-molecular weight &#x02018;conformers&#x02019; and stable monomers co-exist in the human brain [<xref rid="ref079" ref-type="bibr">79</xref>] (<xref ref-type="fig" rid="jpd-10-jpd201965-g001">Fig.&#x000a0;1</xref>). Such a model had heretofore been suggested by a nuclear magnetic resonance (NMR)/computational study [<xref rid="ref064" ref-type="bibr">64</xref>].</p><fig id="jpd-10-jpd201965-g001" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Proposed model of <italic>&#x003b1;</italic>Syn assemblies in health (&#x02018;multimers&#x02019;) and disease (&#x02018;oligomers&#x02019;). Schematic of one cell and extracellular space. Under physiological conditions <italic>(in blue, bottom left)</italic>, <italic>&#x003b1;</italic>Syn comes off the ribosome as a soluble unfolded monomer (blue &#x02018;<italic>&#x003b1;</italic>Syn&#x02019;), which forms helical monomers (blue circle) upon getting in contact with vesicle membranes. Helical monomers at membranes may assemble into metastable physiological multimers (low-<italic>n</italic> assemblies in blue) that eventually fall apart again, initiating a new cycle. Under stress of pathological conditions (<italic>in pink shading, starting bottom middle</italic>), excess of unfolded or helical membrane-bound <italic>&#x003b1;</italic>Syn has been proposed to be the starting point for pathological aggregation into oligomers including dimers, tetramers, annular protofibrils and larger oligomers. We propose that two distinct misfolded states of <italic>&#x003b1;</italic>Syn lead to two distinct aggregation pathways, one forming amyloid fibrils (ON pathway; A11<sup>&#x02013;</sup>/OC<sup>+</sup>), and one forming large non-fibrillar <italic>&#x003b1;</italic>Syn oligomers (OFF pathway, A11+/OC<sup>&#x02013;</sup>). Endogenous oligomeric <italic>&#x003b1;</italic>Syn are likely to be enriched for &#x003b2;-sheet motifs. The endpoint of intracellular aggregation is the so-called Lewy body (<italic>top left</italic>). Mixed intracellular aggregates have also been reported in particular with tau (<italic>red baton</italic>), although the exact <italic>&#x003b1;</italic>Syn oligomer interacting with tau is unknown (indicated by &#x02018;?&#x02019;). Cross-talks between <italic>&#x003b1;</italic>Syn species and huntingtin oligomers (Htt, <italic>orange hexagons</italic>) have also been advanced but require confirmation. Oligomers of <italic>&#x003b1;</italic>Syn may be released into the extracellular space by an ill-defined mechanism (<italic>right</italic>). There, they may further aggregate, which may include the formation of mixed aggregates, with amyloid-&#x003b2; peptides (A&#x003b2;, <italic>purple stars</italic>) in particular with which <italic>&#x003b1;</italic>Syn can form hybrid <italic>&#x003b1;</italic>Syn/A&#x003b2; oligomers. Extracellular aggregates may be taken up by cells and released into the cytosol where they may in turn &#x02018;seed&#x02019; <italic>&#x003b1;</italic>Syn aggregation. Release, uptake and seeding of intracellular pathology might be underlying the phenomenon of &#x003b1;Syn spread and release might correspond to a possible protective mechanism adopted by cells to maintain cellular proteostasis.</p></caption><graphic xlink:href="jpd-10-jpd201965-g001"/></fig><p>Given the complexity of purification, intact-cell methods became increasingly important. A live-cell crosslinking study provided a large variety of controls to suggest abundant physiological, not pathological <italic>&#x003b1;</italic>Syn assemblies [<xref rid="ref075" ref-type="bibr">75</xref>]. A follow-up study [<xref rid="ref071" ref-type="bibr">71</xref>] revealed not only that <italic>&#x003b1;</italic>Syn in fresh human brain was shown to be multimeric by crosslinking but also that familial PD-linked mutations such as A30P and E46K decrease multimer:monomer ratios. In another study [<xref rid="ref070" ref-type="bibr">70</xref>], overexpression of strategic <italic>&#x003b1;</italic>Syn variants that render <italic>&#x003b1;</italic>Syn largely monomeric (plus some dimers) were cytotoxic and prone to forming inclusions in primary rat neurons. Subsequently, it was suggested that lysosomal glucocerebrosidase deficiency overall reduces <italic>&#x003b1;</italic>Syn multimers and increases monomers [<xref rid="ref065" ref-type="bibr">65</xref>]. Intact-cell crosslinking typically traps 60, 80 and 100&#x0200a;kDa species of <italic>&#x003b1;</italic>Syn (<italic>&#x003b1;</italic>S60, -80 and -100), and their identity is not yet clear. They may be tetramer, hexamer and octamer or could all be tetramers that differ by the exact mode of crosslinking. The 60&#x0200a;kDa <italic>&#x003b1;</italic>Syn multimer is typically the most abundant defined multimeric species of intact-cell crosslinking, consistent with a tetramer (monomeric <italic>&#x003b1;</italic>S: 14.5&#x0200a;kDa; 4&#x000d7; 14.5&#x0200a;kDa&#x0200a;=&#x0200a;58&#x0200a;kDa) [<xref rid="ref075" ref-type="bibr">75</xref>]. Burr&#x000e9; et al. sized crosslinked <italic>&#x003b1;</italic>Syn multimers in brain slices, brain homogenates and recombinant <italic>&#x003b1;</italic>Syn on charged liposomes as tetramers, octamers and other multimers, including prominent dimers [<xref rid="ref067" ref-type="bibr">67</xref>]. This pattern differed from that typically reported for intact-cell crosslinking (see above). The same group postulated that the loss of <italic>&#x003b1;</italic>Syn multimerization may occur upstream of <italic>&#x003b1;</italic>Syn aggregation and neurotoxicity [<xref rid="ref080" ref-type="bibr">80</xref>]. Importantly, defined point mutations that abolish <italic>&#x003b1;</italic>Syn multimer intact-cell crosslinking, also prevented <italic>&#x003b1;</italic>Syn-mediated Venus/Yellow fluorescent protein (YFP) complementation [<xref rid="ref071" ref-type="bibr">71</xref>], an orthogonal intact-cell method. Wang et al. used <italic>&#x003b1;</italic>Syn-mediated Venus YFP complementation in live neurons to demonstrate that <italic>&#x003b1;</italic>Syn multimers cluster synaptic vesicles and attenuate recycling [<xref rid="ref043" ref-type="bibr">43</xref>]. Similarly, Burr&#x000e9; et al. used fluorescence resonance energy transfer revealing the detection of normal <italic>&#x003b1;</italic>Syn multimers at membranes [<xref rid="ref067" ref-type="bibr">67</xref>].</p><p>A key concept to understanding <italic>&#x003b1;</italic>Syn cellular behavior may be context-dependent folding [<xref rid="ref072" ref-type="bibr">72</xref>]. For example, <italic>&#x003b1;</italic>Syn may exists primarily as a monomer in intact enteric neurons while <italic>&#x003b1;</italic>Syn may be present in the brain in a different conformation [<xref rid="ref081" ref-type="bibr">81</xref>]. This view is further supported by the finding that <italic>&#x003b1;</italic>Syn (and &#x003b2;Syn) multimers were only efficiently trapped by crosslinking of intact neurons, whereas crosslinking of lysates largely yielded monomers [<xref rid="ref075" ref-type="bibr">75</xref>]. This observation was unique to the synuclein isoforms (control multimeric proteins were trapped both in cells and lysates) and in line with the concept of metastable or &#x02018;dynamic&#x02019; multimers, a model also postulated by others [<xref rid="ref064" ref-type="bibr">64, 69</xref>]. The requirement of molecular crowding or a limiting factor that holds intracellular multimers together would be a possible explanation for the lysis sensitivity and difficulties in purifying multimeric <italic>&#x003b1;</italic>Syn. Of note, several independent reports suggest that (re)folding and (re)assembly of helical <italic>&#x003b1;</italic>Syn <italic>in vitro</italic> might be possible: 1) Killinger et al. suggested that <italic>&#x003b1;</italic>Syn forms multimers during electrophoresis, possibly due to crowding effects [<xref rid="ref082" ref-type="bibr">82</xref>], 2) Iljina et al. used arachidonic acid to reconstitute <italic>&#x003b1;</italic>Syn assemblies <italic>in vitro</italic> that sized as tetramers [<xref rid="ref063" ref-type="bibr">63</xref>] and 3) Rovere et al. proposed a mechanism in which helical <italic>&#x003b1;</italic>Syn folding at membranes is preserved when <italic>&#x003b1;</italic>Syn comes off membranes and hydrophobic interactions may drive cytosolic assembly that is stable for an undetermined amount of time [<xref rid="ref060" ref-type="bibr">60</xref>].</p><p>The list of relevant publications on the topic of native <italic>&#x003b1;</italic>Syn multimers would be incomplete without documenting reports that are skeptical about the relevance of native <italic>&#x003b1;</italic>Syn assemblies. Fauvet et al. reported their inability to purify folded multimers from a variety of available sources [<xref rid="ref077" ref-type="bibr">77</xref>]. Bacterial [<xref rid="ref083" ref-type="bibr">83</xref>] and mammalian [<xref rid="ref084" ref-type="bibr">84</xref>] in-cell NMR analyses were consistent with largely disordered, monomeric states of <italic>&#x003b1;</italic>Syn. Despite the rapidly growing appeal of this novel adaptation of NMR, it is however worth mentioning here some of the limitations of the technique including an inability to detect <italic>&#x003b1;</italic>Syn assemblies due to their size, the necessity to perform measurements below body and even room temperature, and a reliance on proteofection of large amounts of labeled <italic>&#x003b1;</italic>Syn into mammalian cells, which might raise caution towards drawing definite conclusions. Neither can the existence of smaller, but relevant, amounts of folded and assembled <italic>&#x003b1;</italic>Syn be ruled out by the technique [<xref rid="ref085" ref-type="bibr">85</xref>].</p><p>All in all, there is accumulating evidence from multiple independent laboratories to support the existence of native <italic>&#x003b1;</italic>Syn assembly(ies) through a variety of techniques, but also reports that deny their existence and/or relevance. The debate about multimer abundance, exact location (membrane vs. soluble), stability (stable vs. dynamic) and function (storage form vs. active role) will continue and promises to be intellectually stimulating for the field.</p></sec></sec></sec><sec id="sec0030"><title>ENDOGENOUS OLIGOMERIC <italic>&#x003b1;</italic>Syn ASSEMBLIES IN NEURODEGENERATIVE DISEASES</title><sec id="sec0035"><title>Endogenous oligomeric <italic>&#x003b1;</italic>Syn assemblies in neurodegenerative diseases</title><sec id="sec0040"><title>Detection of oligomeric <italic>&#x003b1;</italic>Syn species by disease</title><p><italic>Parkinson&#x02019;s disease</italic>. An emerging view emphasizes o-<italic>&#x003b1;</italic>Syn as the key mediators in synucleinopathies. Soluble <italic>&#x003b1;</italic>Syn oligomeric species associated with polyunsaturated fatty acids have been detected in human PD and DLB brain tissues, as well as in human <italic>&#x003b1;</italic>Syn-expressing transgenic mouse brain tissues. It has been suggested that unlike saturated fatty acids, increased levels of polyunsaturated fatty acids promote <italic>&#x003b1;</italic>Syn oligomerization in PD brains [<xref rid="ref086" ref-type="bibr">86</xref>]. Elevated levels of <italic>&#x003b1;</italic>Syn oligomeric assemblies have been detected in the postmortem brain tissues of PD [<xref rid="ref087" ref-type="bibr">87&#x02013;89</xref>], notably putative &#x0223c;60&#x0200a;kDa <italic>&#x003b1;</italic>Syn tetramers [<xref rid="ref088" ref-type="bibr">88</xref>]. Oligomers of <italic>&#x003b1;</italic>Syn were also detected from the blood plasma and CSF of PD patients present at an increased level compared to controls [<xref rid="ref090" ref-type="bibr">90&#x02013;92</xref>]. Hence, <italic>&#x003b1;</italic>Syn oligomers, as well as a ratio of <italic>&#x003b1;</italic>Syn oligomers to total <italic>&#x003b1;</italic>Syn have been proposed as biomarkers for early diagnosis of PD and PD with dementia [<xref rid="ref093" ref-type="bibr">93, 94</xref>]. Oligomeric <italic>&#x003b1;</italic>Syn has also been detected at an increased level from CSF of PD patients by using a highly sensitive electronic biosensor. This technique enabled the distinction of AD and PD pathologies from cognitively normal control subjects based on the detection of CSF <italic>&#x003b1;</italic>Syn oligomer levels [<xref rid="ref095" ref-type="bibr">95</xref>]. Although the exact mechanism by which <italic>&#x003b1;</italic>Syn oligomers exert their toxic effects is still unknown, the presence of these oligomeric assemblies in the extracellular body fluids indicates their release from affected brain regions and opens up the intriguing possibility of subsequent propagation of these assemblies between cells. Exocytosis via exosomes has been implicated in the spreading of <italic>&#x003b1;</italic>Syn in cell culture [<xref rid="ref096" ref-type="bibr">96</xref>]. The cellular release of <italic>&#x003b1;</italic>Syn oligomers via exosomes was suggested as an alternate pathway for survival upon failure of their clearance via autophagosomes <italic>in vitro</italic> [<xref rid="ref097" ref-type="bibr">97</xref>].</p><p>All known <italic>SNCA</italic> missense mutations associated with familial forms of PD (A30P, E46K, A53T, A53E, H50Q and G51D) reside in the amino-terminal domain of <italic>&#x003b1;</italic>Syn responsible for membrane binding. Amongst those, TgA53T transgenic mice overexpressing the A53T mutant of human <italic>&#x003b1;</italic>Syn have been extensively studied as models of familial PD due to their relatively robust phenotype [<xref rid="ref098" ref-type="bibr">98</xref>]. In TgA53T mice from the G2.3 line [<xref rid="ref098" ref-type="bibr">98</xref>], oligomeric <italic>&#x003b1;</italic>Syn was shown to accumulate in the mitochondrial membrane and impair complex I function [<xref rid="ref099" ref-type="bibr">99</xref>]. Treating these animals with an anti-ER stress molecule, salubrinal, reduced accumulation of such toxic oligomers in the ER and delayed disease onset [<xref rid="ref099" ref-type="bibr">99</xref>], suggesting that <italic>&#x003b1;</italic>Syn oligomer-dependent ER stress may constitute a key event in the pathophysiology of PD.</p><p><italic>Dementia with Lewy bodies</italic>. Elevated levels of oligomeric <italic>&#x003b1;</italic>Syn were detected in the postmortem brain tissues of DLB patients by western blotting and ELISA assays [<xref rid="ref089" ref-type="bibr">89, 100</xref>]. However, CSF o-<italic>&#x003b1;</italic>Syn levels in DLB patients were comparable to that measured in age-matched control subjects contrary to subjects with PD dementia (PDD) or to individuals with AD [<xref rid="ref094" ref-type="bibr">94</xref>].</p><p>In mice, a transgenic animal model expressing mutant E46K <italic>&#x003b1;</italic>Syn associated with the familial form of DLB [<xref rid="ref101" ref-type="bibr">101</xref>] showed deposition of Lewy-like structures and motor impairment [<xref rid="ref102" ref-type="bibr">102</xref>]. Western blot analysis of brain lysates from TgE46K mice (line 47) revealed bands in the stacking gel in the ultracentrifugated high salt fractions, suggestive of the presence of large soluble <italic>&#x003b1;</italic>Syn oligomers [<xref rid="ref102" ref-type="bibr">102</xref>]. These presumably large (&#x0003e;250&#x0200a;kDa) putative <italic>&#x003b1;</italic>Syn oligomers were immunoreactive to antibody Syn211 detecting human <italic>&#x003b1;</italic>Syn and to antibodies detecting phosphorylated <italic>&#x003b1;</italic>Syn at Serine 129 (pS129-<italic>&#x003b1;</italic>Syn), a post-translational modification inducing a higher propensity for <italic>&#x003b1;</italic>Syn to aggregate [<xref rid="ref103" ref-type="bibr">103</xref>].</p><p>In both systems, it thus remains clear that additional studies are needed to fully assess the nature of o-<italic>&#x003b1;</italic>Syn species in DLB samples and the contribution of o-<italic>&#x003b1;</italic>Syn to DLB.</p><p><italic>Multiple system atrophy</italic>. Using homotypic ELISA assays for total o-<italic>&#x003b1;</italic>Syn (with antibody Syn211) or for S129-phosphorylated o-<italic>&#x003b1;</italic>Syn, Foulds and colleagues reported no differences in total CSF o-<italic>&#x003b1;</italic>Syn concentration in MSA patients (<italic>n</italic>&#x0200a;=&#x0200a;8) compared to control subjects. Of note, none of the tested groups (PD, DLB, PSP, MSA and controls) differed for total CSF <italic>&#x003b1;</italic>Syn, total CSF o-<italic>&#x003b1;</italic>Syn and CSF pS129-<italic>&#x003b1;</italic>Syn. However, the concentration of CSF pS129-<italic>&#x003b1;</italic>Syn oligomers was sharply elevated in the postmortem CSF samples of MSA patients compared to all other clinical groups [<xref rid="ref104" ref-type="bibr">104</xref>]. Moreover, recent studies described that o-<italic>&#x003b1;</italic>Syn was abundantly distributed in neurons and oligodendrocytes in MSA brain tissues using homotypic proximity ligation assay detection [<xref rid="ref105" ref-type="bibr">105</xref>].</p><p><italic>Alzheimer&#x02019;s disease</italic>. Accumulating evidence demonstrates the occurrence of <italic>&#x003b1;</italic>Syn pathology, LB and Lewy neurites (LN), in 40&#x02013;55% of AD brains [<xref rid="ref003" ref-type="bibr">3, 13, 15, 106</xref>]. Despite this observation, very few groups have measured the relative abundance of soluble <italic>&#x003b1;</italic>Syn aggregates in postmortem AD brain tissue. Using an agnostic view about the nature of the apparent inter-relationship between <italic>&#x003b1;</italic>Syn and AD pathology, Larson and colleagues found an approximate two-fold increase over controls in soluble monomeric <italic>&#x003b1;</italic>Syn levels in intracellular-enriched (IC) lysates from AD brains in the absence of LB cytopathology [<xref rid="ref107" ref-type="bibr">107</xref>]. Importantly, the abundance of soluble <italic>&#x003b1;</italic>Syn monomers in temporal cortices translated into a better biological correlate of AD-associated cognitive impairment than soluble A&#x003b2; and tau levels [<xref rid="ref107" ref-type="bibr">107</xref>]. Because the abundance and concentration of amyloid proteins directly regulate the aggregation state of said molecules, the same group hypothesized that oligomeric <italic>&#x003b1;</italic>Syn might be elevated in parallel to the increase in IC monomeric <italic>&#x003b1;</italic>Syn. Using a biochemical approach relying on homotypic and heterotypic enzyme-linked immunosorbent assays (ELISA), denaturing and non-denaturing electrophoreses, and size-exclusion chromatography combined with extensive immunoreactivity profiling, the same group identified increases in <italic>&#x003b1;</italic>Syn oligomers in AD brain tissue by 25&#x02013;75% with the largest accumulation in <italic>&#x003b1;</italic>Syn oligomers corresponding to &#x0223c;35&#x0200a;kDa species (68% increase vs. controls) and to &#x0223c;56&#x0200a;kDa species (44% increase vs. controls) [<xref rid="ref108" ref-type="bibr">108</xref>]. The nature of these dimeric and tetrameric assemblies was further confirmed using antibodies differentially detecting aggregated forms of various amyloid proteins (i.e., A11, OC, Officer) or antibodies specific to <italic>&#x003b1;</italic>Syn oligomers (i.e., Syn33 and F8H7). Importantly, the elevation of <italic>&#x003b1;</italic>Syn oligomers in temporal cortex was also observed in additional cortical domains, namely angular, calcarine and entorhinal cortices although with distinct observed profiles for each <italic>&#x003b1;</italic>Syn oligomer [<xref rid="ref108" ref-type="bibr">108</xref>].</p><p>Functionally, soluble <italic>&#x003b1;</italic>Syn IC oligomers were associated with changes in cognitive function and synaptic expression in AD but not in age-matched control subjects [<xref rid="ref108" ref-type="bibr">108</xref>]. Multi-variate analyses revealed that this was particularly true for episodic memory performance whereby 28-, 35- and 56&#x0200a;kDa <italic>&#x003b1;</italic>Syn oligomers inversely correlated with z-scores for this AD-defining memory modality. In a similar fashion, soluble <italic>&#x003b1;</italic>Syn IC oligomers inversely correlated with the abundance of synapsin isoforms [<xref rid="ref108" ref-type="bibr">108</xref>], presynaptic proteins previously identified to be selectively down-regulated in mice overexpressing human wild-type (WT) <italic>&#x003b1;</italic>Syn [<xref rid="ref109" ref-type="bibr">109</xref>]. This relationship was specific to synapsins but not to synaptophysin, another presynaptic protein decreased in AD. Overall, these findings infer a potential contribution of <italic>&#x003b1;</italic>Syn oligomers to AD-associated cognitive decline and synaptic loss.</p><p>Contrasting with the paucity of studies which used postmortem brain tissue to detect and measure <italic>&#x003b1;</italic>Syn oligomers, several groups have used CSF to measure <italic>&#x003b1;</italic>Syn in AD. Contrary to PD and DLB in which CSF <italic>&#x003b1;</italic>Syn is reliably lowered compared to control subjects [<xref rid="ref110" ref-type="bibr">110</xref>], several reports have documented increased concentrations of CSF <italic>&#x003b1;</italic>Syn in AD vs. age-matched controls [<xref rid="ref090" ref-type="bibr">90, 94, 111</xref>]. It is worth noting that CSF <italic>&#x003b1;</italic>Syn concentrations between sporadic AD and controls were unaltered in a longitudinal cohort [<xref rid="ref112" ref-type="bibr">112</xref>], while the same group found elevated CSF <italic>&#x003b1;</italic>Syn concentrations in familial AD subjects vs. noncarriers [<xref rid="ref112" ref-type="bibr">112</xref>]. However, the diagnostic sensitivity/specificity of classical AD CSF biomarkers can be improved when incorporating CSF <italic>&#x003b1;</italic>Syn [<xref rid="ref113" ref-type="bibr">113, 114</xref>]. Overall, this lack of consensus regarding elevated CSF <italic>&#x003b1;</italic>Syn in AD is likely due to several variables, including differences in the ELISA platform used, possible contamination of the samples with erythrocytes, heterogeneity of the subjects included in the respective studies, and specimen storage and preparation.</p><p>Despite these issues, a few studies have measured oligomeric <italic>&#x003b1;</italic>Syn species in CSF from subjects with AD [<xref rid="ref090" ref-type="bibr">90, 94, 115</xref>]. Hansson and colleagues reported decreased CSF concentrations of o-&#x003b1;Syn in AD compared to controls using a homotypic ELISA based on the 211 antibody, whereas total CSF <italic>&#x003b1;</italic>Syn concentration was elevated in the AD cohort [<xref rid="ref094" ref-type="bibr">94</xref>]. In contrast, in their 2017 study, the El-Agnaf group found no differences in CSF concentrations of o-<italic>&#x003b1;</italic>Syn or pS129-<italic>&#x003b1;</italic>Syn between the AD and other neurodegenerative disease (OND) groups while total CSF <italic>&#x003b1;</italic>Syn concentration was markedly elevated in the AD cohort compared to the OND cohort [<xref rid="ref090" ref-type="bibr">90</xref>]. The authors also concluded that inclusion of CSF o-<italic>&#x003b1;</italic>Syn measured by the antibody Syn-O2, detecting <italic>&#x003b1;</italic>Syn fibrils [<xref rid="ref116" ref-type="bibr">116</xref>], did not improve the global diagnostic performance of total CSF <italic>&#x003b1;</italic>Syn in detecting AD [<xref rid="ref090" ref-type="bibr">90</xref>]. Finally in the latter work, neither CSF total <italic>&#x003b1;</italic>Syn nor CSF o-<italic>&#x003b1;</italic>Syn discriminated AD from cognitively normal controls [<xref rid="ref115" ref-type="bibr">115</xref>]. In summary, one study reported a reduction in CSF o-<italic>&#x003b1;</italic>Syn concentration in AD subjects and two other studies found no differences. Like for total CSF <italic>&#x003b1;</italic>Syn, these differences prevent the formation of a clear consensus about the abundance of o-<italic>&#x003b1;</italic>Syn in human CSF and are likely due to the ELISA platform used (homotypic ELISA with 211 vs. heterotypic ELISA with Syn-O2) and heterogeneity of the subjects considering that all three studies were generated in the same laboratory.</p><p><italic>Huntington&#x02019;s disease</italic>. Huntington&#x02019;s disease (HD) is the most common neurological disorder caused by trinucleotide repeat expansions. In HD, the expanded CAG repeats encode polyglutamine (polyQ) sequences in the huntingtin (Htt) protein thereby conferring toxic gain-of-function and loss-of-function properties to the mutant protein [<xref rid="ref117" ref-type="bibr">117</xref>]. Based on a case report documenting the colocalization of <italic>&#x003b1;</italic>Syn with Htt inclusions in the striatum of a male subject with HD and in the brain of transgenic mouse models of HD (HD89, HD94 and R6/1), an aberrant interaction of mutant Htt with <italic>&#x003b1;</italic>Syn has been proposed [<xref rid="ref004" ref-type="bibr">4, 5</xref>]. The exact nature of this inter-relationship is still under investigation with studies indicating that <italic>&#x003b1;</italic>Syn forms independent fibrillar aggregates in neurons harboring Htt deposits in vivo [<xref rid="ref005" ref-type="bibr">5</xref>] while other work relying on bimolecular fluorescence complementation (BiFC) assays found that <italic>&#x003b1;</italic>Syn oligomerizes and co-aggregates with N-terminally truncated Htt (Htt<sub>exon1</sub>) in human H4 neuroglioma cells [<xref rid="ref017" ref-type="bibr">17</xref>]. More recent work expanded these <italic>in vitro</italic> studies by reporting the colocalization and co-aggregation of <italic>&#x003b1;</italic>Syn and mutant Htt in the fly brain [<xref rid="ref018" ref-type="bibr">18</xref>]. Despite the mention of <italic>&#x003b1;</italic>Syn oligomerization, it is worth noting that none of these studies provided direct evidence of a contribution of o-<italic>&#x003b1;</italic>Syn to the interaction with Htt. Overall, additional studies are warranted to better understand the inter-relationship between <italic>&#x003b1;</italic>Syn and Htt <italic>in vivo</italic>.</p></sec><sec id="sec0045"><title>Detection of oligomeric <italic>&#x003b1;</italic>Syn species by selective brain areas</title><p>Neurodegenerative diseases are also defined by the neurodegeneration of distinct brain regions or nuclei, implying a selective vulnerability of neuronal subtypes to the accumulating amyloid protein [<xref rid="ref001" ref-type="bibr">1</xref>]. Across the studies aforementioned above which have measured o-<italic>&#x003b1;</italic>Syn in post-mortem brain tissue, rare are those that analyzed multiple brain regions [<xref rid="ref005" ref-type="bibr">5, 88, 108</xref>].</p><p>Roberts and colleagues detected <italic>&#x003b1;</italic>Syn assemblies using proximity ligation assay (PLA), a technique relying on the close proximity of two molecules in fixed samples using two primary antibodies, in three brain regions, cingulate cortex, midbrain and medulla from control subjects and subjects with PD (Braak stages 3&#x02013;6, <italic>n</italic>&#x0200a;=&#x0200a;8 cases per group) [<xref rid="ref088" ref-type="bibr">88</xref>]. Within each region, three to six areas were examined including the substantia nigra pars compacta and raphe nuclei. The <italic>&#x003b1;</italic>Syn species revealed by PLA (<italic>&#x003b1;</italic>Syn-PLA) indicated lightly compacted pathological aggregates in only three sub-regions of PD brains, namely the medullary intermediary reticular zone, reticular formation and pyramidal cortical neurons, which were different from age-matched control subjects [<xref rid="ref088" ref-type="bibr">88</xref>]. The exact nature of the species reactive to <italic>&#x003b1;</italic>Syn-PLA and the relevance of their spatial distribution remains unclear.</p><p>In their analyses of AD brain tissues, Larson and coworkers also detected o-<italic>&#x003b1;</italic>Syn across five brain regions, including the inferior temporal gyrus (ITG), entorhinal cortex, the midfrontal gyrus (MF), the angular or inferior parietal gyrus (AG), and the calcarine cortex (CALC), encompassing all five cerebral lobes [<xref rid="ref108" ref-type="bibr">108</xref>]. The accumulation of o-<italic>&#x003b1;</italic>Syn principally observed in the ITG, was not limited to this gyrus as other brain regions (parieto-occipital and entorhinal cortices) also displayed marked increases in o-<italic>&#x003b1;</italic>Syn despite a relatively-low number of specimen per clinical group per area (<italic>n</italic>&#x0200a;=&#x0200a;5&#x02013;6) [<xref rid="ref108" ref-type="bibr">108</xref>]. It is interesting to note that all brain areas displaying elevations of o-<italic>&#x003b1;</italic>Syn are part of the default mode network linked to AD, where A&#x003b2; and tau pathologies are prevalent [<xref rid="ref118" ref-type="bibr">118&#x02013;120</xref>]. Clearly, larger studies will be needed in the future to extensively compare regional differences within each subject.</p><p>Lastly, the Lucas group observed <italic>&#x003b1;</italic>Syn-positive inclusions in the striatum and the cerebral cortex of subjects with HD (grade 4 following the criteria of Vonsattel) [<xref rid="ref005" ref-type="bibr">5</xref>]. The group sizes were statistically minimum (<italic>n</italic>&#x0200a;=&#x0200a;3) and the report does not indicate which domain of the cerebral cortex was used for these studies, thereby preventing any rigorous conclusion.</p><p>Overall, extensive work remains to be done to determine the existence, expression, accumulation and potential spreading of o-<italic>&#x003b1;</italic>Syn in disease-specific vulnerable brain areas.</p></sec></sec><sec id="sec0050"><title>Current understanding of oligomeric <italic>&#x003b1;</italic>Syn production and toxicity in vivo</title><sec id="sec0055"><title>Dimers</title><p>Studies by several groups showed that chemical or photochemical crosslinking of <italic>&#x003b1;</italic>Syn in mammalian cells or purified <italic>&#x003b1;</italic>Syn from <italic>E. coli</italic> bacteria results in the formation of a ladder of <italic>&#x003b1;</italic>Syn species ranging from monomers to hexamers, with 35&#x0200a;kDa dimers being the major species [<xref rid="ref025" ref-type="bibr">25, 43, 69, 77, 121</xref>]. Of note, the 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers seem to be the most commonly detected form of <italic>&#x003b1;</italic>Syn assemblies in denaturing polyacrylamide gels and appear to be stable in the presence of conditions that would disrupt their oligomerization state including chemical denaturants, suggesting that they might be covalently crosslinked [<xref rid="ref077" ref-type="bibr">77, 86, 122, 123</xref>].</p><p>Similarly, analysis of protein lysates from human brain tissue also yield equivalent electrophoretic profiles [<xref rid="ref021" ref-type="bibr">21, 67, 107, 108, 124, 125</xref>]. Amongst those reports, Larson and colleagues readily detected the presence of apparent 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers in temporal cortices of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD by western blotting using LB509, an antibody specific to human <italic>&#x003b1;</italic>Syn [<xref rid="ref107" ref-type="bibr">107</xref>]. In follow-up studies, the same group reported similar SDS-PAGE profiles for <italic>&#x003b1;</italic>Syn using the monoclonal antibody 4D6 to <italic>&#x003b1;</italic>Syn, which displayed enhanced sensitivity towards oligomeric <italic>&#x003b1;</italic>Syn [<xref rid="ref108" ref-type="bibr">108</xref>]. Importantly the oligomeric nature of these 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers was confirmed by several approaches including homotypic LB509-LB509 ELISA detection, size-exclusion chromatography (SEC) combined with denaturing and non-denaturing analyses of SEC eluates using antibodies detecting various oligomers of amyloid proteins (A11, OC, Officer), as well as antibodies specific to o-<italic>&#x003b1;</italic>Syn (Syn33 and F8H7) [<xref rid="ref108" ref-type="bibr">108</xref>]. In addition to the 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers, another putative <italic>&#x003b1;</italic>Syn dimer of &#x0223c;28&#x0200a;kDa was also detected in postmortem human brain tissue and in brain tissue from transgenic TgI2.2 mice overexpressing WT human <italic>&#x003b1;</italic>Syn [<xref rid="ref019" ref-type="bibr">19, 98, 107, 108</xref>]. Whereas OC and Officer antibodies detected fibrillar amyloid species co-segregating with the 35&#x0200a;kDa and 72&#x0200a;kDa <italic>&#x003b1;</italic>Syn molecules in both AD and TgI2.2 samples suggesting that these <italic>&#x003b1;</italic>Syn forms are prefibrillar oligomeric <italic>&#x003b1;</italic>Syn assemblies, the 28&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers were instead detected with A11 and F8H7 in AD brain tissue and to a lesser extent in TgI2.2 mice, indicating that this <italic>&#x003b1;</italic>Syn species is a nonfibrillar oligomer [<xref rid="ref108" ref-type="bibr">108</xref>]. As a reminder, OC antibodies detects in-register parallel &#x003b2;-sheets while A11 antibodies recognize out-of-register anti-parallel &#x003b2;-sheet motifs [<xref rid="ref126" ref-type="bibr">126&#x02013;128</xref>]. To our knowledge, these findings were the first to provide indirect evidence of the existence of two separate dimeric assemblies of <italic>&#x003b1;</italic>Syn with distinct conformations, which had been previously suggested [<xref rid="ref025" ref-type="bibr">25</xref>]. It is unclear whether these dimeric forms are apparent multimers of 14- and 17&#x0200a;kDa <italic>&#x003b1;</italic>Syn monomers or conformation variants from the same molecular <italic>&#x003b1;</italic>Syn unit and further studies will be needed to investigate these hypotheses.</p><p>Functionally, multivariate regression analyses revealed inferior temporal gyrus levels of putative 28- and 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers were inversely correlated with episodic memory deficits [<xref rid="ref108" ref-type="bibr">108</xref>]. Beyond these correlative observations, proteo-transduction of SEC-segregated 28&#x0200a;k-Da <italic>&#x003b1;</italic>Syn dimers isolated from TgI2.2 mice onto wild-type primary neurons resulted in a marked suppression of synapsin-I and synapsin-II levels whereas parallel experiments using SEC-segregated monomeric <italic>&#x003b1;</italic>Syn had no effect on synapsins. Note that because the 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers co-segregated with larger <italic>&#x003b1;</italic>Syn assemblies (&#x0003e;70&#x0200a;kDa), it was not possible for the authors to assess a contribution of that assembly unlike the SEC-segregated 28 kDa <italic>&#x003b1;</italic>Syn dimers. Remarkably, the changes induced by SEC-segregated 28 kDa <italic>&#x003b1;</italic>Syn dimers were also observed in <italic>SNCA</italic>-null primary neurons indicating that these species do not dependent on endogenous <italic>&#x003b1;</italic>Syn expression to mediate their effects on synapsins. Promoter activity assays and cellular signaling studies further revealed: 1) that SEC-segregated 28&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers suppress the activation of two <italic>&#x003b1;</italic>Syn-regulated signaling pathways controlled by the cAMP responsive element-binding protein (CREB) and the nuclear receptor related 1 protein (Nurr1) and 2) novel responsive elements to CREB and Nurr1 in the 5<sup>&#x02032;</sup>UTR/promoter region of <italic>SYN1</italic> and <italic>SYN2</italic> genes, two transcription factors known to be suppressed by <italic>&#x003b1;</italic>Syn [<xref rid="ref129" ref-type="bibr">129, 130</xref>]. Finally, independent studies from the Bj&#x000f6;rklund and Perlmann groups also demonstrated that lentivirus-mediated overexpression of full-length human WT <italic>&#x003b1;</italic>Syn (<italic>&#x003b1;</italic>Syn<sup>WT</sup>) in midbrain dopaminergic neurons resulted in the detection of 28&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers and reductions in CREB and Nurr1 signaling [<xref rid="ref130" ref-type="bibr">130</xref>]. Taken together, these results provide molecular insights in neuronal changes induced by isolated <italic>&#x003b1;</italic>Syn dimers and warrant additional work comparing the functional roles of these two distinct dimeric <italic>&#x003b1;</italic>Syn species.</p></sec><sec id="sec0060"><title>Trimers</title><p>Rare studies have documented the existence of putative <italic>&#x003b1;</italic>Syn trimers with a theorical molecular weight ranging between 42&#x02013;51&#x0200a;kDa based on 14- or 17&#x0200a;kDa <italic>&#x003b1;</italic>Syn monomeric units in protein lysates from brain tissue [<xref rid="ref086" ref-type="bibr">86</xref>]. One could argue that a potential reason for the apparent absence of evidence for trimeric <italic>&#x003b1;</italic>Syn assemblies could be related to an observation made by the Haass group years ago. Kahle and colleagues [<xref rid="ref125" ref-type="bibr">125</xref>] noted that putative <italic>&#x003b1;</italic>Syn trimers migrating between the 44 and 71&#x0200a;kDa molecular standards were present in ultracentrifugation supernatants of <italic>in vitro</italic> formed aggregates of recombinant <italic>&#x003b1;</italic>Syn partially solubilized in Tris-buffered saline (TBS). However, addition of 5% SDS to fully solubilize <italic>&#x003b1;</italic>Syn resulted in a nearly complete disappearance of these assemblies in favor of monomeric and 35&#x0200a;kDa dimeric <italic>&#x003b1;</italic>Syn species. It is however possible that, given the low resolution of the immunoreactive band(s) combined with that of the gel used as evidenced by the small distance separating the 44 and 71&#x0200a;kDa standards, the putative trimer might in fact correspond to a tetrameric assembly or both. Another potential confounding factor preventing reliable identification of putative &#x0223c;42&#x02013;51&#x0200a;kDa <italic>&#x003b1;</italic>Syn trimers in lysates from brain tissue relies on inconsistent electrophoretic migration across sample types, suboptimum gel resolution and overreliance on western-blot detection using a single antibody. Accordingly, it is clear that further work will be needed to validate the existence of trimeric <italic>&#x003b1;</italic>Syn in brain tissue.</p></sec><sec id="sec0065"><title>Tetramers</title><p>Contrasting with the anecdotal reports related to possible <italic>&#x003b1;</italic>Syn trimers, several groups have detected putative tetrameric assemblies of <italic>&#x003b1;</italic>Syn in brain lysates [<xref rid="ref067" ref-type="bibr">67, 71, 88, 108</xref>]. The experimental observation of putative tetramers is conceptually appealing considering the prominent detection of <italic>&#x003b1;</italic>Syn dimers and considering the potential diversity of dimeric assemblies (see dedicated chapter above). Based on the same model relying either on 14- or on 17&#x0200a;kDa <italic>&#x003b1;</italic>Syn monomeric units, homomeric <italic>&#x003b1;</italic>Syn tetramers can thus encompass multimeric species whose molecular weights range between 56 to 68&#x0200a;kDa. Like <italic>&#x003b1;</italic>Syn dimers, two tetrameric <italic>&#x003b1;</italic>Syn assemblies may exist, i.e., &#x0223c;58&#x02013;60&#x0200a;kDa <italic>&#x003b1;</italic>Syn species (proposed tetramer of 14.5&#x0200a;kDa <italic>&#x003b1;</italic>Syn) sensitive to SDS [<xref rid="ref071" ref-type="bibr">71</xref>] and &#x0223c;56&#x0200a;kDa <italic>&#x003b1;</italic>Syn species (possible tetramer of 14&#x0200a;kDa <italic>&#x003b1;</italic>Syn or compact tetramer of 17&#x0200a;kDa <italic>&#x003b1;</italic>Syn) resistant to SDS [<xref rid="ref088" ref-type="bibr">88, 108</xref>], based on the conflicting sensitivity of putative physiological tetramers and oligomeric tetramers to this anionic detergent. Despite the apparent resistance to SDS, the 4D6-immunoreactive &#x0223c;56&#x0200a;kDa <italic>&#x003b1;</italic>Syn species identified by Larson and colleagues are not covalently linked as 10 to 20% hexafluoroisopropanol (HFIP) trigger its disassembly in favor of monomeric <italic>&#x003b1;</italic>Syn [<xref rid="ref108" ref-type="bibr">108</xref>]. This finding thus opens the door to the hypothesis that this oligomeric assembly corresponds to a possible homomeric tetramer of 14&#x0200a;kDa <italic>&#x003b1;</italic>Syn, a compact homomeric tetramer of 17&#x0200a;kDa <italic>&#x003b1;</italic>Syn molecular units or a heteromeric tetramer composed of both molecular building blocks. To attempt getting at this question, it can be postulated that, if the 28&#x0200a;kDa or the 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers were the nuclei of the &#x0223c;55&#x02013;56&#x0200a;kDa <italic>&#x003b1;</italic>Syn assembly, then their relative abundance in vivo might be related in brain tissue. Leveraging existing data from the Religious Orders Study cohort initially reported by Larson and coworkers [<xref rid="ref108" ref-type="bibr">108</xref>], we performed pair-wise regression analyses which unexpectedly revealed strong positive correlations between the 35&#x0200a;kDa and 55&#x0200a;kDa <italic>&#x003b1;</italic>Syn species in intracellular-enriched protein fractions from individuals with no cognitive impairment (NCI) and from subjects with AD (<xref ref-type="fig" rid="jpd-10-jpd201965-g002">Fig.&#x000a0;2</xref>A). Quantile density contours readily illustrated the parallel elevation of both species in AD tissue compared to the NCI group (<xref ref-type="fig" rid="jpd-10-jpd201965-g002">Fig.&#x000a0;2</xref>A). By contrast, there was no apparent relationship between the 28&#x0200a;kDa and 55&#x0200a;kDa <italic>&#x003b1;</italic>Syn species in the same biological samples (<xref ref-type="fig" rid="jpd-10-jpd201965-g002">Fig.&#x000a0;2</xref>B). Together, these new results thus favor the notion that the increased amounts of intracellular 55&#x0200a;kDa <italic>&#x003b1;</italic>Syn species in AD brain tissue might depend on the availability of 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers, as opposed to the smaller 28&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers. This hypothesis is further supported by SEC profiles of similar AD lysates in which the 35&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers reliably co-eluted with larger <italic>&#x003b1;</italic>Syn species including 55&#x02013;56&#x0200a;kDa assemblies while the 28&#x0200a;kDa <italic>&#x003b1;</italic>Syn dimers displayed an elution profile consistent with a globular molecule allowing its isolation from other <italic>&#x003b1;</italic>Syn species [<xref rid="ref108" ref-type="bibr">108</xref>].</p><fig id="jpd-10-jpd201965-g002" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Relationships between 28-, 35- and 55&#x0200a;kDa <italic>&#x003b1;</italic>Syn oligomers in human brain tissue from cognitively intact subjects and subjects with AD within the ROS cohort. Regression analyses and quantile density contours for pair-wise comparisons between 35&#x0200a;kDa (A) or 28&#x0200a;kDa (B) dimeric <italic>&#x003b1;</italic>Syn and the &#x0223c;55&#x02013;56&#x0200a;kDa putative <italic>&#x003b1;</italic>Syn tetramer detected in the intracellular-enriched fraction (IC). All species were detected with the monoclonal antibody 4D6. NCI, no cognitive impairment; AD, Alzheimer&#x02019;s disease; ROS, Religious Orders Study.</p></caption><graphic xlink:href="jpd-10-jpd201965-g002"/></fig><p>Beyond the differences in their respective intrinsic biochemical properties, the SDS-sensitive &#x0223c;58&#x02013;60&#x0200a;kDa <italic>&#x003b1;</italic>Syn tetramers, also called <italic>&#x003b1;</italic>Syn &#x02018;multimers&#x02019; [<xref rid="ref071" ref-type="bibr">71</xref>], and the SDS-resistant &#x0223c;55&#x02013;60&#x0200a;kDa <italic>&#x003b1;</italic>Syn species [<xref rid="ref108" ref-type="bibr">108</xref>] also appear to possess markedly different functions. As a brief reminder, genetic destabilization of <italic>&#x003b1;</italic>Syn multimers in mice was recently shown to produce a phenotype reminiscent of PD [<xref rid="ref073" ref-type="bibr">73</xref>], indicating a supportive or physiological function of <italic>&#x003b1;</italic>Syn multimers in healthy conditions [<xref rid="ref058" ref-type="bibr">58</xref>]. Contrasting with this role, brain levels of SDS-resistant &#x0223c;55&#x0200a;kDa <italic>&#x003b1;</italic>Syn oligomers inversely correlated with episodic memory and semantic memory performance in subjects with AD [<xref rid="ref108" ref-type="bibr">108</xref>]. Moreover, SEC-segregated <italic>&#x003b1;</italic>Syn species containing SDS-resistant &#x0223c;55&#x0200a;kDa <italic>&#x003b1;</italic>Syn oligomers caused a selective suppression of synapsin-1 and synapsin-2 proteins in cultured cortical neurons by a prion-like mechanism requiring <italic>&#x003b1;</italic>Syn expression [<xref rid="ref108" ref-type="bibr">108</xref>]. These results therefore indicate divergent functions of distinct <italic>&#x003b1;</italic>Syn tetramers in health and disease.</p></sec><sec id="sec0070"><title>Annular protofibrils</title><p>Earlier it was shown that A30P and A53T mutants can form pore-like annular protofibrils faster than <italic>&#x003b1;</italic>Syn<sup>WT</sup> and were capable of permeabilizing <italic>in vitro</italic> prepared phosphatidylglycerol (PG) vesicles. It was proposed that an increase in <italic>&#x003b1;</italic>Syn protofibril structures might occur in an early stage of PD, thus suggesting a possible mechanism of toxicity in PD [<xref rid="ref131" ref-type="bibr">131</xref>]. Moreover, the same study had also demonstrated that in addition to annular protofibrils, A53T mutant synuclein can form tubular protofibrils. An ordered assembly of <italic>&#x003b1;</italic>Syn<sup>WT</sup> oligomers into protofibrils significantly permeabilized synthetic lipid vesicles, implying their ability to disrupt cellular membranes [<xref rid="ref132" ref-type="bibr">132</xref>]. Using multiple techniques, including cryo-EM, another study has demonstrated the formation of two types of annular assemblies of <italic>&#x003b1;</italic>Syn, one with a typical ring shape and another with a cylindrical shape. Addition of these assemblies into rat midbrain neuronal cultures not only generated reactive oxygen species but also significantly disrupted synthetic lipid vesicles compared to monomeric or fibrillar <italic>&#x003b1;</italic>Syn [<xref rid="ref133" ref-type="bibr">133</xref>]. However, in another study, <italic>&#x003b1;</italic>Syn pre-fibrillar oligomers (PFOs) showed comparatively stronger membrane-permeabilizing activity than the annular protofibrils of <italic>&#x003b1;</italic>Syn. Furthermore, <italic>&#x003b1;</italic>Syn PFOs were significantly more toxic when applied exogenously to SH-SY5Y cells compared to <italic>&#x003b1;</italic>Syn annular protofibrils [<xref rid="ref134" ref-type="bibr">134</xref>]. As different types of o-<italic>&#x003b1;</italic>Syn were shown to cause cellular toxicity at different degrees, such mixed observations with annular protofibrils toxicity imply the complex nature of these amyloid assemblies.</p></sec><sec id="sec0075"><title>Other assemblies</title><p>Large oligomers of <italic>&#x003b1;</italic>Syn preferentially bind to the SNARE protein synaptobrevin-2 and inhibit SNARE complex formation, thus impeding vesicle docking and neurotransmitter release [<xref rid="ref135" ref-type="bibr">135</xref>]. Small diffused granular <italic>&#x003b1;</italic>Syn aggregates were enormously detected in the presynaptic terminals of neurons in DLB brain tissues along with significant loss of postsynaptic dendritic spines, suggesting the role of such granular <italic>&#x003b1;</italic>Syn aggregates in synaptic dysfunction [<xref rid="ref136" ref-type="bibr">136</xref>].</p><p>Using newly generated transgenic mice expressing split luciferase <italic>&#x003b1;</italic>Syn probes (the constitutive S1/S2 mice and the inducible VS1/VS2 mice), recent work from the Danzer group demonstrated an age-dependent accumulation of endogenous 8&#x02013;16-mer o-<italic>&#x003b1;</italic>Syn species, which reached its maximum levels in 24-month-old animals [<xref rid="ref137" ref-type="bibr">137</xref>]. At a subcellular level, these o-<italic>&#x003b1;</italic>Syn species appear to accumulate preferentially within the presynaptic compartments and not within the neuronal soma, perhaps due to the enrichment of synucleins in this element. Importantly, 24-month-old S1/S2 mice displayed a reduced anxiety-like behavior, a phenotype also observed in transgenic mice overexpressing mutant A53T <italic>&#x003b1;</italic>Syn [<xref rid="ref138" ref-type="bibr">138</xref>].</p></sec></sec><sec id="sec0080"><title>Future directions</title><p>As summarized above, many forms of putative oligomeric assemblies of <italic>&#x003b1;</italic>Syn have been detected across several neurological diseases. To improve the reproducibility of o-<italic>&#x003b1;</italic>Syn detection and to facilitate comparisons across independent groups, we here advocate for a reduced reliance on single antibody detection following western blotting and for increasing the necessity to include biochemical analyses comprising combinations of non-denaturing (e.g., homotypic ELISA, heterotypic ELISA with oligomer-specific antibodies, liquid-phase chromatography separation, clear native-PAGE, dot/spot blotting) and denaturing approaches (western-blotting, co-immunoprecipitations) with extensive panels of pan-, conformation- or oligomer-specific antibodies. In particular, we would like to draw attention to characterizing all brain-derived <italic>&#x003b1;</italic>Syn oligomers using A11 and OC due to their demonstrated preference in detecting distinct &#x003b2;-sheet conformers [<xref rid="ref126" ref-type="bibr">126&#x02013;128</xref>]. Given the heterogeneity among the oligomeric assemblies of <italic>&#x003b1;</italic>Syn and pending an amelioration of the isolation techniques for oligomeric <italic>&#x003b1;</italic>Syn from brain tissues or cells (typically generating low to very low yields), cryo-electron microscopy (Cryo-EM) and NMR studies will likely prove essential to dissect out the structural and conformational variants of various oligomers.</p><p>Post-translational modifications including truncation [<xref rid="ref139" ref-type="bibr">139</xref>], nitration [<xref rid="ref140" ref-type="bibr">140</xref>] and phosphorylation [<xref rid="ref141" ref-type="bibr">141, 142</xref>] might play important roles in <italic>&#x003b1;</italic>Syn aggregation and hence its toxicity (see for review [<xref rid="ref143" ref-type="bibr">143</xref>]). Paleologou and colleagues showed oligomeric pS129-<italic>&#x003b1;</italic>Syn in the membrane fractions of DLB and MSA brain tissues ranging from &#x0223c;28 to 98&#x0200a;kDa molecular weights. Similarly, monomeric (&#x0223c;17&#x0200a;kDa) and oligomeric (&#x0223c;42&#x0200a;kDa) pS129-<italic>&#x003b1;</italic>Syn were also detected in the membrane fractions of brain tissues from transgenic mouse models of synucleinopathies [<xref rid="ref141" ref-type="bibr">141</xref>]. Finally, studies in flies demonstrated that soluble endogenous o-<italic>&#x003b1;</italic>Syn was increased by pS129 and decreased by phosphorylation at tyrosine 125 (pY125) [<xref rid="ref142" ref-type="bibr">142</xref>]. Moreover, biochemical analysis of postmortem human brain tissues revealed a reduction of pY125-<italic>&#x003b1;</italic>Syn with aging and in subjects with DLB [<xref rid="ref142" ref-type="bibr">142</xref>]. These findings suggest that <italic>&#x003b1;</italic>Syn-induced toxicity may result from a dysregulation between an oligomer-promoting effect of pS129 and an oligomer-inhibiting effect of pY125. Therefore, mass spectrometry-based analysis of post-translational modifications of <italic>in vivo</italic> occurring <italic>&#x003b1;</italic>Syn aggregates (including o-<italic>&#x003b1;</italic>Syn) would be important to gain more understanding of the pathogenic <italic>&#x003b1;</italic>Syn assemblies.</p><p>If achieved, these largely technical improvements should allow the field to compare the function of multiple <italic>&#x003b1;</italic>Syn species in parallel, reminiscent of the work done for A&#x003b2; oligomers in the AD field. It would be indeed surprising to find that each o-<italic>&#x003b1;</italic>Syn member of this pleiotropic ensemble acts similarly on neuronal and glial cells in the brain.</p><p>Lastly, two very recent studies from the Holtzman and Bu groups investigated whether <italic>APOE</italic>
<italic>&#x0025b;</italic>4 genotype, a major risk factor for neurodegenerative diseases, affected <italic>&#x003b1;</italic>Syn pathology in mice and subjects with PD [<xref rid="ref144" ref-type="bibr">144, 145</xref>]. While both studies relied on <italic>APOE</italic> knock-in (E2/E3/E4) backgrounds to compare the impact of <italic>APOE</italic>
<italic>&#x0025b;</italic>2/<italic>&#x0025b;</italic>3/<italic>&#x0025b;</italic>4 alleles in mouse models of synucleinopathy, Davis and colleagues used G2.3 TgA53T mice [<xref rid="ref145" ref-type="bibr">145</xref>]; Zhao and coworkers opted for an AAV-mediated overexpression of human <italic>&#x003b1;</italic>Syn<sup>WT</sup>, which does not cause amyloid inclusions as defined by a lack of Thioflavin-S positivity [<xref rid="ref144" ref-type="bibr">144, 146</xref>]. In both experimental settings, E4 exacerbated <italic>&#x003b1;</italic>Syn pathology, including pathological conformational changes detected by the antibody 5G4 and pS129-<italic>&#x003b1;</italic>Syn accumulation, and worsened motor deficits. However, none of these reports assessed the exact nature of the accumulating <italic>&#x003b1;</italic>Syn. A qualitative western blot analysis using Syn1 and MJFR-13 antibodies detecting total <italic>&#x003b1;</italic>Syn and pS129-<italic>&#x003b1;</italic>Syn respectively revealed &#x0223c;23&#x0200a;kDa and &#x0223c;30&#x0200a;kDa bands, in addition to monomeric &#x0223c;14&#x0200a;kDa <italic>&#x003b1;</italic>Syn, in the SDS-soluble fraction of symptomatic G2.3 TgA53T mice which the authors interpreted as o-<italic>&#x003b1;</italic>Syn oligomers [<xref rid="ref145" ref-type="bibr">145</xref>]. Several points are problematic with this analysis: (i) there are no quantitative measurements provided; (ii) these additional bands are detected in symptomatic TgA53T/E4, TgA53T/E3 and TgA53T lacking murine APOE (TgA53T/EKO) with no apparent difference across <italic>APOE</italic> genotype; (iii) the molecular weights (&#x0223c;23&#x0200a;kDa and &#x0223c;30&#x0200a;kDa) are inconsistent with those previously reported for o-<italic>&#x003b1;</italic>Syn by electrophoretic separation as discussed above in this section. Based on these findings, further work is needed to determine if <italic>&#x003b1;</italic>Syn oligomerization is altered by <italic>APOE</italic>
<italic>&#x0025b;</italic>4 and, if it were, what o-<italic>&#x003b1;</italic>Syn species are differentially accumulating across <italic>APOE</italic> genotypes.</p></sec></sec><sec id="sec0085"><title>SPREADING OF OLIGOMERIC <italic>&#x003b1;</italic>SYN SPECIES</title><sec id="sec0090"><title>Introduction to prion-like propagation of <italic>&#x003b1;</italic>Syn</title><p>A group of highly infectious neurodegenerative diseases, known as transmissible spongiform encephalopathy (TSE) or prion diseases is caused by the infectious prion protein or PrP [<xref rid="ref147" ref-type="bibr">147</xref>]. Animals affected with prion diseases exhibit different phenotypes. One of the most astonishing phenomena in prion diseases is that animals infected with the same pathogenic infectious agent displayed different clinical phenotypes [<xref rid="ref148" ref-type="bibr">148&#x02013;150</xref>]. Moreover, when such infectious protein aggregates were isolated and inoculated in identical hosts, they induced distinct prion disease specific phenotypes [<xref rid="ref151" ref-type="bibr">151</xref>]. Growing experimental evidence suggests that many neurodegenerative diseases share common characteristics with prion diseases. Indeed, the pathogenic protein conformers of amyloid proteins defining neurodegenerative diseases can seed and promote the aggregation of their natively-folded counterparts in a prion-like manner [<xref rid="ref152" ref-type="bibr">152</xref>].</p><p>Based on the course of the Lewy pathology in the enteric nervous system (ENS), peripheral nervous system (PNS) and central nervous system (CNS) together with clinical symptoms of patients with sporadic PD, Del Tredici and Braak have proposed the following staging procedure [<xref rid="ref153" ref-type="bibr">153</xref>]. At stage 1, the Lewy pathology initially develops somewhere in ENS, PNS or CNS, then is detected in olfactory structures (bulb and nucleus) and in the medulla oblongata, specifically in the dorsal motor nucleus of the vagal nerve (CN X) and/or intermediate reticular zone. At stage 2, LNs and LBs are found in peripheral parasympathetic and sympathetic nerves, medullary nuclei including the locus coeruleus and lower raphe nuclei. Stage 3 is characterized by <italic>&#x003b1;</italic>Syn pathology in the substantia nigra, pars compacta and the magnocellular nuclei of the basal forebrain. At stage 4, intralaminar thalamic nuclei and anteromedial temporal cortex (including entorhinal cortex and hippocampus) are affected. At stage 5, the high-order sensory association areas of the neocortex and prefrontal fields are affected while at stage 6, first-order sensory association, premotor, primary motor and sensory areas are also affected, ultimately coinciding with dementia. This mostly ascending caudo-rostral neuropathological pattern is suggesting that, once formed, <italic>&#x003b1;</italic>Syn aggregates seem capable of propagating between neurons synaptically interconnected.</p><p>In the late 2000s, several reports documented host-to-graft propagation of <italic>&#x003b1;</italic>Syn pathology in fetal mesencephalic transplants of subjects with PD [<xref rid="ref154" ref-type="bibr">154, 155</xref>]. Shortly thereafter, Desplats and colleagues demonstrated that neurons overexpressing <italic>&#x003b1;</italic>Syn can transmit the protein to neighboring cortical neuronal stem cells expressing the green fluorescent protein (GFP) in vitro and in vivo [<xref rid="ref156" ref-type="bibr">156</xref>]. In the accompanying commentary, Olanow and Prusiner openly questioned whether PD was a prion disorder [<xref rid="ref157" ref-type="bibr">157</xref>] promoting vast interest in the field to entertain the hypothesis that some forms of <italic>&#x003b1;</italic>Syn, perhaps including oligomeric or small fibrillar assemblies, might act as prion-like conformers and promote the misfolding of additional wild-type proteins. By extension, these studies also suggested that <italic>&#x003b1;</italic>Syn aggregates may propagate in anatomically connected neural networks.</p></sec><sec id="sec0095"><title>Spreading of endogenous oligomeric <italic>&#x003b1;</italic>Syn species in vitro</title><p>Although the exact mechanism by which o-<italic>&#x003b1;</italic>Syn exert their toxic effects is still unknown, the presence of these oligomeric assemblies in the extracellular body fluids suggests their release from affected brain regions and subsequent potential spreading between cells. The cell-to-cell propagation of o-<italic>&#x003b1;</italic>Syn could occur through the internalization of these species via receptor-mediated endocytosis as demonstrated in several cell lines and primary neurons [<xref rid="ref158" ref-type="bibr">158&#x02013;161</xref>]. In addition, exogenously added o-<italic>&#x003b1;</italic>Syn can act as seeds promoting the aggregation of endogenous <italic>&#x003b1;</italic>Syn in primary neuronal cells as well as in neuronal cell lines, suggesting that extracellular release of o- <italic>&#x003b1;</italic>Syn coupled with reuptake as a plausible mechanism for the spreading of <italic>&#x003b1;</italic>Syn pathology [<xref rid="ref162" ref-type="bibr">162</xref>]. Specifically, secretion of <italic>&#x003b1;</italic>Syn within exosomes has been proposed to amplify and propagate PD-associated <italic>&#x003b1;</italic>Syn pathology in cell culture systems [<xref rid="ref096" ref-type="bibr">96, 97</xref>]. It has been suggested that effective propagation of <italic>&#x003b1;</italic>Syn aggregates is dependent on both the templated seeding process and the <italic>in vivo</italic> cellular condition [<xref rid="ref163" ref-type="bibr">163</xref>].</p></sec><sec id="sec0100"><title>Spreading of endogenous oligomeric <italic>&#x003b1;</italic>Syn species in vivo</title><p>To our knowledge, experimental evidence demonstrating a spreading of endogenous o-<italic>&#x003b1;</italic>Syn is rare [<xref rid="ref137" ref-type="bibr">137</xref>] in contrast to strategies relying on exogenous injection of recombinant aggregated <italic>&#x003b1;</italic>Syn preparations in rodent brains [<xref rid="ref164" ref-type="bibr">164&#x02013;169</xref>]. Leveraging newly created conditional S1/S2 and VS1/VS2 transgenic mice in which protein-fragment complementation of tagged <italic>&#x003b1;</italic>Syn occurs, Kiechle and coworkers provided novel evidence of o-<italic>&#x003b1;</italic>Syn formation at presynaptic terminals, age-dependent accumulation of 8&#x02013;16-mer <italic>&#x003b1;</italic>Syn oligomeric assemblies and trans-synaptic spreading of endogenous o-<italic>&#x003b1;</italic>Syn species from transgene-expressing neurons to synaptically-connected nuclei which did not express the transgene [<xref rid="ref137" ref-type="bibr">137</xref>]. These changes were accompanied by reduced locomotor deficits, behavioral abnormalities (e.g., reduced anxiety-like behavior), olfactory dysfunction, reduced striatal dopamine concentrations and ultimately loss of dopaminergic neurons in the substantia nigra [<xref rid="ref137" ref-type="bibr">137</xref>]. While further elaboration on such elegant study is necessary to better understand the extent of oligomeric <italic>&#x003b1;</italic>Syn-induced synaptotoxicity, these findings add weight to prior work demonstrating that endogenous o-<italic>&#x003b1;</italic>Syn species alter synaptic structure and function <italic>in vivo</italic> [<xref rid="ref108" ref-type="bibr">108</xref>].</p></sec></sec><sec id="sec0105"><title>INTERACTIONS BETWEEN OLIGOMERIC <italic>&#x003b1;</italic>SYN ASSEMBLIES AND OTHER AMYLOID PROTEINS</title><p>Although amyloidogenic proteins might follow unique cascades of pathological events, the majority of them shares certain common mechanisms for toxicity. Membrane permeabilization is one of such mechanisms that has been suggested for many amyloid proteins [<xref rid="ref170" ref-type="bibr">170</xref>]. Co-occurrence of multiple protein pathologies represents a wide range of neurodegenerative disorders where comorbidity and overlap between the diseases are frequently observed [<xref rid="ref171" ref-type="bibr">171</xref>]. In addition to LB, senile plaques of A&#x003b2;, neurofibrillary tangles (NFTs) and neuropil threads composed of tau were observed in the cerebral cortex of PD brain tissues [<xref rid="ref172" ref-type="bibr">172</xref>]. Senile plaques and NFTs are often found together in DLB cases [<xref rid="ref173" ref-type="bibr">173</xref>]. Thus, there is a considerable overlap between <italic>&#x003b1;</italic>Syn, tau and A&#x003b2; protein pathologies in synucleinopathies, suggesting their potential synergistic effects on pathogenesis.</p><p>For the context of this review, we will differentiate the terms &#x0201c;cross-talk&#x0201d; as defined by direct or indirect molecular interactions in absence of enhanced fibrillization from &#x0201c;cross-seeding&#x0201d; which occurs when oligomers composed by one misfolded amyloid protein induce the oligomerization of a distinct amyloid protein.</p><sec id="sec0110"><title><italic>&#x003b1;</italic>Syn/A&#x003b2; hybrid species</title><sec id="sec0115"><title>Cross-talk</title><p>While many studies have suggested that <italic>&#x003b1;</italic>Syn and A&#x003b2; are capable of direct and indirect molecular cross-talks in the brain along with hybrid oligomer formation [<xref rid="ref021" ref-type="bibr">21, 174&#x02013;179</xref>], few studies have demonstrated that endogenous A&#x003b2; and <italic>&#x003b1;</italic>Syn directly interact in cultured cells or <italic>in vivo</italic> [<xref rid="ref021" ref-type="bibr">21</xref>]. Specifically, Tsigelny and colleagues reported that <italic>&#x003b1;</italic>Syn and A&#x003b2; directly interact in the brains of small (<italic>n</italic>&#x0200a;=&#x0200a;4) groups of patients with AD, DLB and in APP/<italic>&#x003b1;</italic>-syn tg mice (Thy1-APPmut tg [line 41] x PDGF&#x003b2;-<italic>&#x003b1;</italic>-syn tg mice [line D]) using co-immunoprecipitation analyses of membrane fractions. Although immunoreactive bands at &#x0223c;28, &#x0223c;40 and &#x0223c;70&#x0200a;kDa labeled as <italic>&#x003b1;</italic>Syn dimers, trimers and pentamers by the authors were readily detected by western blotting using unspecified <italic>&#x003b1;</italic>Syn antibodies in the membrane fractions of AD, DLB and APP/<italic>&#x003b1;</italic>-syn tg brain tissue, only monomeric <italic>&#x003b1;</italic>Syn (or A&#x003b2;) and no oligomeric species were identified by coimmunoprecipitation. By contrast, two independent studies from the Lesn&#x000e9; group failed to observe putative <italic>&#x003b1;</italic>Syn/A&#x003b2; hybrid species in AD brain lysates and in double transgenic APP/<italic>&#x003b1;</italic>Syn mice (PDGF&#x003b2;-APPmut tg [line J20] &#x000d7;PrP-<italic>&#x003b1;</italic>Syn tg mice [line TgI2.2]) using non-denaturing dot blotting following size exclusion chromatography with several monoclonal <italic>&#x003b1;</italic>Syn antibodies (LB509, 4B12 and 4D6) or using coimmunoprecipitation with the LB509 <italic>&#x003b1;</italic>Syn antibody [<xref rid="ref019" ref-type="bibr">19, 108</xref>]. All three studies used the monoclonal antibody 6E10 to detect human A&#x003b2;. Overall, these findings are not consistent and additional work is needed to confirm the presence of endogenous <italic>&#x003b1;</italic>Syn/A&#x003b2; hybrid assemblies and to assess whether differences in the approaches and/or in the biological specimens might be responsible for these diverging observations.</p><p>To assess whether A&#x003b2; and <italic>&#x003b1;</italic>Syn aggregation co-occurs or whether a potential cross-talk between these two amyloid precursors, Bassil and coworkers (2020) injected mouse <italic>&#x003b1;</italic>Syn preformed fibrils (<italic>&#x003b1;</italic>Syn-mPFFs) into young adult 5XFAD mice harboring amyloid plaques. The presence of A&#x003b2; deposits enhanced <italic>&#x003b1;</italic>Syn pathology and spreading throughout the brain [<xref rid="ref180" ref-type="bibr">180</xref>]. Mechanistically, the injection of <italic>&#x003b1;</italic>Syn-mPFFs altered APP processing favoring A&#x003b2; production resulting from a decrease in ADAM-10 protein abundance coupled to an increase in presenilin-2 and nicastrin, two members of the <italic>&#x003b3;</italic>-secretase complex. These findings have led the authors to suggest a &#x0201c;feed-forward&#x0201d; mechanism whereby A&#x003b2; plaques potentiate <italic>&#x003b1;</italic>Syn seeding and spreading over time [<xref rid="ref180" ref-type="bibr">180</xref>]. It is however worth noting that soluble APP-<italic>&#x003b1;</italic> (sAPP<italic>&#x003b1;</italic>) levels were remarkably unchanged despite a &#x000a0;50% reduction in ADAM-10, a proponent candidate of <italic>&#x003b1;</italic>-secretase activity, arguing against an overall decrease in <italic>&#x003b1;</italic>-secretase activity. In addition, these putative alterations of APP processing induced by <italic>&#x003b1;</italic>Syn were not observed in two other recent studies examining the interaction between A&#x003b2; and <italic>&#x003b1;</italic>Syn [<xref rid="ref019" ref-type="bibr">19, 20</xref>]. Furthermore, these latter two studies actually reported effects of <italic>&#x003b1;</italic>Syn on A&#x003b2; deposition opposite to that described by Bassil and colleagues, whereby overexpression of either mutant human <italic>&#x003b1;</italic>Syn<sup>A30P</sup> or <italic>&#x003b1;</italic>Syn<sup>WT</sup> in two distinct APP transgenic mice led to a reduction in A&#x003b2; burden [<xref rid="ref019" ref-type="bibr">19, 20</xref>]. Both independent groups validated these <italic>in vivo</italic> findings with <italic>in vitro</italic> approaches relying on thioflavin-T analyses with recombinant proteins [<xref rid="ref020" ref-type="bibr">20</xref>] and relying on measurement of on-pathway amyloid oligomers using conformation-specific OC antibodies [<xref rid="ref019" ref-type="bibr">19</xref>]. Of particular interest, the forebrain abundance of o-<italic>&#x003b1;</italic>Syn detected with oligomeric <italic>&#x003b1;</italic>Syn-specific antibody Syn33 was highest in bigenic APP/<italic>&#x003b1;</italic>Syn mice when A&#x003b2; deposits were the lowest [<xref rid="ref019" ref-type="bibr">19</xref>]. Furthermore, ablation of the <italic>SNCA</italic> gene encoding for <italic>&#x003b1;</italic>Syn in the same APP transgenic model led Khan and colleagues to witness a bidirectional effect of <italic>&#x003b1;</italic>Syn on A&#x003b2; deposition, by which the genetic removal of <italic>&#x003b1;</italic>Syn elevated A&#x003b2; deposition [<xref rid="ref019" ref-type="bibr">19</xref>] reminiscent of prior work by the Zheng group [<xref rid="ref181" ref-type="bibr">181</xref>]. While differences in APP transgenic mouse models could in principle account for these differences, it is more likely that the nature of the <italic>&#x003b1;</italic>Syn molecules introduced in these various models is contributing to the diverging observations. Indeed, while <italic>&#x003b1;</italic>Syn-mPFFs are created by sonicating long, pre-formed fibrils are injected in young mice, transgene-derived expressions of human <italic>&#x003b1;</italic>Syn used by the Meyer-Luehmann and Lesn&#x000e9; groups do not induce <italic>&#x003b1;</italic>Syn fibrillization. Therefore, it is likely that the crosstalk between A&#x003b2; and <italic>&#x003b1;</italic>Syn differs based on the conformational nature of each component, i.e., oligomers vs. fibrils, and with dramatically distinct functional consequences.</p></sec></sec><sec id="sec0120"><title><italic>&#x003b1;</italic>Syn/tau species</title><p>While <italic>&#x003b1;</italic>Syn aggregates are considered as the main pathogenic entities in synucleinopathies, tau pathology is also abundantly detected in these diseases (in&#x0200a;&#x0003e;&#x0200a;92% of subjects with synucleinopathies [<xref rid="ref003" ref-type="bibr">3</xref>]). Abnormal accumulation of the microtubule binding protein tau has been implicated in a group of neurodegenerative diseases known as tauopathies [<xref rid="ref182" ref-type="bibr">182</xref>]. However, an increasing amount of studies has demonstrated the possible interaction between <italic>&#x003b1;</italic>Syn and tau. NFTs consisting of hyperphosphorylated tau have long been studied in PD and DLB cases. Genome-wide association studies (GWAS) have indicated a strong association between <italic>SNCA</italic> and <italic>MAPT</italic> genes coding for <italic>&#x003b1;</italic>Syn and tau, respectively, in PD and DLB pathogenesis [<xref rid="ref183" ref-type="bibr">183, 184</xref>]. Moreover, tau aggregates have been reported in several transgenic mouse models of PD and DLB [<xref rid="ref102" ref-type="bibr">102, 185&#x02013;189</xref>].</p><p>There is also accumulating evidence that spreading of pathogenic protein aggregates is a necessary event in the progression of neurodegenerative diseases [<xref rid="ref190" ref-type="bibr">190&#x02013;193</xref>]. To this end, studies have also been directed to dissecting out the mechanisms by which amyloidogenic protein aggregates spread from cell to cell [<xref rid="ref190" ref-type="bibr">190, 191</xref>]. Walker et al. have suggested a templating mechanism of misfolded protein in which once a small amount of aggregate is formed, it serves as &#x0201c;seed&#x0201d; for further aggregation. Such seeds can recruit newly-formed protein by templating their conformation to the newly added proteins [<xref rid="ref194" ref-type="bibr">194</xref>], including <italic>&#x003b1;</italic>Syn [<xref rid="ref195" ref-type="bibr">195</xref>] and tau [<xref rid="ref196" ref-type="bibr">196, 197</xref>].</p><sec id="sec0125"><title>Cross-talk</title><p>Using human brain cytosol from unspecified source and characterization, early studies reported that <italic>&#x003b1;</italic>Syn directly interacts with the microtubule binding region of tau thereby modulating the phosphorylation state of tau proteins at least at two serine residues (S262 and S356), suggesting a possibility of direct physical interaction between <italic>&#x003b1;</italic>Syn and tau [<xref rid="ref198" ref-type="bibr">198</xref>]. <italic>In situ</italic>, LBs found in PD and DLB cases also contain hyperphosphorylated tau [<xref rid="ref199" ref-type="bibr">199, 200</xref>]. A few years later, transgenic TgA53T mice overexpressing mutant human <italic>&#x003b1;</italic>Syn<sup>A53T</sup> (M83 line) were shown to display abundant tau pathology as threads, grains, spheroids and pre-tangles in several brain regions [<xref rid="ref201" ref-type="bibr">201, 202</xref>], whereas transgenic mice overexpressing human wildtype <italic>&#x003b1;</italic>Syn<sup>WT</sup> (unspecified line from PDGF-<italic>&#x003b1;</italic>Syn mice [<xref rid="ref203" ref-type="bibr">203</xref>]) develop spontaneous pathological tau changes including tau hyperphosphorylation and tau misfolding [<xref rid="ref189" ref-type="bibr">189</xref>]. Profound neuronal tau inclusions resembling NFTs were also found in transgenic mice overexpressing another human <italic>&#x003b1;</italic>Syn mutation, E46K [<xref rid="ref102" ref-type="bibr">102</xref>]. Despite the demonstration that mutant <italic>&#x003b1;</italic>Syn<sup>E46K</sup> is less efficient than <italic>&#x003b1;</italic>Syn<sup>WT</sup> at promoting tau inclusions in cultured QBI293 cells, it is worth noting that TgE46K mice displayed a greater number of tau inclusions compared to TgA53T mice [<xref rid="ref102" ref-type="bibr">102</xref>], suggesting the marked effects of the environment, species and cell type differences on potential molecular interactions between <italic>&#x003b1;</italic>Syn and tau. To date, the reason for the accumulation of hyperphosphorylated tau inclusions in TgE46K mice remains unclear and may warrant additional work, specifically with respect to <italic>&#x003b1;</italic>Syn and tau oligomers. Beyond the detection of co-occurring aggregates of tau and <italic>&#x003b1;</italic>Syn in neurons from M83 TgA53T mice, this co-aggregation was also exacerbated in oligodendrocytes from a bigenic CNP-TauP301L/<italic>&#x003b1;</italic>SynWT mouse model overexpressing mutant P301L tau and human <italic>&#x003b1;</italic>Syn<sup>WT</sup> driven by an oligodendrocyte-specific promoter (2<sup>&#x02032;</sup>,3<sup>&#x02032;</sup>-cyclic nucleotide 3<sup>&#x02032;</sup>-phosphodiesterase or CNP) [<xref rid="ref201" ref-type="bibr">201</xref>]. In these cells, inclusions were positive to Thioflavin S [<xref rid="ref201" ref-type="bibr">201</xref>], denoting advanced fibrillization.</p><p>However, these seminal studies focused on fibril formation as opposed to oligomerization per se. Consequently, the functional role of oligomeric <italic>&#x003b1;</italic>Syn/tau cross-talks <italic>in vivo</italic> was investigated by several groups. In recent studies, the co-occurrence of <italic>&#x003b1;</italic>Syn and tau in their toxic oligomeric forms was observed in postmortem brain tissues of PD and DLB patients [<xref rid="ref089" ref-type="bibr">89</xref>]. In this study, Sengupta and colleagues demonstrated a co-immunoprecipitation of o-<italic>&#x003b1;</italic>Syn with tau oligomers (o-Tau) coupled with a cytoplasmic colocalization of these species in brain tissue from individuals with PD [<xref rid="ref089" ref-type="bibr">89</xref>]. Recognizing that mixed protein pathologies of <italic>&#x003b1;</italic>Syn and tau are observed in PD whereas tau pathology alone is found without any documented <italic>&#x003b1;</italic>Syn pathology in progressive supranuclear palsy (PSP), Castillo-Carranza and coworkers investigated the toxicity of hybrid o-<italic>&#x003b1;</italic>Syn/o-Tau assemblies by injecting either complexes of oligomeric <italic>&#x003b1;</italic>Syn and tau hybrid species derived from PD brain tissues or PSP-derived o-Tau alone in human tau transgenic Htau animals overexpressing human tau isoforms in a murine tau background [<xref rid="ref023" ref-type="bibr">23</xref>]. Hybrid o-<italic>&#x003b1;</italic>Syn/o-Tau complexes accelerated endogenous tau aggregation along with memory deficits in Htau animals compared to o-Tau [<xref rid="ref023" ref-type="bibr">23</xref>]. Importantly, the functional interaction of <italic>&#x003b1;</italic>Syn/tau cross-talks <italic>in vivo</italic> was further investigated by Gerson and coworkers using passive immunotherapy with the tau oligomer-specific monoclonal antibody (TOMA) in M83 TgA53T mice [<xref rid="ref204" ref-type="bibr">204</xref>]. Compared to mice injected with control immunoglobulins, TgA53T mice treated with TOMA displayed reduced synaptic loss, premature deaths and cognitive and motor deficits [<xref rid="ref204" ref-type="bibr">204</xref>]. Importantly, TOMA-mediated lowering of tau oligomers in TgA53T mice was accompanied by a marked reduction in LB-like pathology and by an increase in o-<italic>&#x003b1;</italic>Syn detected by F8H7 and Syn33 antibodies. Based on the properties of TOMA antibodies, which preferentially detect off-pathway o-Tau [<xref rid="ref205" ref-type="bibr">205</xref>], and based on those for F8H7 and Syn33, which preferentially bind off-pathway o-<italic>&#x003b1;</italic>Syn [<xref rid="ref089" ref-type="bibr">89</xref>], these findings highlight complex molecular interactions between o-<italic>&#x003b1;</italic>Syn and o-Tau, which are not fully clear at this time.</p><p>Furthermore, the role of tau in mediating impairment of hippocampal neurotransmission and memory deficits in a similar transgenic animal model, TgA53T mice overexpressing mutant A53T human <italic>&#x003b1;</italic>Syn (line G2.3), has been recently demonstrated suggesting a tau-dependent mechanism of <italic>&#x003b1;</italic>Syn pathology [<xref rid="ref206" ref-type="bibr">206</xref>]. However, this work from Singh and colleagues suggests that the role of tau in young and middle-aged adult G2.3 TgA53T mice is independent of o-<italic>&#x003b1;</italic>Syn/o-Tau cross-talks because no differences in o-<italic>&#x003b1;</italic>Syn nor o-Tau were found in absence or presence of <italic>MAPT</italic> deletion [<xref rid="ref206" ref-type="bibr">206</xref>]. We speculate that this molecular cross-talk would strengthen with aging and have an impact on the phenotype of this PD mouse model.</p><p>Combined, these findings thus suggest the existence of hybrid o-<italic>&#x003b1;</italic>Syn/o-Tau complexes and of an influence of these oligomeric assemblies on each other&#x02019;s aggregation via an interface in synucleinopathies. The exact nature of this interface and the exact functional impact of these o-<italic>&#x003b1;</italic>Syn/o-Tau hybrid forms remain unknown to date and gaining a better understanding of this molecular interaction could lead to the identification of novel therapeutic compounds for subjects affected by synucleinopathies.</p><p>Beyond a potentially direct effect of <italic>&#x003b1;</italic>Syn on tau hyperphosphorylation and/or aggregation, several studies from the Sidhu group indicate that <italic>&#x003b1;</italic>Syn may regulate the activity of glycogen synthase kinase-3&#x003b2; (GSK3&#x003b2;), a major tau kinase, in cell models of PD, signifying a possible indirect functional cross-talk between these two proteins [<xref rid="ref187" ref-type="bibr">187, 188</xref>]. In this potential heteromeric <italic>&#x003b1;</italic>Syn/Tau/GSK3&#x003b2; complex, GSK3b could trigger the co-aggregation of <italic>&#x003b1;</italic>Syn and Tau into early oligomeric assemblies upon phosphorylation of both amyloid proteins thereby creating an interface permitting both proteins to influence each other&#x02019;s aggregation in a discrete subcellular compartment.</p><p>Overall, these studies strongly support the importance of functional crosstalk between <italic>&#x003b1;</italic>Syn and tau.</p></sec><sec id="sec0130"><title>Cross-seeding</title><p>As overlapping protein pathologies are frequently observed in multiple neurodegenerative diseases, cross-seeding between disparate proteins has been suggested as a possible mechanism underlying the detection of mixed pathologies in the same brain tissue [<xref rid="ref207" ref-type="bibr">207, 208</xref>]. While it has been proposed that both tau and <italic>&#x003b1;</italic>Syn exert synergistic effects on each other&#x02019;s aggregation, resulting in fibrillar amyloid structure formation <italic>in vitro</italic> and <italic>in vivo</italic>, most of the studies supporting this claim relied on recombinant forms of <italic>&#x003b1;</italic>Syn (oligomeric or fibrillar) with unclear disease relevance [<xref rid="ref024" ref-type="bibr">24, 201, 209</xref>]. Few studies have assessed the cross-seeding propensity of endogenous or transgene-derived <italic>&#x003b1;</italic>Syn and tau <italic>in vivo</italic>. Clinton and colleagues demonstrated that crossing M83 TgA53T mice with the Alzheimer&#x02019;s disease transgenic mouse model 3&#x000d7;Tg-AD [<xref rid="ref210" ref-type="bibr">210</xref>] led to a reciprocal enhancement of the aggregation of all three transgene-derived amyloid proteins, i.e., A&#x003b2;, tau and <italic>&#x003b1;</italic>Syn, accompanied by an acceleration of cognitive deficits [<xref rid="ref211" ref-type="bibr">211</xref>]. These findings suggested a synergistic interaction between <italic>&#x003b1;</italic>Syn, tau and A&#x003b2; (i.e., exacerbating each other&#x02019;s aggregation) even though the aggregation nature of these amyloid proteins in this interaction remains unclear.</p><p>In more recent studies however, the bilateral intracerebroventricular injection of o-<italic>&#x003b1;</italic>Syn/o-Tau hybrid complexes, immunocaptured from PD brain tissue using a combination of o-Tau specific antibodies T22 and o-<italic>&#x003b1;</italic>Syn specific antibodies F8H7, in young Htau mice led to a delay in NFT formation compared to animals injected with o-Tau alone [<xref rid="ref023" ref-type="bibr">23</xref>]. Supported by <italic>in vitro</italic> studies using recombinant proteins, Castillo-Carranza and coworkers proposed that o-<italic>&#x003b1;</italic>Syn/o-Tau complexes extend the lifespan of toxic tau conformers, leading to enhanced tau oligomerization and hippocampal neuron loss <italic>in vivo</italic> [<xref rid="ref023" ref-type="bibr">23</xref>]. These results therefore suggest that: (i) the cross-seeding of tau induced by off-pathway F8H7-positive o-<italic>&#x003b1;</italic>Syn occurs in PD and (ii) <italic>&#x003b1;</italic>Syn oligomers enhance the deleterious effects of tau in synucleinopathies by reducing tau deposition.</p><p>Together, these <italic>&#x003b1;</italic>Syn/tau cross-seeding studies appear to indicate that the state of <italic>&#x003b1;</italic>Syn aggregates might be an important contributor in determining the fate of its interaction with tau.</p></sec></sec><sec id="sec0135"><title><italic>&#x003b1;</italic>Syn/HTT species</title><sec id="sec0140"><title>Cross-talk</title><p>As discussed earlier, an aberrant interaction of mutant Htt with <italic>&#x003b1;</italic>Syn has been proposed based on the colocalization of <italic>&#x003b1;</italic>Syn with Htt within striatal inclusions of a male subject with HD and in the brain of transgenic mouse models of HD [<xref rid="ref004" ref-type="bibr">4, 5</xref>]. Disparate conclusions have questioned the exact nature of a putative cross-talk between endogenous <italic>&#x003b1;</italic>Syn and Htt: 1) studies noted that <italic>&#x003b1;</italic>Syn forms independent fibrillar aggregates in neurons harboring Htt deposits <italic>in vivo</italic> [<xref rid="ref005" ref-type="bibr">5</xref>] and 2) other work using BiFC assays found that <italic>&#x003b1;</italic>Syn oligomerizes and co-aggregates with N-terminally truncated Htt (Htt<sub>exon1</sub>) in human H4 neuroglioma cells [<xref rid="ref017" ref-type="bibr">17</xref>]. More recently, expansion of these <italic>in vitro</italic> BiFC studies led to the identification of colocalized and co-aggregated <italic>&#x003b1;</italic>Syn and mutant Htt in the fly brain [<xref rid="ref018" ref-type="bibr">18</xref>]. Again, it is worth noting that none of these studies provided direct evidence of a contribution of o-<italic>&#x003b1;</italic>Syn to the interaction with Htt.</p><p>Overall, further investigation is needed to better understand the molecular inter-relationship between <italic>&#x003b1;</italic>Syn and Htt aggregates (including oligomers) <italic>in vivo</italic>. This task might be challenging in light of experimental studies performed in HD mice in which genetic modulation of <italic>&#x003b1;</italic>Syn expression bidirectionally affected autophagy and HD phenotypes [<xref rid="ref212" ref-type="bibr">212</xref>].</p></sec></sec></sec><sec id="sec0145"><title>OLIGOMERIC <italic>&#x003b1;</italic>SYN SPECIES AS DRUG TARGET(S)</title><sec id="sec0150"><title>Monotherapy</title><p>With the discovery of cell-to-cell spreading of <italic>&#x003b1;</italic>Syn oligomers, targeting extracellular protein aggregates to promote their clearance has been an active area of research. Studies involving both active and passive immunotherapy are being performed in preclinical settings. Developing antibodies that will specifically target the oligomeric forms of <italic>&#x003b1;</italic>Syn and using them for passive immunotherapy are getting more attraction. However, obtaining highly specific antibodies is a challenging task raising important questions to consider: would antibodies detecting common structural elements of <italic>&#x003b1;</italic>Syn oligomers be more beneficial? Or should developing antibodies specific to distinct o-<italic>&#x003b1;</italic>Syn assemblies be favored? In addition, several key variables can affect the outcome of such approaches including the delivery route of immunotherapy, internalization or cellular uptake of the antibody and the <italic>in vivo</italic> localization of the targeted oligomeric species [<xref rid="ref213" ref-type="bibr">213</xref>]. Detection of o-<italic>&#x003b1;</italic>Syn in the CSF and blood plasma raises the possibility of early detection of pathological changes occurring in the CNS. To this end, probes specifically targeting o-<italic>&#x003b1;</italic>Syn with high sensitivity and high affinity hold great promise [<xref rid="ref214" ref-type="bibr">214</xref>]. Of note, it is important to indicate here that higher CSF <italic>&#x003b1;</italic>Syn concentrations can be linked to blood contamination due to the expression of <italic>&#x003b1;</italic>Syn in erythrocytes [<xref rid="ref215" ref-type="bibr">215</xref>], thereby requiring strict and rigorous markers for blood contamination and/or a standardized grade system for blood levels in CSF samples. Studies are also being performed to find molecules blocking the endocytosis of <italic>&#x003b1;</italic>Syn oligomers, thus preventing healthy cells from taking up pathogenic <italic>&#x003b1;</italic>Syn species, which could serve as a potential strategy for reducing oligomeric <italic>&#x003b1;</italic>Syn-mediated toxicity [<xref rid="ref214" ref-type="bibr">214</xref>].</p><p>Molecules that can modulate the aggregation process by decreasing the load of <italic>&#x003b1;</italic>Syn oligomers have also been considered as therapeutic potential. The diphenyl-pyrazole molecule anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole], an oligomer modulator was shown to inhibit <italic>&#x003b1;</italic>Syn oligomer formation both <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="ref216" ref-type="bibr">216</xref>]. This molecule strongly inhibited the formation and accumulation of o-<italic>&#x003b1;</italic>Syn and neuronal degeneration thereby suppressing disease progression in the TgA30P PD transgenic mouse model [<xref rid="ref216" ref-type="bibr">216, 217</xref>]. Based on spectral emission properties in presence of o-<italic>&#x003b1;</italic>Syn, the authors proposed that this molecule targets directly o-<italic>&#x003b1;</italic>Syn <italic>in vivo</italic> [<xref rid="ref216" ref-type="bibr">216</xref>], a hypothesis which was further supported by all-atom molecular dynamic simulations [<xref rid="ref218" ref-type="bibr">218</xref>]. Both studies suggest Anle138b as a promising disease-modifying agent not only for synucleinopathies, but also for other amyloid forming proteins as reported recently for PrP<sup>C</sup>, A&#x003b2; and tau [<xref rid="ref216" ref-type="bibr">216, 218&#x02013;221</xref>]. Several other molecules such as NPT100-18A and NPT200-11 have also been reported as promising therapeutic agents that modulate o-<italic>&#x003b1;</italic>Syn formation. Among these, the small molecule <italic>&#x003b1;</italic>Syn misfolding inhibitor, NPT200-11 (Neuropore Therapies Inc./UCB), produced multiple benefits in the TgWT mice overexpressing <italic>&#x003b1;</italic>Syn<sup>WT</sup> (line 61) used as model of PD [<xref rid="ref203" ref-type="bibr">203</xref>], including attenuation of motor deficits and rescue of striatal dopamine transporter expression [<xref rid="ref222" ref-type="bibr">222</xref>]. While the phase 1 clinical trial assessing safety, tolerability and pharmacokinetics of NPT200-11 was completed on February 2016 (NCT02606682; see for review [<xref rid="ref223" ref-type="bibr">223</xref>]), no results have been reported as of yet. Other promising inhibitors of <italic>&#x003b1;</italic>Syn aggregation currently tested in phase 1 clinical trials include PBT434 (Alterity Therapeutic; U1111&#x02013;1211-0052) and ENT-01 (Enterin; NCT03938922); both started last year. Curcumin, a natural polyphenolic antioxidant derived from turmeric, has demonstrated anti-inflammatory and neuroprotective effects in the Tg2576 AD mouse model despite poor bioavailability and presumably-poor blood-brain barrier penetrance of the parent compound [<xref rid="ref224" ref-type="bibr">224&#x02013;226</xref>]. <italic>In vitro</italic>, curcumin and its analogs have been shown to bind to pre-formed <italic>&#x003b1;</italic>Syn oligomers and to reduce their toxicity by modulating their morphologies and biophysical properties [<xref rid="ref227" ref-type="bibr">227, 228</xref>]. Molecular chaperones, including heat shock proteins (HSPs), have also been considered as potential therapeutic alternatives against oligomeric <italic>&#x003b1;</italic>Syn-mediated toxicity [<xref rid="ref229" ref-type="bibr">229</xref>]. Proof of principle studies in which overexpressing the chaperone HSP104 proved to be a safe approach in protecting dopaminergic neurons by disassembling o-<italic>&#x003b1;</italic>Syn in a lentivirus-mediated A30P-<italic>&#x003b1;</italic>Syn rat model of PD supported this view [<xref rid="ref230" ref-type="bibr">230</xref>]. Molecules regulating HSP70 or HSP90 activity were also shown to be effective by lowering o-<italic>&#x003b1;</italic>Syn levels and their associated toxicity in a rat model of parkinsonism [<xref rid="ref231" ref-type="bibr">231</xref>]. Such molecules might serve as effective therapeutic strategy for synucleinopathies.</p></sec><sec id="sec0155"><title>Multi-therapy with other amyloid proteins</title><p>Most neurodegenerative diseases, including synucleinopathies, encompass various protein pathologies. Passive TOMA immunotherapy targeting tau oligomers in the M83 Tg53T animal model of PD prevents cognitive and motor deficits as well as brain protein pathology [<xref rid="ref204" ref-type="bibr">204</xref>]. The importance of synergistic effects of <italic>&#x003b1;</italic>Syn and tau as outlined in above sections, indicates that a combinatorial immunotherapy against both <italic>&#x003b1;</italic>Syn and tau oligomers may constitute a better option to protect neurons from their toxicity. Given the complexity of synucleinopathies, multi-therapy that targets multiple proteins at their oligomeric states as well as altered biological pathways might turn out to be superior to monotherapies. Lastly, immunotherapies may be combined with modifiers of intracellular <italic>&#x003b1;</italic>Syn dynamics [<xref rid="ref232" ref-type="bibr">232, 233</xref>] or lipid pathways that affect <italic>&#x003b1;</italic>Syn biology [<xref rid="ref234" ref-type="bibr">234&#x02013;236</xref>].</p></sec></sec><sec id="sec0160"><title>CONCLUSIONS</title><p>Aggregation of <italic>&#x003b1;</italic>Syn is a hallmark feature in synucleinopathies. Since the discovery of <italic>&#x003b1;</italic>Syn protein as the main component of the neuropathological lesions defining synucleinopathies, LB and LN, there has been a continuous effort to better understand the underlying mechanisms of these debilitating diseases. Despite significant advances made in recent years, the exact reasons behind the selective vulnerability of different neuronal and non-neuronal cell populations as well as brain regions to the aggregation of <italic>&#x003b1;</italic>Syn remain unknown. The implication of soluble <italic>&#x003b1;</italic>Syn oligomers in impairing multiple cellular processes has led to the consideration of such oligomeric assemblies as the main pathogenic entity in synucleinopathies. Hence, better understanding the molecular events leading to <italic>&#x003b1;</italic>Syn oligomer formation, seeding and propagation in vivo are of utmost importance. Unexpected findings such as the identification of native <italic>&#x003b1;</italic>Syn assembly [<xref rid="ref068" ref-type="bibr">68</xref>] or the presence of a strong lipidic component in LB [<xref rid="ref237" ref-type="bibr">237</xref>] will have to be critically investigated. Intensive and collaborative studies involving multi-disciplinary approaches will be necessary to further our understanding of these debilitating diseases and identify disease-modifying interventions.</p></sec><sec sec-type="COI-statement" id="sec0165"><title>CONFLICT OF INTEREST</title><p>The authors have no conflict of interest to report.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by grants from the National Institutes of Health (NIH) to SEL (RF1-AG044342, R21-AG065693, R01-NS092918, R01-AG062135 and R56-NS113549), to RK (R01-AG054025, R01-NS094557 and RF1-AG055771) and to UD (R01-NS099328). Additional support included start-up funds from the University of Minnesota Foundation and bridge funds from the Institute of Translational Neuroscience to SEL, grants from Gilson Longenbaugh Foundation and Mitchell Center for Neurodegenerative Diseases to RK. We thank the study participants and staff of the Rush Alzheimer&#x02019;s Disease Center and its director Dr. David Bennett at Rush University.</p></ack><ref-list><title>REFERENCES</title><ref id="ref001"><label>[1]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ross</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Poirier</surname>
<given-names>MA</given-names>
</string-name> (<year>2004</year>) <article-title>Protein aggregation and neurodegenerative disease</article-title>. <source>Nat Med</source>
<volume>10</volume>, <fpage>S10</fpage>&#x02013;<lpage>S17</lpage>.<pub-id pub-id-type="pmid">15272267</pub-id></mixed-citation></ref><ref id="ref002"><label>[2]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Arnold</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Toledo</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Appleby</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>SX</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L-S</given-names>
</string-name>, <string-name>
<surname>Baek</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wolk</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name> (<year>2013</year>) <article-title>Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases</article-title>. <source>J Comp Neurol</source>
<volume>521</volume>, <fpage>4339</fpage>&#x02013;<lpage>4355</lpage>.<pub-id pub-id-type="pmid">23881776</pub-id></mixed-citation></ref><ref id="ref003"><label>[3]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Robinson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>SX</given-names>
</string-name>, <string-name>
<surname>Rennert</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Suh</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bredenberg</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Caswell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van Deerlin</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yousef</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hurtig</surname>
<given-names>HI</given-names>
</string-name>, <string-name>
<surname>Siderowf</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McMillan</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Duda</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Irwin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Wolk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Elman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>McCluskey</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen-Plotkin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Brettschneider</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name> (<year>2018</year>) <article-title>Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated</article-title>. <source>Brain</source>
<volume>141</volume>, <fpage>2181</fpage>&#x02013;<lpage>2193</lpage>.<pub-id pub-id-type="pmid">29878075</pub-id></mixed-citation></ref><ref id="ref004"><label>[4]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Charles</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mezey</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Dehejia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Polymeropoulos</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Brownstein</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Tagle</surname>
<given-names>DA</given-names>
</string-name> (<year>2000</year>) <article-title>Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington&#x02019;s disease patients and transgenic mouse models</article-title>. <source>Neurosci Lett</source>
<volume>289</volume>, <fpage>29</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">10899401</pub-id></mixed-citation></ref><ref id="ref005"><label>[5]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tom&#x000e1;s-Zapico</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>D&#x000ed;ez-Zaera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ferrer</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez-Ramos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mor&#x000e1;n</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Miras-Portugal</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>D&#x000ed;az-Hern&#x000e1;ndez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>
<given-names>JJ</given-names>
</string-name> (<year>2012</year>) <article-title><italic>&#x003b1;</italic>-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington&#x02019;s disease</article-title>. <source>Hum Mol Genet</source>
<volume>21</volume>, <fpage>495</fpage>&#x02013;<lpage>510</lpage>.<pub-id pub-id-type="pmid">22045698</pub-id></mixed-citation></ref><ref id="ref006"><label>[6]</label><mixed-citation publication-type="journal">
<string-name>
<surname>St-Amour</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Turgeon</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goupil</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Planel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>H&#x000e9;bert</surname>
<given-names>SS</given-names>
</string-name> (<year>2018</year>) <article-title>Co-occurrence of mixed proteinopathies in late-stage Huntington&#x02019;s disease</article-title>. <source>Acta Neuropathol</source>
<volume>135</volume>, <fpage>249</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">29134321</pub-id></mixed-citation></ref><ref id="ref007"><label>[7]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Arvanitakis</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Leurgans</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name> (<year>2009</year>) <article-title>The neuropathology of probable Alzheimer disease and mild cognitive impairment</article-title>. <source>Ann Neurol</source>
<volume>66</volume>, <fpage>200</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">19743450</pub-id></mixed-citation></ref><ref id="ref008"><label>[8]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Arvanitakis</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Bang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name> (<year>2007</year>) <article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title>. <source>Neurology</source>
<volume>69</volume>, <fpage>2197</fpage>&#x02013;<lpage>2204</lpage>.<pub-id pub-id-type="pmid">17568013</pub-id></mixed-citation></ref><ref id="ref009"><label>[9]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kapasi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>DeCarli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name> (<year>2017</year>) <article-title>Impact of multiple pathologies on the threshold for clinically overt dementia</article-title>. <source>Acta Neuropathol</source>
<volume>134</volume>, <fpage>171</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">28488154</pub-id></mixed-citation></ref><ref id="ref010"><label>[10]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Buchman</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name> (<year>2012</year>) <article-title>Relation of neuropathology to cognition in persons without cognitive impairment</article-title>. <source>Ann Neurol</source>
<volume>72</volume>, <fpage>599</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">23109154</pub-id></mixed-citation></ref><ref id="ref011"><label>[11]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Boyle</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name> (<year>2013</year>) <article-title>Relation of neuropathology with cognitive decline among older persons without dementia</article-title>. <source>Front Aging Neurosci</source>
<volume>5</volume>, <fpage>50</fpage>.<pub-id pub-id-type="pmid">24058343</pub-id></mixed-citation></ref><ref id="ref012"><label>[12]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Boyle</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Leurgans</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name> (<year>2018</year>) <article-title>Person-specific contribution of neuropathologies to cognitive loss in old age</article-title>. <source>Ann Neurol</source>
<volume>83</volume>, <fpage>74</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">29244218</pub-id></mixed-citation></ref><ref id="ref013"><label>[13]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hamilton</surname>
<given-names>RL</given-names>
</string-name> (<year>2000</year>) <article-title>Lewy bodies in Alzheimer&#x02019;s disease: a neuropathological review of 145 cases using <italic>&#x003b1;</italic>-synuclein immunohistochemistry</article-title>. <source>Brain Pathol</source>
<volume>10</volume>, <fpage>378</fpage>&#x02013;<lpage>384</lpage>.<pub-id pub-id-type="pmid">10885656</pub-id></mixed-citation></ref><ref id="ref014"><label>[14]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name> (<year>2002</year>) <article-title>Emerging Alzheimer&#x02019;s disease therapies: focusing on the future</article-title>. <source>Neurobiol Aging</source>
<volume>23</volume>, <fpage>985</fpage>&#x02013;<lpage>990</lpage>.</mixed-citation></ref><ref id="ref015"><label>[15]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Spires-Jones</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Attems</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thal</surname>
<given-names>DR</given-names>
</string-name> (<year>2017</year>) <article-title>Interactions of pathological proteins in neurodegenerative diseases</article-title>. <source>Acta Neuropathol</source>
<volume>134</volume>, <fpage>187</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">28401333</pub-id></mixed-citation></ref><ref id="ref016"><label>[16]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Mudher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2016</year>) <article-title>Potential mechanisms and implications for the formation of tau oligomeric strains</article-title>. <source>Crit Rev Biochem Mol Biol</source>
<volume>51</volume>, <fpage>482</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">27650389</pub-id></mixed-citation></ref><ref id="ref017"><label>[17]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Herrera</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Outeiro</surname>
<given-names>TF</given-names>
</string-name> (<year>2012</year>) <article-title><italic>&#x003b1;</italic>-Synuclein modifies huntingtin aggregation in living cells</article-title>. <source>FEBS Lett</source>
<volume>586</volume>, <fpage>7</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">22119730</pub-id></mixed-citation></ref><ref id="ref018"><label>[18]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Po&#x000e7;as</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Branco-Santos</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Herrera</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Outeiro</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Domingos</surname>
<given-names>PM</given-names>
</string-name> (<year>2015</year>) <article-title><italic>&#x003b1;</italic>-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila</article-title>. <source>Hum Mol Genet</source>
<volume>24</volume>, <fpage>1898</fpage>&#x02013;<lpage>1907</lpage>.<pub-id pub-id-type="pmid">25452431</pub-id></mixed-citation></ref><ref id="ref019"><label>[19]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Khan</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>LaCroix</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Amar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Aldaco</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Bloom</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2018</year>) <article-title>Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons</article-title>. <source>Acta Neuropathol</source>
<volume>136</volume>, <fpage>589</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">29995210</pub-id></mixed-citation></ref><ref id="ref020"><label>[20]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bachhuber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Katzmarski</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>McCarter</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Loreth</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tahirovic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kamp</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Abou-Ajram</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nuscher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Serrano-Pozo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prinz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Haass</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Meyer-Luehmann</surname>
<given-names>M</given-names>
</string-name> (<year>2015</year>) <article-title>Inhibition of amyloid-&#x003b2; plaque formation by <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Nat Med</source>
<volume>21</volume>, <fpage>802</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26099047</pub-id></mixed-citation></ref><ref id="ref021"><label>[21]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tsigelny</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Crews</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Desplats</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Shaked</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Sharikov</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Trejo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Platoshyn</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>JX-J</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2008</year>) <article-title>Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer&#x02019;s and Parkinson&#x02019;s diseases</article-title>. <source>PLoS One</source>
<volume>3</volume>, <fpage>e3135</fpage>.<pub-id pub-id-type="pmid">18769546</pub-id></mixed-citation></ref><ref id="ref022"><label>[22]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2017</year>) <article-title>Tau oligomers as pathogenic seeds: preparation and propagation in vitro and in vivo</article-title>. <source>Methods Mol Biol</source>
<volume>1523</volume>, <fpage>141</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">27975249</pub-id></mixed-citation></ref><ref id="ref023"><label>[23]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Guerrero-Mu&#x000f1;oz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2018</year>) <article-title><italic>&#x003b1;</italic>-Synuclein oligomers induce a unique toxic tau strain</article-title>. <source>Biol Psychiatry</source>
<volume>84</volume>, <fpage>499</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">29478699</pub-id></mixed-citation></ref><ref id="ref024"><label>[24]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Guo</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Covell</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Iba</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stieber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Riddle</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Kwong</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VMY</given-names>
</string-name> (<year>2013</year>) <article-title>Distinct <italic>&#x003b1;</italic>-synuclein strains differentially promote tau inclusions in neurons</article-title>. <source>Cell</source>
<volume>154</volume>, <fpage>103</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">23827677</pub-id></mixed-citation></ref><ref id="ref025"><label>[25]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Overk</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Oueslati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2013</year>) <article-title><italic>&#x003b1;</italic>-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities</article-title>. <source>Nat Rev Neurosci</source>
<volume>14</volume>, <fpage>38</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">23254192</pub-id></mixed-citation></ref><ref id="ref026"><label>[26]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ingelsson</surname>
<given-names>M</given-names>
</string-name> (<year>2016</year>) <article-title>Alpha-synuclein oligomers&#x02014;neurotoxic molecules in Parkinson&#x02019;s disease and other Lewy body disorders</article-title>. <source>Front Neurosci</source>
<volume>10</volume>, <fpage>408</fpage>.<pub-id pub-id-type="pmid">27656123</pub-id></mixed-citation></ref><ref id="ref027"><label>[27]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Alam</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bousset</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Melki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Otzen</surname>
<given-names>DE</given-names>
</string-name> (<year>2019</year>) <article-title><italic>&#x003b1;</italic>-synuclein oligomers and fibrils: a spectrum of species, a of toxicities</article-title>. <source>J Neurochem</source>
<volume>150</volume>, <fpage>522</fpage>&#x02013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">31254394</pub-id></mixed-citation></ref><ref id="ref028"><label>[28]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Melki</surname>
<given-names>R</given-names>
</string-name> (<year>2015</year>) <article-title>Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases</article-title>. <source>J Parkinsons Dis</source>
<volume>5</volume>, <fpage>217</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">25757830</pub-id></mixed-citation></ref><ref id="ref029"><label>[29]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bengoa-Vergniory</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Wade-Martins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alegre-Abarrategui</surname>
<given-names>J</given-names>
</string-name> (<year>2017</year>) <article-title>Alpha-synuclein oligomers: a new hope</article-title>. <source>Acta Neuropathol</source>
<volume>134</volume>, <fpage>819</fpage>&#x02013;<lpage>838</lpage>.<pub-id pub-id-type="pmid">28803412</pub-id></mixed-citation></ref><ref id="ref030"><label>[30]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lasagna-Reeves</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Guerrero-Munoz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Kiritoshi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Neugebauer</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2012</year>) <article-title>Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau</article-title>. <source>Sci Rep</source>
<volume>2</volume>, <fpage>700</fpage>.<pub-id pub-id-type="pmid">23050084</pub-id></mixed-citation></ref><ref id="ref031"><label>[31]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Larson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2012</year>) <article-title>Soluble A&#x003b2; oligomer production and toxicity</article-title>. <source>J Neurochem</source>
<volume>120 Suppl 1</volume>, <fpage>125</fpage>&#x02013;<lpage>139</lpage>.</mixed-citation></ref><ref id="ref032"><label>[32]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>LaCroix</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Amar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Larson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aguzzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Ramsden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2016</year>) <article-title>Soluble conformers of A&#x003b2; and tau alter selective proteins governing axonal transport</article-title>. <source>J Neurosci</source>
<volume>36</volume>, <fpage>9647</fpage>&#x02013;<lpage>9658</lpage>.<pub-id pub-id-type="pmid">27629715</pub-id></mixed-citation></ref><ref id="ref033"><label>[33]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Larson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Amar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nuvolone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Aguzzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2012</year>) <article-title>The complex PrP(c)-Fyn couples human oligomeric A&#x003b2; with pathological tau changes in Alzheimer&#x02019;s disease</article-title>. <source>J Neurosci</source>
<volume>32</volume>, <fpage>16857</fpage>&#x02013;<lpage>16871a</lpage>.<pub-id pub-id-type="pmid">23175838</pub-id></mixed-citation></ref><ref id="ref034"><label>[34]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Amar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Larson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>G&#x000f6;tz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Buisson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2017</year>) <article-title>The amyloid-&#x003b2; oligomer A&#x003b2;*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation</article-title>. <source>Sci Signal</source>
<volume>10</volume>, <fpage>eaal2021</fpage>.<pub-id pub-id-type="pmid">28487416</pub-id></mixed-citation></ref><ref id="ref035"><label>[35]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Stroh&#x000e4;ker</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Liou</surname>
<given-names>S-H</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>CO</given-names>
</string-name>, <string-name>
<surname>Riedel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Bennati</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S-J</given-names>
</string-name>, <string-name>
<surname>Zweckstetter</surname>
<given-names>M</given-names>
</string-name> (<year>2019</year>) <article-title>Structural heterogeneity of <italic>&#x003b1;</italic>-synuclein fibrils amplified from patient brain extracts</article-title>. <source>Nat Commun</source>
<volume>10</volume>, <fpage>5535</fpage>.<pub-id pub-id-type="pmid">31797870</pub-id></mixed-citation></ref><ref id="ref036"><label>[36]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Abeliovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schmitz</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fari&#x000f1;as</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Choi-Lundberg</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Castillo</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Shinsky</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Verdugo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Armanini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hynes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sulzer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>A</given-names>
</string-name> (<year>2000</year>) <article-title>Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system</article-title>. <source>Neuron</source>
<volume>25</volume>, <fpage>239</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">10707987</pub-id></mixed-citation></ref><ref id="ref037"><label>[37]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bendor</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Logan</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>RH</given-names>
</string-name> (<year>2013</year>) <article-title>The function of <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Neuron</source>
<volume>79</volume>, <fpage>1044</fpage>&#x02013;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">24050397</pub-id></mixed-citation></ref><ref id="ref038"><label>[38]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sulzer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>RH</given-names>
</string-name> (<year>2019</year>) <article-title>The physiological role of <italic>&#x003b1;</italic>-synuclein and its relationship to Parkinson&#x02019;s disease</article-title>. <source>J Neurochem</source>
<volume>150</volume>, <fpage>475</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">31269263</pub-id></mixed-citation></ref><ref id="ref039"><label>[39]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Logan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bendor</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Toupin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Thorn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>RH</given-names>
</string-name> (<year>2017</year>) <article-title><italic>&#x003b1;</italic>-Synuclein promotes dilation of the exocytotic fusion pore</article-title>. <source>Nat Neurosci</source>
<volume>20</volume>, <fpage>681</fpage>&#x02013;<lpage>689</lpage>.<pub-id pub-id-type="pmid">28288128</pub-id></mixed-citation></ref><ref id="ref040"><label>[40]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ben Gedalya</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Loeb</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Israeli</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Altschuler</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Sharon</surname>
<given-names>R</given-names>
</string-name> (<year>2009</year>) <article-title>Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling</article-title>. <source>Traffic</source>
<volume>10</volume>, <fpage>218</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">18980610</pub-id></mixed-citation></ref><ref id="ref041"><label>[41]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Vargas</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Makani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Westphal</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Castillo</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>SS</given-names>
</string-name> (<year>2014</year>) <article-title>Synucleins regulate the kinetics of synaptic vesicle endocytosis</article-title>. <source>J Neurosci</source>
<volume>34</volume>, <fpage>9364</fpage>&#x02013;<lpage>9376</lpage>.<pub-id pub-id-type="pmid">25009269</pub-id></mixed-citation></ref><ref id="ref042"><label>[42]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Vargas</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Schrod</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fernandez-Busnadiego</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Taguchi</surname>
<given-names>YV</given-names>
</string-name>, <string-name>
<surname>Laugks</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Lucic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>SS</given-names>
</string-name> (<year>2017</year>) <article-title>Synucleins have multiple effects on presynaptic architecture</article-title>. <source>Cell Rep</source>
<volume>18</volume>, <fpage>161</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">28052246</pub-id></mixed-citation></ref><ref id="ref043"><label>[43]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Roy</surname>
<given-names>S</given-names>
</string-name> (<year>2014</year>) <article-title><italic>&#x003b1;</italic>-synuclein multimers cluster synaptic vesicles and attenuate recycling</article-title>. <source>Curr Biol</source>
<volume>24</volume>, <fpage>2319</fpage>&#x02013;<lpage>2326</lpage>.<pub-id pub-id-type="pmid">25264250</pub-id></mixed-citation></ref><ref id="ref044"><label>[44]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Burr&#x000e9;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsetsenis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Buchman</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Etherton</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>S&#x000fc;dhof</surname>
<given-names>TC</given-names>
</string-name> (<year>2010</year>) <article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title>. <source>Science</source>
<volume>329</volume>, <fpage>1663</fpage>&#x02013;<lpage>1667</lpage>.<pub-id pub-id-type="pmid">20798282</pub-id></mixed-citation></ref><ref id="ref045"><label>[45]</label><mixed-citation publication-type="journal">
<string-name>
<surname>DeWitt</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Rhoades</surname>
<given-names>E</given-names>
</string-name> (<year>2013</year>) <article-title><italic>&#x003b1;</italic>-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers</article-title>. <source>Biochemistry</source>
<volume>52</volume>, <fpage>2385</fpage>&#x02013;<lpage>2387</lpage>.<pub-id pub-id-type="pmid">23528131</pub-id></mixed-citation></ref><ref id="ref046"><label>[46]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Nuscher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kamp</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mehnert</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Odoy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haass</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kahle</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Beyer</surname>
<given-names>K</given-names>
</string-name> (<year>2004</year>) <article-title>Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study</article-title>. <source>J Biol Chem</source>
<volume>279</volume>, <fpage>21966</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">15028717</pub-id></mixed-citation></ref><ref id="ref047"><label>[47]</label><mixed-citation publication-type="journal">
<string-name>
<surname>George</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Clayton</surname>
<given-names>DF</given-names>
</string-name> (<year>1995</year>) <article-title>Characterization of a novel protein regulated during the critical period for song learning in the zebra finch</article-title>. <source>Neuron</source>
<volume>15</volume>, <fpage>361</fpage>&#x02013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">7646890</pub-id></mixed-citation></ref><ref id="ref048"><label>[48]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Maroteaux</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scheller</surname>
<given-names>RH</given-names>
</string-name> (<year>1991</year>) <article-title>The rat brain synucleins; family of proteins transiently associated with neuronal membrane</article-title>. <source>Brain Res Mol Brain Res</source>
<volume>11</volume>, <fpage>335</fpage>&#x02013;<lpage>343</lpage>.<pub-id pub-id-type="pmid">1661825</pub-id></mixed-citation></ref><ref id="ref049"><label>[49]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Withers</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Banker</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Clayton</surname>
<given-names>DF</given-names>
</string-name> (<year>1997</year>) <article-title>Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons</article-title>. <source>Brain Res Dev Brain Res</source>
<volume>99</volume>, <fpage>87</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">9088569</pub-id></mixed-citation></ref><ref id="ref050"><label>[50]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jensen</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Bhatia</surname>
<given-names>VK</given-names>
</string-name>, <string-name>
<surname>Jao</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Langen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stamou</surname>
<given-names>D</given-names>
</string-name> (<year>2011</year>) <article-title>Membrane curvature sensing by amphipathic helices: a single liposome study using alpha-synuclein and annexin B12</article-title>. <source>J Biol Chem</source>
<volume>286</volume>, <fpage>42603</fpage>&#x02013;<lpage>42614</lpage>.<pub-id pub-id-type="pmid">21953452</pub-id></mixed-citation></ref><ref id="ref051"><label>[51]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Alderson</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Markley</surname>
<given-names>JL</given-names>
</string-name> (<year>2013</year>) <article-title>Biophysical characterization of <italic>&#x003b1;</italic>-synuclein and its controversial structure</article-title>. <source>Intrinsically Disord Proteins</source>
<volume>1</volume>, <fpage>e26255</fpage>.</mixed-citation></ref><ref id="ref052"><label>[52]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wietek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haralampiev</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Amoussouvi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>St&#x000f6;ckl</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>Membrane bound <italic>&#x003b1;</italic>-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain</article-title>. <source>FEBS Lett</source>
<volume>587</volume>, <fpage>2572</fpage>&#x02013;<lpage>2577</lpage>.<pub-id pub-id-type="pmid">23831067</pub-id></mixed-citation></ref><ref id="ref053"><label>[53]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tsigelny</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Sharikov</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wrasidlo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Desplats</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Crews</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2012</year>) <article-title>Role of <italic>&#x003b1;</italic>-synuclein penetration into the membrane in the mechanisms of oligomer pore formation</article-title>. <source>FEBS J</source>
<volume>279</volume>, <fpage>1000</fpage>&#x02013;<lpage>1013</lpage>.<pub-id pub-id-type="pmid">22251432</pub-id></mixed-citation></ref><ref id="ref054"><label>[54]</label><mixed-citation publication-type="journal">
<string-name>
<surname>West</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brummel</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Rhoades</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>JN</given-names>
</string-name> (<year>2016</year>) <article-title>Membrane remodeling and mechanics: Experiments and simulations of <italic>&#x003b1;</italic>-Synuclein</article-title>. <source>Biochim Biophys Acta</source>
<volume>1858</volume>, <fpage>1594</fpage>&#x02013;<lpage>1609</lpage>.<pub-id pub-id-type="pmid">26972046</pub-id></mixed-citation></ref><ref id="ref055"><label>[55]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Cheng</surname>
<given-names>C-Y</given-names>
</string-name>, <string-name>
<surname>Varkey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ambroso</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Langen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>S</given-names>
</string-name> (<year>2013</year>) <article-title>Hydration dynamics as an intrinsic ruler for refining protein structure at lipid membrane interfaces</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>110</volume>, <fpage>16838</fpage>&#x02013;<lpage>16843</lpage>.<pub-id pub-id-type="pmid">24082088</pub-id></mixed-citation></ref><ref id="ref056"><label>[56]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jao</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Hegde</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haworth</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Langen</surname>
<given-names>R</given-names>
</string-name> (<year>2008</year>) <article-title>Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>105</volume>, <fpage>19666</fpage>&#x02013;<lpage>19671</lpage>.<pub-id pub-id-type="pmid">19066219</pub-id></mixed-citation></ref><ref id="ref057"><label>[57]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Diao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>C</given-names>
</string-name> (<year>2016</year>) <article-title>Versatile structures of <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Front Mol Neurosci</source>
<volume>9</volume>, <fpage>48</fpage>.<pub-id pub-id-type="pmid">27378848</pub-id></mixed-citation></ref><ref id="ref058"><label>[58]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name> (<year>2018</year>) <article-title>Rationally designed variants of <italic>&#x003b1;</italic>-synuclein illuminate its in vivo structural properties in health and disease</article-title>. <source>Front Neurosci</source>
<volume>12</volume>, <fpage>623</fpage>.<pub-id pub-id-type="pmid">30319334</pub-id></mixed-citation></ref><ref id="ref059"><label>[59]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Yeboah</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>T-E</given-names>
</string-name>, <string-name>
<surname>Bill</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name> (<year>2019</year>) <article-title>Dynamic behaviors of <italic>&#x003b1;</italic>-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration</article-title>. <source>Neurobiol Dis</source>
<volume>132</volume>, <fpage>104543</fpage>.<pub-id pub-id-type="pmid">31351173</pub-id></mixed-citation></ref><ref id="ref060"><label>[60]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rovere</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sanderson</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Fonseca-Ornelas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name> (<year>2018</year>) <article-title>Refolding of helical soluble <italic>&#x003b1;</italic>-synuclein through transient interaction with lipid interfaces</article-title>. <source>FEBS Lett</source>
<volume>592</volume>, <fpage>1464</fpage>&#x02013;<lpage>1472</lpage>.<pub-id pub-id-type="pmid">29633780</pub-id></mixed-citation></ref><ref id="ref061"><label>[61]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Weinreb</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Zhen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Poon</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Conway</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Lansbury</surname>
<given-names>PT</given-names>
<suffix>Jr</suffix>
</string-name> (<year>1996</year>) <article-title>NACP, a protein implicated in Alzheimer&#x02019;s disease and learning, is natively unfolded</article-title>. <source>Biochemistry</source>
<volume>35</volume>, <fpage>13709</fpage>&#x02013;<lpage>13715</lpage>.<pub-id pub-id-type="pmid">8901511</pub-id></mixed-citation></ref><ref id="ref062"><label>[62]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Ramalingam</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>von Saucken</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>T-E</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Terry-Kantor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nuber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ericsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fanning</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name> (<year>2017</year>) <article-title>Loss of native <italic>&#x003b1;</italic>-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells</article-title>. <source>Hum Mol Genet</source>
<volume>26</volume>, <fpage>3466</fpage>&#x02013;<lpage>3481</lpage>.<pub-id pub-id-type="pmid">28911198</pub-id></mixed-citation></ref><ref id="ref063"><label>[63]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Iljina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tosatto</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Sang</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Gandhi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klenerman</surname>
<given-names>D</given-names>
</string-name> (<year>2016</year>) <article-title>Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein</article-title>. <source>Sci Rep</source>
<volume>6</volume>, <fpage>33928</fpage>.<pub-id pub-id-type="pmid">27671749</pub-id></mixed-citation></ref><ref id="ref064"><label>[64]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gurry</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ullman</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Perovic</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Pochapsky</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stultz</surname>
<given-names>CM</given-names>
</string-name> (<year>2013</year>) <article-title>The dynamic structure of <italic>&#x003b1;</italic>-synuclein multimers</article-title>. <source>J Am Chem Soc</source>
<volume>135</volume>, <fpage>3865</fpage>&#x02013;<lpage>3872</lpage>.<pub-id pub-id-type="pmid">23398399</pub-id></mixed-citation></ref><ref id="ref065"><label>[65]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Umanah</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Bandaru</surname>
<given-names>VVR</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Rhee</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Karuppagounder</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>
<given-names>S-H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pandey</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>HS</given-names>
</string-name> (<year>2018</year>) <article-title>GBA1 deficiency negatively affects physiological <italic>&#x003b1;</italic>-synuclein tetramers and related multimers</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>115</volume>, <fpage>798</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">29311330</pub-id></mixed-citation></ref><ref id="ref066"><label>[66]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Luth</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</string-name> (<year>2015</year>) <article-title>Purification of <italic>&#x003b1;</italic>-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity</article-title>. <source>Biochemistry</source>
<volume>54</volume>, <fpage>279</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">25490121</pub-id></mixed-citation></ref><ref id="ref067"><label>[67]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Burr&#x000e9;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>S&#x000fc;dhof</surname>
<given-names>TC</given-names>
</string-name> (<year>2014</year>) <article-title><italic>&#x003b1;</italic>-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>111</volume>, <fpage>E4274</fpage>&#x02013;<lpage>4283</lpage>.<pub-id pub-id-type="pmid">25246573</pub-id></mixed-citation></ref><ref id="ref068"><label>[68]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</string-name> (<year>2011</year>) <article-title><italic>&#x003b1;</italic>-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation</article-title>. <source>Nature</source>
<volume>477</volume>, <fpage>107</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">21841800</pub-id></mixed-citation></ref><ref id="ref069"><label>[69]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Perovic</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Chittuluru</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaganovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>LTT</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Auclair</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Landeru</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Simorellis</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Ju</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Asturias</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Agar</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ringe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Petsko</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Pochapsky</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Hoang</surname>
<given-names>QQ</given-names>
</string-name> (<year>2011</year>) <article-title>A soluble <italic>&#x003b1;</italic>-synuclein construct forms a dynamic tetramer</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>108</volume>, <fpage>17797</fpage>&#x02013;<lpage>17802</lpage>.<pub-id pub-id-type="pmid">22006323</pub-id></mixed-citation></ref><ref id="ref070"><label>[70]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>von Saucken</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name> (<year>2015</year>) <article-title>KTKEGV repeat motifs are key mediators of normal <italic>&#x003b1;</italic>-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>112</volume>, <fpage>9596</fpage>&#x02013;<lpage>9601</lpage>.<pub-id pub-id-type="pmid">26153422</pub-id></mixed-citation></ref><ref id="ref071"><label>[71]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Soldner</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Luth</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>von Saucken</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Sanderson</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name> (<year>2015</year>) <article-title>Parkinson-causing <italic>&#x003b1;</italic>-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation</article-title>. <source>Nat Commun</source>
<volume>6</volume>, <fpage>7314</fpage>.<pub-id pub-id-type="pmid">26076669</pub-id></mixed-citation></ref><ref id="ref072"><label>[72]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Pochapsky</surname>
<given-names>TC</given-names>
</string-name> (<year>2015</year>) <article-title>From intrinsically disordered protein to context-dependent folding: The <italic>&#x003b1;</italic>-synuclein tetramer is teased out of hiding</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>112</volume>, <fpage>9502</fpage>&#x02013;<lpage>9503</lpage>.<pub-id pub-id-type="pmid">26204916</pub-id></mixed-citation></ref><ref id="ref073"><label>[73]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Nuber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rajsombath</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Minakaki</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Ericsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caldarone</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</string-name> (<year>2018</year>) <article-title>Abrogating native <italic>&#x003b1;</italic>-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson&#x02019;s disease</article-title>. <source>Neuron</source>
<volume>100</volume>, <fpage>75</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">30308173</pub-id></mixed-citation></ref><ref id="ref074"><label>[74]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Westphal</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>SS</given-names>
</string-name> (<year>2013</year>) <article-title>Monomeric synucleins generate membrane curvature</article-title>. <source>J Biol Chem</source>
<volume>288</volume>, <fpage>1829</fpage>&#x02013;<lpage>1840</lpage>.<pub-id pub-id-type="pmid">23184946</pub-id></mixed-citation></ref><ref id="ref075"><label>[75]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Luth</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name> (<year>2013</year>) <article-title>In vivo cross-linking reveals principally oligomeric forms of <italic>&#x003b1;</italic>-synuclein and &#x003b2;-synuclein in neurons and non-neural cells</article-title>. <source>J Biol Chem</source>
<volume>288</volume>, <fpage>6371</fpage>&#x02013;<lpage>6385</lpage>.<pub-id pub-id-type="pmid">23319586</pub-id></mixed-citation></ref><ref id="ref076"><label>[76]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Trexler</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Rhoades</surname>
<given-names>E</given-names>
</string-name> (<year>2012</year>) <article-title>N-Terminal acetylation is critical for forming <italic>&#x003b1;</italic>-helical oligomer of <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Protein Sci</source>
<volume>21</volume>, <fpage>601</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">22407793</pub-id></mixed-citation></ref><ref id="ref077"><label>[77]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Fauvet</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mbefo</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Fares</surname>
<given-names>M-B</given-names>
</string-name>, <string-name>
<surname>Desobry</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Michael</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ardah</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Tsika</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Coune</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Prudent</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lion</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Eliezer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Aebischer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</string-name> (<year>2012</year>) <article-title><italic>&#x003b1;</italic>-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer</article-title>. <source>J Biol Chem</source>
<volume>287</volume>, <fpage>15345</fpage>&#x02013;<lpage>15364</lpage>.<pub-id pub-id-type="pmid">22315227</pub-id></mixed-citation></ref><ref id="ref078"><label>[78]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Burr&#x000e9;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vivona</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Diao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brunger</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>S&#x000fc;dhof</surname>
<given-names>TC</given-names>
</string-name> (<year>2013</year>) <article-title>Properties of native brain <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Nature</source>
<volume>498</volume>, <fpage>E4</fpage>&#x02013;<lpage>6</lpage>; discussion E6-7.<pub-id pub-id-type="pmid">23765500</pub-id></mixed-citation></ref><ref id="ref079"><label>[79]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gould</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mor</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Lightfoot</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Malkus</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ischiropoulos</surname>
<given-names>H</given-names>
</string-name> (<year>2014</year>) <article-title>Evidence of native alpha-synuclein conformers in the human brain</article-title>. <source>J Biol Chem</source>
<volume>289</volume>, <fpage>7929</fpage>&#x02013;<lpage>7934</lpage>.<pub-id pub-id-type="pmid">24474688</pub-id></mixed-citation></ref><ref id="ref080"><label>[80]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Burr&#x000e9;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>S&#x000fc;dhof</surname>
<given-names>TC</given-names>
</string-name> (<year>2015</year>) <article-title>Definition of a molecular pathway mediating <italic>&#x003b1;</italic>-synuclein neurotoxicity</article-title>. <source>J Neurosci</source>
<volume>35</volume>, <fpage>5221</fpage>&#x02013;<lpage>5232</lpage>.<pub-id pub-id-type="pmid">25834048</pub-id></mixed-citation></ref><ref id="ref081"><label>[81]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Corbill&#x000e9;</surname>
<given-names>A-G</given-names>
</string-name>, <string-name>
<surname>Neunlist</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Derkinderen</surname>
<given-names>P</given-names>
</string-name> (<year>2016</year>) <article-title>Cross-linking for the analysis of <italic>&#x003b1;</italic>-synuclein in the enteric nervous system</article-title>. <source>J Neurochem</source>
<volume>139</volume>, <fpage>839</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">27637918</pub-id></mixed-citation></ref><ref id="ref082"><label>[82]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Killinger</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Moszczynska</surname>
<given-names>A</given-names>
</string-name> (<year>2016</year>) <article-title>Characterization of <italic>&#x003b1;</italic>-synuclein multimer stoichiometry in complex biological samples by electrophoresis</article-title>. <source>Anal Chem</source>
<volume>88</volume>, <fpage>4071</fpage>&#x02013;<lpage>4084</lpage>.<pub-id pub-id-type="pmid">26937787</pub-id></mixed-citation></ref><ref id="ref083"><label>[83]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Binolfi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Theillet</surname>
<given-names>F-X</given-names>
</string-name>, <string-name>
<surname>Selenko</surname>
<given-names>P</given-names>
</string-name> (<year>2012</year>) <article-title>Bacterial in-cell NMR of human <italic>&#x003b1;</italic>-synuclein: a disordered monomer by nature?</article-title>
<source>Biochem Soc Trans</source>
<volume>40</volume>, <fpage>950</fpage>&#x02013;<lpage>954</lpage>.<pub-id pub-id-type="pmid">22988846</pub-id></mixed-citation></ref><ref id="ref084"><label>[84]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Theillet</surname>
<given-names>F-X</given-names>
</string-name>, <string-name>
<surname>Binolfi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bekei</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Martorana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Stuiver</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Verzini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lorenz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>van Rossum</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goldfarb</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Selenko</surname>
<given-names>P</given-names>
</string-name> (<year>2016</year>) <article-title>Structural disorder of monomeric <italic>&#x003b1;</italic>-synuclein persists in mammalian cells</article-title>. <source>Nature</source>
<volume>530</volume>, <fpage>45</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">26808899</pub-id></mixed-citation></ref><ref id="ref085"><label>[85]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Alderson</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Bax</surname>
<given-names>A</given-names>
</string-name> (<year>2016</year>) <article-title>Parkinson&#x02019;s disease: Disorder in the court</article-title>. <source>Nature</source>
<volume>530</volume>, <fpage>38</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">26808901</pub-id></mixed-citation></ref><ref id="ref086"><label>[86]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sharon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bar-Joseph</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Frosch</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</string-name> (<year>2003</year>) <article-title>The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson&#x02019;s disease</article-title>. <source>Neuron</source>
<volume>37</volume>, <fpage>583</fpage>&#x02013;<lpage>595</lpage>.<pub-id pub-id-type="pmid">12597857</pub-id></mixed-citation></ref><ref id="ref087"><label>[87]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Roberts</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Bengoa-Vergniory</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Alegre-Abarrategui</surname>
<given-names>J</given-names>
</string-name> (<year>2019</year>) <article-title>Alpha-synuclein proximity ligation assay (AS-PLA) in brain sections to probe for alpha-synuclein oligomers</article-title>. <source>Methods Mol Biol</source>
<volume>1948</volume>, <fpage>69</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">30771171</pub-id></mixed-citation></ref><ref id="ref088"><label>[88]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Roberts</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Wade-Martins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alegre-Abarrategui</surname>
<given-names>J</given-names>
</string-name> (<year>2015</year>) <article-title>Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson&#x02019;s disease brain</article-title>. <source>Brain</source>
<volume>138</volume>, <fpage>1642</fpage>&#x02013;<lpage>1657</lpage>.<pub-id pub-id-type="pmid">25732184</pub-id></mixed-citation></ref><ref id="ref089"><label>[89]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Guerrero-Mu&#x000f1;oz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Lasagna-Reeves</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Paulucci-Holthauzen</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Krishnamurthy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Farhed</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2015</year>) <article-title>Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies</article-title>. <source>Biol Psychiatry</source>
<volume>78</volume>, <fpage>672</fpage>&#x02013;<lpage>683</lpage>.<pub-id pub-id-type="pmid">25676491</pub-id></mixed-citation></ref><ref id="ref090"><label>[90]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Majbour</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Chiasserini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vaikath</surname>
<given-names>NN</given-names>
</string-name>, <string-name>
<surname>Eusebi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tokuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Berg</surname>
<given-names>W van de</given-names>
</string-name>, <string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Calabresi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OMA</given-names>
</string-name> (<year>2017</year>) <article-title>Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer&#x02019;s disease</article-title>. <source>Sci Rep</source>
<volume>7</volume>, <fpage>40263</fpage>.<pub-id pub-id-type="pmid">28071698</pub-id></mixed-citation></ref><ref id="ref091"><label>[91]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Park</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cheon</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JW</given-names>
</string-name> (<year>2011</year>) <article-title>Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson&#x02019;s disease</article-title>. <source>J Clin Neurol</source>
<volume>7</volume>, <fpage>215</fpage>&#x02013;<lpage>222</lpage>.<pub-id pub-id-type="pmid">22259618</pub-id></mixed-citation></ref><ref id="ref092"><label>[92]</label><mixed-citation publication-type="journal">
<string-name>
<surname>El-Agnaf</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Salem</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Paleologou</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Curran</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Court</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Schlossmacher</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Allsop</surname>
<given-names>D</given-names>
</string-name> (<year>2006</year>) <article-title>Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson&#x02019;s disease</article-title>. <source>FASEB J</source>
<volume>20</volume>, <fpage>419</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">16507759</pub-id></mixed-citation></ref><ref id="ref093"><label>[93]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chiasserini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bellomo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Giannandrea</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>De Carlo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Qureshi</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Ardah</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Varghese</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bonanni</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Borroni</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tambasco</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Eusebi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Onofrj</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Padovani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Calabresi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>O</given-names>
</string-name> (<year>2011</year>) <article-title>Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson&#x02019;s disease and degenerative dementias</article-title>. <source>Mov Disord</source>
<volume>26</volume>, <fpage>1428</fpage>&#x02013;<lpage>1435</lpage>.<pub-id pub-id-type="pmid">21469206</pub-id></mixed-citation></ref><ref id="ref094"><label>[94]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>&#x000d6;hrfelt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Minthon</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>N&#x000e4;gga</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Londos</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Varghese</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Majbour</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Al-Hayani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OM</given-names>
</string-name> (<year>2014</year>) <article-title>Levels of cerebrospinal fluid <italic>&#x003b1;</italic>-synuclein oligomers are increased in Parkinson&#x02019;s disease with dementia and dementia with Lewy bodies compared to Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Res Ther</source>
<volume>6</volume>, <fpage>25</fpage>.<pub-id pub-id-type="pmid">24987465</pub-id></mixed-citation></ref><ref id="ref095"><label>[95]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sierks</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Chatterjee</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>McGraw</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kasturirangan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Prasad</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>) <article-title>CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease</article-title>. <source>Integr Biol (Camb)</source>
<volume>3</volume>, <fpage>1188</fpage>&#x02013;<lpage>1196</lpage>.<pub-id pub-id-type="pmid">22076255</pub-id></mixed-citation></ref><ref id="ref096"><label>[96]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Emmanouilidou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Melachroinou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Roumeliotis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Garbis</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Ntzouni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Margaritis</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Stefanis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vekrellis</surname>
<given-names>K</given-names>
</string-name> (<year>2010</year>) <article-title>Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival</article-title>. <source>J Neurosci</source>
<volume>30</volume>, <fpage>6838</fpage>&#x02013;<lpage>6851</lpage>.<pub-id pub-id-type="pmid">20484626</pub-id></mixed-citation></ref><ref id="ref097"><label>[97]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Danzer</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Haasen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Karow</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Moussaud</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Habeck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kretzschmar</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hengerer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kostka</surname>
<given-names>M</given-names>
</string-name> (<year>2007</year>) <article-title>Different species of alpha-synuclein oligomers induce calcium influx and seeding</article-title>. <source>J Neurosci</source>
<volume>27</volume>, <fpage>9220</fpage>&#x02013;<lpage>9232</lpage>.<pub-id pub-id-type="pmid">17715357</pub-id></mixed-citation></ref><ref id="ref098"><label>[98]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Stirling</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Qui</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mandir</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Copeland</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Jenkins</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>DL</given-names>
</string-name> (<year>2002</year>) <article-title>Human alpha-synuclein-harboring familial Parkinson&#x02019;s disease-linked Ala-53 &#x02013;&#x0003e;Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>99</volume>, <fpage>8968</fpage>&#x02013;<lpage>8973</lpage>.<pub-id pub-id-type="pmid">12084935</pub-id></mixed-citation></ref><ref id="ref099"><label>[99]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Colla</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Glabe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name> (<year>2012</year>) <article-title>Accumulation of toxic <italic>&#x003b1;</italic>-synuclein oligomer within endoplasmic reticulum occurs in <italic>&#x003b1;</italic>-synucleinopathy {in vivo</article-title>. <source>J Neurosci</source>
<volume>32</volume>, <fpage>3301</fpage>&#x02013;<lpage>3305</lpage>.<pub-id pub-id-type="pmid">22399752</pub-id></mixed-citation></ref><ref id="ref100"><label>[100]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Paleologou</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Kragh</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Salem</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Al-Shami</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Allsop</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hassan</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OM</given-names>
</string-name> (<year>2009</year>) <article-title>Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies</article-title>. <source>Brain</source>
<volume>132</volume>, <fpage>1093</fpage>&#x02013;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">19155272</pub-id></mixed-citation></ref><ref id="ref101"><label>[101]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zarranz</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Alegre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez-Esteban</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Lezcano</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ros</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ampuero</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Vidal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hoenicka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Atar&#x000e9;s</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Llorens</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gomez Tortosa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>del Ser</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>de Yebenes</surname>
<given-names>JG</given-names>
</string-name> (<year>2004</year>) <article-title>The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia</article-title>. <source>Ann Neurol</source>
<volume>55</volume>, <fpage>164</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">14755719</pub-id></mixed-citation></ref><ref id="ref102"><label>[102]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Emmer</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Waxman</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Covy</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>BI</given-names>
</string-name> (<year>2011</year>) <article-title>E46K human <italic>&#x003b1;</italic>-synuclein transgenic mice develop lewy-like and tau pathology associated with age-dependent, detrimental motor impairment</article-title>. <source>J Biol Chem</source>
<volume>286</volume>, <fpage>35104</fpage>&#x02013;<lpage>35118</lpage>.<pub-id pub-id-type="pmid">21846727</pub-id></mixed-citation></ref><ref id="ref103"><label>[103]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Samuel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Flavin</surname>
<given-names>WP</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pacelli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sri Renganathan</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Trudeau</surname>
<given-names>L-E</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Tandon</surname>
<given-names>A</given-names>
</string-name> (<year>2016</year>) <article-title>Effects of serine 129 phosphorylation on <italic>&#x003b1;</italic>-synuclein aggregation, membrane association, and internalization</article-title>. <source>J Biol Chem</source>
<volume>291</volume>, <fpage>4374</fpage>&#x02013;<lpage>4385</lpage>.<pub-id pub-id-type="pmid">26719332</pub-id></mixed-citation></ref><ref id="ref104"><label>[104]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Foulds</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Yokota</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Thurston</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Holton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Akiyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Arai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gerhard</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Allsop</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>DM</given-names>
</string-name> (<year>2012</year>) <article-title>Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson&#x02019;s disease and dementia with Lewy bodies</article-title>. <source>Neurobiol Dis</source>
<volume>45</volume>, <fpage>188</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">21856424</pub-id></mixed-citation></ref><ref id="ref105"><label>[105]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sekiya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kowa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Koga</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takata</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Satake</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Futamura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Funakawa</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Jinnai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ueno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kanagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Toda</surname>
<given-names>T</given-names>
</string-name> (<year>2019</year>) <article-title>Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation</article-title>. <source>Acta Neuropathol</source>
<volume>137</volume>, <fpage>455</fpage>&#x02013;<lpage>466</lpage>.<pub-id pub-id-type="pmid">30721406</pub-id></mixed-citation></ref><ref id="ref106"><label>[106]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lippa</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Fujiwara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Baba</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Nee</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Connell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pollen</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>St George-Hyslop</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ghetti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nochlin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Cairns</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name> (<year>1998</year>) <article-title>Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer&#x02019;s disease patients with mutations in presenilin and amyloid precursor protein genes</article-title>. <source>Am J Pathol</source>
<volume>153</volume>, <fpage>1365</fpage>&#x02013;<lpage>1370</lpage>.<pub-id pub-id-type="pmid">9811326</pub-id></mixed-citation></ref><ref id="ref107"><label>[107]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Larson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Greimel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kuskowski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2012</year>) <article-title>Soluble <italic>&#x003b1;</italic>-synuclein is a novel modulator of Alzheimer&#x02019;s disease pathophysiology</article-title>. <source>J Neurosci</source>
<volume>32</volume>, <fpage>10253</fpage>&#x02013;<lpage>10266</lpage>.<pub-id pub-id-type="pmid">22836259</pub-id></mixed-citation></ref><ref id="ref108"><label>[108]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Larson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Greimel</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Amar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>LaCroix</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Schley</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Benfenati</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name> (<year>2017</year>) <article-title>Selective lowering of synapsins induced by oligomeric <italic>&#x003b1;</italic>-synuclein exacerbates memory deficits</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>114</volume>, <fpage>E4648</fpage>&#x02013;<lpage>E4657</lpage>.<pub-id pub-id-type="pmid">28533388</pub-id></mixed-citation></ref><ref id="ref109"><label>[109]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Nemani</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Berge</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Onoa</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Chaudhry</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Nicoll</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>RH</given-names>
</string-name> (<year>2010</year>) <article-title>Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis</article-title>. <source>Neuron</source>
<volume>65</volume>, <fpage>66</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">20152114</pub-id></mixed-citation></ref><ref id="ref110"><label>[110]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gaetani</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Eusebi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Paciotti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Mollenhauer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Calabresi</surname>
<given-names>P</given-names>
</string-name> (<year>2019</year>) <article-title>CSF and blood biomarkers for Parkinson&#x02019;s disease</article-title>. <source>Lancet Neurol</source>
<volume>18</volume>, <fpage>573</fpage>&#x02013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">30981640</pub-id></mixed-citation></ref><ref id="ref111"><label>[111]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Mollenhauer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Locascio</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Schulz-Schaeffer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sixel-D&#x000f6;ring</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Trenkwalder</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schlossmacher</surname>
<given-names>MG</given-names>
</string-name> (<year>2011</year>) <article-title><italic>&#x003b1;</italic>-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study</article-title>. <source>Lancet Neurol</source>
<volume>10</volume>, <fpage>230</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">21317042</pub-id></mixed-citation></ref><ref id="ref112"><label>[112]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Twohig</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rodriguez-Vieitez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sando</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Berge</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lauridsen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>M&#x000f8;ller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gr&#x000f8;ntvedt</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Br&#x000e5;then</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Patra</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Benzinger</surname>
<given-names>TLS</given-names>
</string-name>, <string-name>
<surname>Karch</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Fagan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Bateman</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Nordberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>HM</given-names>
</string-name>, <collab>Dominantly Inherited Alzheimer Network (DIAN)</collab> (<year>2018</year>) <article-title>The relevance of cerebrospinal fluid <italic>&#x003b1;</italic>-synuclein levels to sporadic and familial Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol Commun</source>
<volume>6</volume>, <fpage>130</fpage>.<pub-id pub-id-type="pmid">30477568</pub-id></mixed-citation></ref><ref id="ref113"><label>[113]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Toledo</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Korff</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name> (<year>2013</year>) <article-title>CSF <italic>&#x003b1;</italic>-synuclein improves diagnostic and prognostic performance of CSF tau and A&#x003b2; in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source>
<volume>126</volume>, <fpage>683</fpage>&#x02013;<lpage>697</lpage>.<pub-id pub-id-type="pmid">23812319</pub-id></mixed-citation></ref><ref id="ref114"><label>[114]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Slaets</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vanmechelen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Le Bastard</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Decraemer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Vandijck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>J-J</given-names>
</string-name>, <string-name>
<surname>De Deyn</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Engelborghs</surname>
<given-names>S</given-names>
</string-name> (<year>2014</year>) <article-title>Increased CSF <italic>&#x003b1;</italic>-synuclein levels in Alzheimer&#x02019;s disease: correlation with tau levels</article-title>. <source>Alzheimers Dement</source>
<volume>10</volume>, <fpage>S290</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">24439167</pub-id></mixed-citation></ref><ref id="ref115"><label>[115]</label><mixed-citation publication-type="journal">
<string-name>
<surname>van Steenoven</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Majbour</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Vaikath</surname>
<given-names>NN</given-names>
</string-name>, <string-name>
<surname>Berendse</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>van der Flier</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>van de Berg</surname>
<given-names>WDJ</given-names>
</string-name>, <string-name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Lemstra</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OMA</given-names>
</string-name> (<year>2018</year>) <article-title><italic>&#x003b1;</italic>-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies</article-title>. <source>Mov Disord</source>
<volume>33</volume>, <fpage>1724</fpage>&#x02013;<lpage>1733</lpage>.<pub-id pub-id-type="pmid">30440090</pub-id></mixed-citation></ref><ref id="ref116"><label>[116]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Vaikath</surname>
<given-names>NN</given-names>
</string-name>, <string-name>
<surname>Majbour</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Paleologou</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Ardah</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>van Dam</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van de Berg</surname>
<given-names>WDJ</given-names>
</string-name>, <string-name>
<surname>Forrest</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Parkkinen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gai</surname>
<given-names>W-P</given-names>
</string-name>, <string-name>
<surname>Hattori</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Takanashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S-J</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>DMA</given-names>
</string-name>, <string-name>
<surname>Imai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J-Yi</given-names>
</string-name>, <string-name>
<surname>El-Agnaf</surname>
<given-names>OMA</given-names>
</string-name> (<year>2015</year>) <article-title>Generation and characterization of novel conformation-specific monoclonal antibodies for <italic>&#x003b1;</italic>-synuclein pathology</article-title>. <source>Neurobiol Dis</source>
<volume>79</volume>, <fpage>81</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">25937088</pub-id></mixed-citation></ref><ref id="ref117"><label>[117]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bates</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Dorsey</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gusella</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Hayden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Kay</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Leavitt</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Nance</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Scahill</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Wetzel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wild</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Tabrizi</surname>
<given-names>SJ</given-names>
</string-name> (<year>2015</year>) <article-title>Huntington disease</article-title>. <source>Nat Rev Dis Primers</source>
<volume>1</volume>, <fpage>15005</fpage>.<pub-id pub-id-type="pmid">27188817</pub-id></mixed-citation></ref><ref id="ref118"><label>[118]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chhatwal</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Benzinger</surname>
<given-names>TLS</given-names>
</string-name>, <string-name>
<surname>Jack</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ances</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Salloway</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Ringman</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Koeppe</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Marcus</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Saykin</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Correia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schofield</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Brickman</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>McDade</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bateman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fagan</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Goate</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buckles</surname>
<given-names>VD</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Sperling</surname>
<given-names>RA</given-names>
</string-name> (<year>2013</year>) <article-title>Impaired default network functional connectivity in autosomal dominant Alzheimer disease</article-title>. <source>Neurology</source>
<volume>81</volume>, <fpage>736</fpage>&#x02013;<lpage>744</lpage>.<pub-id pub-id-type="pmid">23884042</pub-id></mixed-citation></ref><ref id="ref119"><label>[119]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Schultz</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Chhatwal</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Hedden</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mormino</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Hanseeuw</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Sepulcre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huijbers</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>LaPoint</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Buckley</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Sperling</surname>
<given-names>RA</given-names>
</string-name> (<year>2017</year>) <article-title>Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals</article-title>. <source>J Neurosci</source>
<volume>37</volume>, <fpage>4323</fpage>&#x02013;<lpage>4331</lpage>.<pub-id pub-id-type="pmid">28314821</pub-id></mixed-citation></ref><ref id="ref120"><label>[120]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ward</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Mormino</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Huijbers</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Hedden</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sperling</surname>
<given-names>RA</given-names>
</string-name> (<year>2015</year>) <article-title>Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits</article-title>. <source>Neurobiol Aging</source>
<volume>36</volume>, <fpage>265</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">25113793</pub-id></mixed-citation></ref><ref id="ref121"><label>[121]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Medeiros</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Soll</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Tessari</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bubacco</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>JR</given-names>
</string-name> (<year>2017</year>) <article-title><italic>&#x003b1;</italic>-Synuclein dimers impair vesicle fission during clathrin-mediated synaptic vesicle recycling</article-title>. <source>Front Cell Neurosci</source>
<volume>11</volume>, <fpage>388</fpage>.<pub-id pub-id-type="pmid">29321725</pub-id></mixed-citation></ref><ref id="ref122"><label>[122]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Souza</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name>, <string-name>
<surname>Ischiropoulos</surname>
<given-names>H</given-names>
</string-name> (<year>2000</year>) <article-title>Dityrosine cross-linking promotes formation of stable <italic>&#x003b1;</italic>-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies</article-title>. <source>J Biol Chem</source>
<volume>275</volume>, <fpage>18344</fpage>&#x02013;<lpage>18349</lpage>.<pub-id pub-id-type="pmid">10747881</pub-id></mixed-citation></ref><ref id="ref123"><label>[123]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Masuda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Taniguchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nonaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hisanaga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>) <article-title>Small molecule inhibitors of <italic>&#x003b1;</italic>-synuclein filament assembly</article-title>. <source>Biochemistry</source>
<volume>45</volume>, <fpage>6085</fpage>&#x02013;<lpage>6094</lpage>.<pub-id pub-id-type="pmid">16681381</pub-id></mixed-citation></ref><ref id="ref124"><label>[124]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nuber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Overk</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Ubhi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mante</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Patrick</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Adame</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Trejo-Morales</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gerez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Picotti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Campioni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Riek</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gage</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Winner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2014</year>) <article-title>Accumulation of oligomer-prone <italic>&#x003b1;</italic>-synuclein exacerbates synaptic and neuronal degeneration in vivo</article-title>. <source>Brain</source>
<volume>137</volume>, <fpage>1496</fpage>&#x02013;<lpage>1513</lpage>.<pub-id pub-id-type="pmid">24662516</pub-id></mixed-citation></ref><ref id="ref125"><label>[125]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kahle</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ozmen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Odoy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wakabayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bogdanovic</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Riederer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kretzschmar</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Haass</surname>
<given-names>C</given-names>
</string-name> (<year>2001</year>) <article-title>Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model</article-title>. <source>Am J Pathol</source>
<volume>159</volume>, <fpage>2215</fpage>&#x02013;<lpage>2225</lpage>.<pub-id pub-id-type="pmid">11733371</pub-id></mixed-citation></ref><ref id="ref126"><label>[126]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Breydo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Isas</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kuznetsov</surname>
<given-names>YG</given-names>
</string-name>, <string-name>
<surname>Langen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Glabe</surname>
<given-names>C</given-names>
</string-name> (<year>2010</year>) <article-title>Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation</article-title>. <source>J Biol Chem</source>
<volume>285</volume>, <fpage>6071</fpage>&#x02013;<lpage>6079</lpage>.<pub-id pub-id-type="pmid">20018889</pub-id></mixed-citation></ref><ref id="ref127"><label>[127]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Laganowsky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sawaya</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Whitelegge</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pensalfini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Soriaga</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Landau</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Cascio</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Glabe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Eisenberg</surname>
<given-names>D</given-names>
</string-name> (<year>2012</year>) <article-title>Atomic view of a toxic amyloid small oligomer</article-title>. <source>Science</source>
<volume>335</volume>, <fpage>1228</fpage>&#x02013;<lpage>1231</lpage>.<pub-id pub-id-type="pmid">22403391</pub-id></mixed-citation></ref><ref id="ref128"><label>[128]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Reed</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Kotilinek</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>MKO</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Qiang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shapiro</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Reichl</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>
<given-names>ACA</given-names>
</string-name>, <string-name>
<surname>Jankowsky</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Wilmot</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cleary</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Zahs</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Ashe</surname>
<given-names>KH</given-names>
</string-name> (<year>2015</year>) <article-title>Quaternary structure defines a large class of amyloid-&#x003b2; oligomers neutralized by sequestration</article-title>. <source>Cell Rep</source>
<volume>11</volume>, <fpage>1760</fpage>&#x02013;<lpage>1771</lpage>.<pub-id pub-id-type="pmid">26051935</pub-id></mixed-citation></ref><ref id="ref129"><label>[129]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Decressac</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kadkhodaei</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mattsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Laguna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perlmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bj&#x000f6;rklund</surname>
<given-names>A</given-names>
</string-name> (<year>2012</year>) <article-title><italic>&#x003b1;</italic>-Synuclein&#x02013;induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons</article-title>. <source>Sci Transl Med</source>
<volume>4</volume>, <fpage>163ra156</fpage>&#x02013;<lpage>163ra156</lpage>.</mixed-citation></ref><ref id="ref130"><label>[130]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Volakakis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tiklova</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Decressac</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Papathanou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mattsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gillberg</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nobre</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bj&#x000f6;rklund</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perlmann</surname>
<given-names>T</given-names>
</string-name> (<year>2015</year>) <article-title>Nurr1 and retinoid X receptor ligands stimulate ret signaling in dopamine neurons and can alleviate <italic>&#x003b1;</italic>-synuclein disrupted gene expression</article-title>. <source>J. Neurosci</source>
<volume>35</volume>, <fpage>14370</fpage>&#x02013;<lpage>14385</lpage>.<pub-id pub-id-type="pmid">26490873</pub-id></mixed-citation></ref><ref id="ref131"><label>[131]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Petre</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Wall</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nowak</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Walz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lansbury</surname>
<given-names>PT</given-names>
</string-name> (<year>2002</year>) <article-title>Alpha-synuclein, especially the Parkinson&#x02019;s disease-associated mutants, forms pore-like annular and tubular protofibrils</article-title>. <source>J Mol Biol</source>
<volume>322</volume>, <fpage>1089</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">12367530</pub-id></mixed-citation></ref><ref id="ref132"><label>[132]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Volles</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Rochet</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Shtilerman</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Lansbury</surname>
<given-names>PT</given-names>
</string-name> (<year>2001</year>) <article-title>Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson&#x02019;s disease</article-title>. <source>Biochemistry</source>
<volume>40</volume>, <fpage>7812</fpage>&#x02013;<lpage>7819</lpage>.<pub-id pub-id-type="pmid">11425308</pub-id></mixed-citation></ref><ref id="ref133"><label>[133]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Drakulic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Deas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ouberai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aprile</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Arranz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ness</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Roodveldt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Guilliams</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>De-Genst</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Klenerman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Knowles</surname>
<given-names>TPJ</given-names>
</string-name>, <string-name>
<surname>Alfonso</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rivas</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Abramov</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Valpuesta</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Dobson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cremades</surname>
<given-names>N</given-names>
</string-name> (<year>2015</year>) <article-title>Structural characterization of toxic oligomers that are kinetically trapped during <italic>&#x003b1;</italic>-synuclein fibril formation</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>112</volume>, <fpage>E1994</fpage>&#x02013;<lpage>2003</lpage>.<pub-id pub-id-type="pmid">25855634</pub-id></mixed-citation></ref><ref id="ref134"><label>[134]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pensalfini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Margol</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sokolov</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sarsoza</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Head</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Glabe</surname>
<given-names>C</given-names>
</string-name> (<year>2009</year>) <article-title>Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer</article-title>. <source>J Biol Chem</source>
<volume>284</volume>, <fpage>4230</fpage>&#x02013;<lpage>4237</lpage>.<pub-id pub-id-type="pmid">19098006</pub-id></mixed-citation></ref><ref id="ref135"><label>[135]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Choi</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kweon</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>YK</given-names>
</string-name> (<year>2013</year>) <article-title>Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>110</volume>, <fpage>4087</fpage>&#x02013;<lpage>4092</lpage>.<pub-id pub-id-type="pmid">23431141</pub-id></mixed-citation></ref><ref id="ref136"><label>[136]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kramer</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Schulz-Schaeffer</surname>
<given-names>WJ</given-names>
</string-name> (<year>2007</year>) <article-title>Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies</article-title>. <source>J Neurosci</source>
<volume>27</volume>, <fpage>1405</fpage>&#x02013;<lpage>1410</lpage>.<pub-id pub-id-type="pmid">17287515</pub-id></mixed-citation></ref><ref id="ref137"><label>[137]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kiechle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>von Einem</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>H&#x000f6;fs</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Voehringer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Grozdanov</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Markx</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parlato</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wiesner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sakk</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Baumann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lukassen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liss</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ekici</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Ludolph</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Walther</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ferger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Falkenburger</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Weishaupt</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Danzer</surname>
<given-names>KM</given-names>
</string-name> (<year>2019</year>) <article-title>In vivo protein complementation demonstrates presynaptic <italic>&#x003b1;</italic>-synuclein oligomerization and age-dependent accumulation of 8-16-mer oligomer species</article-title>. <source>Cell Rep</source>
<volume>29</volume>, <fpage>2862</fpage>&#x02013;<lpage>2874</lpage>.e9.<pub-id pub-id-type="pmid">31775051</pub-id></mixed-citation></ref><ref id="ref138"><label>[138]</label><mixed-citation publication-type="journal">
<string-name>
<surname>George</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>van den Buuse</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>San Mok</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Masters</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Q-X</given-names>
</string-name>, <string-name>
<surname>Culvenor</surname>
<given-names>JG</given-names>
</string-name> (<year>2008</year>) <article-title>Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour</article-title>. <source>Exp Neurol</source>
<volume>210</volume>, <fpage>788</fpage>&#x02013;<lpage>792</lpage>.<pub-id pub-id-type="pmid">18295208</pub-id></mixed-citation></ref><ref id="ref139"><label>[139]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sung</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>C-H</given-names>
</string-name>, <string-name>
<surname>Um</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S-T</given-names>
</string-name>, <string-name>
<surname>Paik</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>KC</given-names>
</string-name> (<year>2005</year>) <article-title>Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases</article-title>. <source>J Biol Chem</source>
<volume>280</volume>, <fpage>25216</fpage>&#x02013;<lpage>25224</lpage>.<pub-id pub-id-type="pmid">15863497</pub-id></mixed-citation></ref><ref id="ref140"><label>[140]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hodara</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Norris</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Mishizen-Eberz</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name>, <string-name>
<surname>Ischiropoulos</surname>
<given-names>H</given-names>
</string-name> (<year>2004</year>) <article-title>Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation</article-title>. <source>J Biol Chem</source>
<volume>279</volume>, <fpage>47746</fpage>&#x02013;<lpage>47753</lpage>.<pub-id pub-id-type="pmid">15364911</pub-id></mixed-citation></ref><ref id="ref141"><label>[141]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Paleologou</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Oueslati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shakked</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rospigliosi</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H-Y</given-names>
</string-name>, <string-name>
<surname>Lamberto</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>CO</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chegini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gai</surname>
<given-names>WP</given-names>
</string-name>, <string-name>
<surname>Chiappe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moniatte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Aebischer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Eliezer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zweckstetter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</string-name> (<year>2010</year>) <article-title>Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions</article-title>. <source>J Neurosci</source>
<volume>30</volume>, <fpage>3184</fpage>&#x02013;<lpage>3198</lpage>.<pub-id pub-id-type="pmid">20203178</pub-id></mixed-citation></ref><ref id="ref142"><label>[142]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Periquet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Negro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Feany</surname>
<given-names>MB</given-names>
</string-name> (<year>2009</year>) <article-title>Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation</article-title>. <source>J Clin Invest</source>
<volume>119</volume>, <fpage>3257</fpage>&#x02013;<lpage>3265</lpage>.<pub-id pub-id-type="pmid">19855133</pub-id></mixed-citation></ref><ref id="ref143"><label>[143]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Barrett</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Timothy Greenamyre</surname>
<given-names>J</given-names>
</string-name> (<year>2015</year>) <article-title>Post-translational modification of <italic>&#x003b1;</italic>-synuclein in Parkinson&#x02019;s disease</article-title>. <source>Brain Res</source>
<volume>1628</volume>, <fpage>247</fpage>&#x02013;<lpage>253</lpage>.<pub-id pub-id-type="pmid">26080075</pub-id></mixed-citation></ref><ref id="ref144"><label>[144]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zhao</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Attrebi</surname>
<given-names>ON</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Qiao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sonustun</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Martens</surname>
<given-names>YA</given-names>
</string-name>, <string-name>
<surname>Meneses</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shue</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Van Ingelgom</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Kurti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Linares</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Delenclos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>C-C</given-names>
</string-name>, <string-name>
<surname>Fryer</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Asmann</surname>
<given-names>YW</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Bu</surname>
<given-names>G</given-names>
</string-name> (<year>2020</year>) <article-title>APOE4 exacerbates <italic>&#x003b1;</italic>-synuclein pathology and related toxicity independent of amyloid.eaay</article-title>. <source>Sci Transl Med</source>
<volume>12</volume>, <fpage>1809</fpage>.</mixed-citation></ref><ref id="ref145"><label>[145]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Davis</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Inman</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Wargel</surname>
<given-names>ZM</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Freeberg</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Galluppi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Haines</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Dhavale</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Choudhury</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Cruchaga</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Perlmutter</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ulrich</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Benitez</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Kotzbauer</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</string-name> (<year>2020</year>) <article-title>APOE genotype regulates pathology and disease progression in synucleinopathy</article-title>. <source>Sci Transl Med</source>
<volume>12</volume>, <fpage>eaay3069</fpage>.<pub-id pub-id-type="pmid">32024799</pub-id></mixed-citation></ref><ref id="ref146"><label>[146]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Delenclos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Faroqi</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kurti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Castanedes-Casey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rousseau</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Fryer</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name> (<year>2017</year>) <article-title>Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain</article-title>. <source>Acta Neuropathol Commun</source>
<volume>5</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">28057070</pub-id></mixed-citation></ref><ref id="ref147"><label>[147]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Collinge</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sidle</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Meads</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ironside</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>AF</given-names>
</string-name> (<year>1996</year>) <article-title>Molecular analysis of prion strain variation and the aetiology of &#x0201c;new variant&#x0201d; CJD</article-title>. <source>Nature</source>
<volume>383</volume>, <fpage>685</fpage>&#x02013;<lpage>690</lpage>.<pub-id pub-id-type="pmid">8878476</pub-id></mixed-citation></ref><ref id="ref148"><label>[148]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bessen</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>RF</given-names>
</string-name> (<year>1992</year>) <article-title>Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters</article-title>. <source>J Gen Virol</source>
<volume>73</volume>, <fpage>329</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">1531675</pub-id></mixed-citation></ref><ref id="ref149"><label>[149]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bartz</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Bessen</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>McKenzie</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Aiken</surname>
<given-names>JM</given-names>
</string-name> (<year>2000</year>) <article-title>Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy</article-title>. <source>J Virol</source>
<volume>74</volume>, <fpage>5542</fpage>&#x02013;<lpage>5547</lpage>.<pub-id pub-id-type="pmid">10823860</pub-id></mixed-citation></ref><ref id="ref150"><label>[150]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Klimova</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Makarava</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Baskakov</surname>
<given-names>IV</given-names>
</string-name> (<year>2015</year>) <article-title>The diversity and relationship of prion protein self-replicating states</article-title>. <source>Virus Res</source>
<volume>207</volume>, <fpage>113</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">25312451</pub-id></mixed-citation></ref><ref id="ref151"><label>[151]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Morales</surname>
<given-names>R</given-names>
</string-name> (<year>2017</year>) <article-title>Prion strains in mammals: Different conformations leading to disease</article-title>. <source>PLoS Pathog</source>
<volume>13</volume>, <fpage>e1006323</fpage>.<pub-id pub-id-type="pmid">28683090</pub-id></mixed-citation></ref><ref id="ref152"><label>[152]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Polymenidou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cleveland</surname>
<given-names>DW</given-names>
</string-name> (<year>2011</year>) <article-title>The seeds of neurodegeneration: prion-like spreading in ALS</article-title>. <source>Cell</source>
<volume>147</volume>, <fpage>498</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">22036560</pub-id></mixed-citation></ref><ref id="ref153"><label>[153]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tredici</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name> (<year>2016</year>) <article-title>Review: Sporadic Parkinson&#x02019;s disease: development and distribution of <italic>&#x003b1;</italic>-synuclein pathology</article-title>. <source>Neuropathol Appl Neurobiol</source>
<volume>42</volume>, <fpage>33</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">26662475</pub-id></mixed-citation></ref><ref id="ref154"><label>[154]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Olanow</surname>
<given-names>CW</given-names>
</string-name> (<year>2008</year>) <article-title>Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x02019;s disease</article-title>. <source>Nat Med</source>
<volume>14</volume>, <fpage>504</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">18391962</pub-id></mixed-citation></ref><ref id="ref155"><label>[155]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>J-Y</given-names>
</string-name>, <string-name>
<surname>Englund</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Holton</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Soulet</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hagell</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Lashley</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Quinn</surname>
<given-names>NP</given-names>
</string-name>, <string-name>
<surname>Rehncrona</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bj&#x000f6;rklund</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Widner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Revesz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lindvall</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Brundin</surname>
<given-names>P</given-names>
</string-name> (<year>2008</year>) <article-title>Lewy bodies in grafted neurons in subjects with Parkinson&#x02019;s disease suggest host-to-graft disease propagation</article-title>. <source>Nat Med</source>
<volume>14</volume>, <fpage>501</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">18391963</pub-id></mixed-citation></ref><ref id="ref156"><label>[156]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Desplats</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H-J</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>E-J</given-names>
</string-name>, <string-name>
<surname>Patrick</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Crews</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S-J</given-names>
</string-name> (<year>2009</year>) <article-title>Inclusion formation and neuronal cell death through neuron-to-neuron transmission of <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>, <fpage>13010</fpage>&#x02013;<lpage>13015</lpage>.<pub-id pub-id-type="pmid">19651612</pub-id></mixed-citation></ref><ref id="ref157"><label>[157]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Olanow</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Prusiner</surname>
<given-names>SB</given-names>
</string-name> (<year>2009</year>) <article-title>Is Parkinson&#x02019;s disease a prion disorder?</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>, <fpage>12571</fpage>&#x02013;<lpage>12572</lpage>.<pub-id pub-id-type="pmid">19666621</pub-id></mixed-citation></ref><ref id="ref158"><label>[158]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Khoshaghideh</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</string-name> (<year>2004</year>) <article-title>Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway</article-title>. <source>J Neurosci</source>
<volume>24</volume>, <fpage>1888</fpage>&#x02013;<lpage>1896</lpage>.<pub-id pub-id-type="pmid">14985429</pub-id></mixed-citation></ref><ref id="ref159"><label>[159]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Suk</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Paik</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</string-name> (<year>2008</year>) <article-title>Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein</article-title>. <source>Int J Biochem Cell Biol</source>
<volume>40</volume>, <fpage>1835</fpage>&#x02013;<lpage>1849</lpage>.<pub-id pub-id-type="pmid">18291704</pub-id></mixed-citation></ref><ref id="ref160"><label>[160]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Domert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sackmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Severinsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Agholme</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bergstrom</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ingelsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hallbeck</surname>
<given-names>M</given-names>
</string-name> (<year>2016</year>) <article-title>Aggregated alpha-synuclein transfer efficiently between cultured human neuron-like cells and localize to lysosomes</article-title>. <source>PloS One</source>
<volume>11</volume>, <fpage>e0168700</fpage>.<pub-id pub-id-type="pmid">28030591</pub-id></mixed-citation></ref><ref id="ref161"><label>[161]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hoffmann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Minakaki</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Menges</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Salvi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Savitskiy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kazman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vicente Miranda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mielenz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Klucken</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>
<given-names>W</given-names>
</string-name> (<year>2019</year>) <article-title>Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose</article-title>. <source>Sci Rep</source>
<volume>9</volume>, <fpage>544</fpage>.<pub-id pub-id-type="pmid">30679445</pub-id></mixed-citation></ref><ref id="ref162"><label>[162]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Danzer</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Krebs</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Birk</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hengerer</surname>
<given-names>B</given-names>
</string-name> (<year>2009</year>) <article-title>Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology</article-title>. <source>J Neurochem</source>
<volume>111</volume>, <fpage>192</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">19686384</pub-id></mixed-citation></ref><ref id="ref163"><label>[163]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Iljina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Horrocks</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Tosatto</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Ganzinger</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Abramov</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Gandhi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Cremades</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Dobson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Knowles</surname>
<given-names>TPJ</given-names>
</string-name>, <string-name>
<surname>Klenerman</surname>
<given-names>D</given-names>
</string-name> (<year>2016</year>) <article-title>Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>113</volume>, <fpage>E1206</fpage>&#x02013;<lpage>1215</lpage>.<pub-id pub-id-type="pmid">26884195</pub-id></mixed-citation></ref><ref id="ref164"><label>[164]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Peelaerts</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bousset</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Van der Perren</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moskalyuk</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pulizzi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Van den Haute</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Melki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Baekelandt</surname>
<given-names>V</given-names>
</string-name> (<year>2015</year>) <article-title>alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration</article-title>. <source>Nature</source>
<volume>522</volume>, <fpage>340</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">26061766</pub-id></mixed-citation></ref><ref id="ref165"><label>[165]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rey</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Petit</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Bousset</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Melki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Brundin</surname>
<given-names>P</given-names>
</string-name> (<year>2013</year>) <article-title>Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice</article-title>. <source>Acta Neuropathol</source>
<volume>126</volume>, <fpage>555</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">23925565</pub-id></mixed-citation></ref><ref id="ref166"><label>[166]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rey</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Bousset</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Madaj</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Meyerdirk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Melki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Brundin</surname>
<given-names>P</given-names>
</string-name> (<year>2019</year>) <article-title><italic>&#x003b1;</italic>-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb</article-title>. <source>Acta Neuropathol Commun</source>
<volume>7</volume>, <fpage>221</fpage>.<pub-id pub-id-type="pmid">31888771</pub-id></mixed-citation></ref><ref id="ref167"><label>[167]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Volpicelli-Daley</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Luk</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Tanik</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Riddle</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Stieber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Meaney</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name> (<year>2011</year>) <article-title>Exogenous <italic>&#x003b1;</italic>-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death</article-title>. <source>Neuron</source>
<volume>72</volume>, <fpage>57</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21982369</pub-id></mixed-citation></ref><ref id="ref168"><label>[168]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Luk</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Kehm</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Brien</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name> (<year>2012</year>) <article-title>Pathological <italic>&#x003b1;</italic>-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice</article-title>. <source>Science</source>
<volume>338</volume>, <fpage>949</fpage>&#x02013;<lpage>953</lpage>.<pub-id pub-id-type="pmid">23161999</pub-id></mixed-citation></ref><ref id="ref169"><label>[169]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Luk</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Kehm</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Brien</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VMY</given-names>
</string-name> (<year>2012</year>) <article-title>Intracerebral inoculation of pathological <italic>&#x003b1;</italic>-synuclein initiates a rapidly progressive neurodegenerative <italic>&#x003b1;</italic>-synucleinopathy in mice</article-title>. <source>J Exp Med</source>
<volume>209</volume>, <fpage>975</fpage>&#x02013;<lpage>986</lpage>.<pub-id pub-id-type="pmid">22508839</pub-id></mixed-citation></ref><ref id="ref170"><label>[170]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Glabe</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2006</year>) <article-title>Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis</article-title>. <source>Neurology</source>
<volume>66</volume>, <fpage>S74</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">16432151</pub-id></mixed-citation></ref><ref id="ref171"><label>[171]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Moussaud</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Moussaud-Lamodi&#x000e8;re</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Delenclos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name> (<year>2014</year>) <article-title>Alpha-synuclein and tau: Teammates in neurodegeneration?</article-title>
<source>Mol Neurodegener</source>
<volume>9</volume>, <fpage>43</fpage>.<pub-id pub-id-type="pmid">25352339</pub-id></mixed-citation></ref><ref id="ref172"><label>[172]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>E</given-names>
</string-name> (<year>1990</year>) <article-title>Cognitive impairment in Parkinson&#x02019;s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex</article-title>. <source>J Neural Transm Park Dis Dement Sect</source>
<volume>2</volume>, <fpage>45</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">2357270</pub-id></mixed-citation></ref><ref id="ref173"><label>[173]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jacobson</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Morshed</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dugger</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Beach</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Hentz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Shill</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Sabbagh</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Belden</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sue</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Caviness</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>, <collab>Arizona Parkinson&#x02019;s Disease Consortium</collab> (<year>2014</year>) <article-title>Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations</article-title>. <source>Parkinsonism Relat Disord</source>
<volume>20</volume>, <fpage>1009</fpage>&#x02013;<lpage>1014</lpage>.<pub-id pub-id-type="pmid">25027359</pub-id></mixed-citation></ref><ref id="ref174"><label>[174]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Veinbergs</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sagara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mallory</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mucke</surname>
<given-names>L</given-names>
</string-name> (<year>2001</year>) <article-title>Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>98</volume>, <fpage>12245</fpage>&#x02013;<lpage>12250</lpage>.<pub-id pub-id-type="pmid">11572944</pub-id></mixed-citation></ref><ref id="ref175"><label>[175]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Mandal</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Pettegrew</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Mandal</surname>
<given-names>R</given-names>
</string-name> (<year>2006</year>) <article-title>Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer&#x02019;s and Parkinson&#x02019;s in dementia with Lewy body disease</article-title>. <source>Neurochem Res</source>
<volume>31</volume>, <fpage>1153</fpage>&#x02013;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">16947080</pub-id></mixed-citation></ref><ref id="ref176"><label>[176]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ono</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamada</surname>
<given-names>M</given-names>
</string-name> (<year>2012</year>) <article-title>Cross-seeding effects of amyloid &#x003b2;-protein and <italic>&#x003b1;</italic>-synuclein</article-title>. <source>J Neurochem</source>
<volume>122</volume>, <fpage>883</fpage>&#x02013;<lpage>890</lpage>.<pub-id pub-id-type="pmid">22734715</pub-id></mixed-citation></ref><ref id="ref177"><label>[177]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Marsh</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Blurton-Jones</surname>
<given-names>M</given-names>
</string-name> (<year>2012</year>) <article-title>Examining the mechanisms that link &#x003b2;-amyloid and <italic>&#x003b1;</italic>-synuclein pathologies</article-title>. <source>Alzheimers Res Ther</source>
<volume>4</volume>, <fpage>11</fpage>.<pub-id pub-id-type="pmid">22546279</pub-id></mixed-citation></ref><ref id="ref178"><label>[178]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Flagmeier</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Habchi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lattanzi</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Linse</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dobson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Knowles</surname>
<given-names>TPJ</given-names>
</string-name>, <string-name>
<surname>Vendruscolo</surname>
<given-names>M</given-names>
</string-name> (<year>2017</year>) <article-title>Monomeric and fibrillar <italic>&#x003b1;</italic>-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of A&#x003b2;42 aggregates</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>114</volume>, <fpage>8005</fpage>&#x02013;<lpage>8010</lpage>.<pub-id pub-id-type="pmid">28698377</pub-id></mixed-citation></ref><ref id="ref179"><label>[179]</label><mixed-citation publication-type="journal">
<string-name>
<surname>K&#x000f6;ppen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schulze</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Machner</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wermann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eichentopf</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Guthardt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>H&#x000e4;hnel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Klehm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kriegeskorte</surname>
<given-names>M-C</given-names>
</string-name>, <string-name>
<surname>Hartlage-R&#x000fc;bsamen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morawski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>von H&#x000f6;rsten</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Demuth</surname>
<given-names>H-U</given-names>
</string-name>, <string-name>
<surname>Ro&#x000df;ner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schilling</surname>
<given-names>S</given-names>
</string-name> (<year>2020</year>) <article-title>Amyloid-beta peptides trigger aggregation of alpha-synuclein in vitro</article-title>. <source>Molecules</source>
<volume>25</volume>, <fpage>E580</fpage>.<pub-id pub-id-type="pmid">32013170</pub-id></mixed-citation></ref><ref id="ref180"><label>[180]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bassil</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Pattabhiraman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iwasyk</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Maghames</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Meymand</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>TO</given-names>
</string-name>, <string-name>
<surname>Riddle</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name> (<year>2020</year>) <article-title>Amyloid-beta (A&#x003b2;) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with A&#x003b2; pathology</article-title>. <source>Neuron</source>
<volume>105</volume>, <fpage>260</fpage>&#x02013;<lpage>275</lpage>.e6.<pub-id pub-id-type="pmid">31759806</pub-id></mixed-citation></ref><ref id="ref181"><label>[181]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kallhoff</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Peethumnongsin</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>H</given-names>
</string-name> (<year>2007</year>) <article-title>Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source>
<volume>2</volume>, <fpage>6</fpage>.<pub-id pub-id-type="pmid">17367539</pub-id></mixed-citation></ref><ref id="ref182"><label>[182]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Orr</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Frost</surname>
<given-names>B</given-names>
</string-name> (<year>2017</year>) <article-title>A brief overview of tauopathy: causes, consequences, and therapeutic strategies</article-title>. <source>Trends Pharmacol Sci</source>
<volume>38</volume>, <fpage>637</fpage>&#x02013;<lpage>648</lpage>.<pub-id pub-id-type="pmid">28455089</pub-id></mixed-citation></ref><ref id="ref183"><label>[183]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Simon-Sanchez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schulte</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bras</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gibbs</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Berg</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Paisan-Ruiz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lichtner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Scholz</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Hernandez</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Kruger</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Federoff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goate</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perlmutter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bonin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Illig</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gieger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Houlden</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Steffens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okun</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Racette</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Foote</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Schreiber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Arepalli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zonozi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gwinn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>van der Brug</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chanock</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Schatzkin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hollenbeck</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Lorenz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Deuschl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Riess</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Gasser</surname>
<given-names>T</given-names>
</string-name> (<year>2009</year>) <article-title>Genome-wide association study reveals genetic risk underlying Parkinson&#x02019;s disease</article-title>. <source>Nat Genet</source>
<volume>41</volume>, <fpage>1308</fpage>&#x02013;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">19915575</pub-id></mixed-citation></ref><ref id="ref184"><label>[184]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Colom-Cadena</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gelpi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Charif</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dols-Icardo</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Blesa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Clarim&#x000f3;n</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lle&#x000f3;</surname>
<given-names>A</given-names>
</string-name> (<year>2013</year>) <article-title>MAPT H1 haplotype is associated with enhanced <italic>&#x003b1;</italic>-synuclein deposition in dementia with Lewy bodies</article-title>. <source>Neurobiol Aging</source>
<volume>34</volume>, <fpage>936</fpage>&#x02013;<lpage>942</lpage>.<pub-id pub-id-type="pmid">22819391</pub-id></mixed-citation></ref><ref id="ref185"><label>[185]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kaul</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Credle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haggerty</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Oaks</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</string-name> (<year>2011</year>) <article-title>Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson&#x02019;s disease</article-title>. <source>BMC Neurosci</source>
<volume>12</volume>, <fpage>79</fpage>.<pub-id pub-id-type="pmid">21812967</pub-id></mixed-citation></ref><ref id="ref186"><label>[186]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Frasier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Walzer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Magnuson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Haas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kahle</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wolozin</surname>
<given-names>B</given-names>
</string-name> (<year>2005</year>) <article-title>Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein</article-title>. <source>Exp Neurol</source>
<volume>192</volume>, <fpage>274</fpage>&#x02013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">15755545</pub-id></mixed-citation></ref><ref id="ref187"><label>[187]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Duka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Duka</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Joyce</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</string-name> (<year>2009</year>) <article-title>Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson&#x02019;s disease models</article-title>. <source>FASEB J</source>
<volume>23</volume>, <fpage>2820</fpage>&#x02013;<lpage>2830</lpage>.<pub-id pub-id-type="pmid">19369384</pub-id></mixed-citation></ref><ref id="ref188"><label>[188]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Duka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rusnak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Drolet</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Duka</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Wersinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goudreau</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</string-name> (<year>2006</year>) <article-title>Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism</article-title>. <source>FASEB J</source>
<volume>20</volume>, <fpage>2302</fpage>&#x02013;<lpage>2312</lpage>.<pub-id pub-id-type="pmid">17077307</pub-id></mixed-citation></ref><ref id="ref189"><label>[189]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Haggerty</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Credle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Wills</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Oaks</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</string-name> (<year>2011</year>) <article-title>Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson&#x02019;s disease</article-title>. <source>Eur J Neurosci</source>
<volume>33</volume>, <fpage>1598</fpage>&#x02013;<lpage>1610</lpage>.<pub-id pub-id-type="pmid">21453448</pub-id></mixed-citation></ref><ref id="ref190"><label>[190]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Peng</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name> (<year>2020</year>) <article-title>Protein transmission in neurodegenerative disease</article-title>. <source>Nat Rev Neurol</source>
<volume>16</volume>, <fpage>199</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">32203399</pub-id></mixed-citation></ref><ref id="ref191"><label>[191]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jucker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>LC</given-names>
</string-name> (<year>2011</year>) <article-title>Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders</article-title>. <source>Ann Neurol</source>
<volume>70</volume>, <fpage>532</fpage>&#x02013;<lpage>540</lpage>.<pub-id pub-id-type="pmid">22028219</pub-id></mixed-citation></ref><ref id="ref192"><label>[192]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M</given-names>
</string-name> (<year>2015</year>) <article-title>Neurodegeneration. Alzheimer&#x02019;s and Parkinson&#x02019;s diseases: The prion concept in relation to assembled A&#x003b2;, tau, and <italic>&#x003b1;</italic>-synuclein</article-title>. <source>Science</source>
<volume>349</volume>, <fpage>1255555</fpage>.<pub-id pub-id-type="pmid">26250687</pub-id></mixed-citation></ref><ref id="ref193"><label>[193]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Caughey</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kraus</surname>
<given-names>A</given-names>
</string-name> (<year>2019</year>) <article-title>Transmissibility versus pathogenicity of self-propagating protein aggregates</article-title>. <source>Viruses</source>
<volume>11</volume>, <fpage>E1044</fpage>.<pub-id pub-id-type="pmid">31717531</pub-id></mixed-citation></ref><ref id="ref194"><label>[194]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Walker</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Diamond</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</string-name> (<year>2013</year>) <article-title>Mechanisms of protein seeding in neurodegenerative diseases</article-title>. <source>JAMA Neurol</source>
<volume>70</volume>, <fpage>304</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">23599928</pub-id></mixed-citation></ref><ref id="ref195"><label>[195]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Prusiner</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Woerman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Mordes</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Rampersaud</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oehler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lowe</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Kravitz</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Glidden</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Middleton</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Gentleman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Grinberg</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Giles</surname>
<given-names>K</given-names>
</string-name> (<year>2015</year>) <article-title>Evidence for <italic>&#x003b1;</italic>-synuclein prions causing multiple system atrophy in humans with parkinsonism</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>112</volume>, <fpage>E5308</fpage>&#x02013;<lpage>5317</lpage>.<pub-id pub-id-type="pmid">26324905</pub-id></mixed-citation></ref><ref id="ref196"><label>[196]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Clavaguera</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Akatsu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Crowther</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hench</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Probst</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Reichwald</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Staufenbiel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ghetti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tolnay</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>110</volume>, <fpage>9535</fpage>&#x02013;<lpage>9540</lpage>.<pub-id pub-id-type="pmid">23690619</pub-id></mixed-citation></ref><ref id="ref197"><label>[197]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Clavaguera</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hench</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tolnay</surname>
<given-names>M</given-names>
</string-name> (<year>2015</year>) <article-title>Invited review: Prion-like transmission and spreading of tau pathology</article-title>. <source>Neuropathol Appl Neurobiol</source>
<volume>41</volume>, <fpage>47</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">25399729</pub-id></mixed-citation></ref><ref id="ref198"><label>[198]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jensen</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Hager</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>H&#x000f8;jrup</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gliemann</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jakes</surname>
<given-names>R</given-names>
</string-name> (<year>1999</year>) <article-title><italic>&#x003b1;</italic>-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356</article-title>. <source>J Biol Chem</source>
<volume>274</volume>, <fpage>25481</fpage>&#x02013;<lpage>25489</lpage>.<pub-id pub-id-type="pmid">10464279</pub-id></mixed-citation></ref><ref id="ref199"><label>[199]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Iseki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Takayama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Marui</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kosaka</surname>
<given-names>K</given-names>
</string-name> (<year>2002</year>) <article-title>Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains</article-title>. <source>J Neurol Sci</source>
<volume>195</volume>, <fpage>85</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">11867079</pub-id></mixed-citation></ref><ref id="ref200"><label>[200]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Arima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hirai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sunohara</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Aoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Izumiyama</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kawai</surname>
<given-names>M</given-names>
</string-name> (<year>1999</year>) <article-title>Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson&#x02019;s disease and in dementia with Lewy bodies</article-title>. <source>Brain Res</source>
<volume>843</volume>, <fpage>53</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">10528110</pub-id></mixed-citation></ref><ref id="ref201"><label>[201]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Giasson</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Golbe</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Graves</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Kotzbauer</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>VM-Y</given-names>
</string-name> (<year>2003</year>) <article-title>Initiation and synergistic fibrillization of tau and alpha-synuclein</article-title>. <source>Science</source>
<volume>300</volume>, <fpage>636</fpage>&#x02013;<lpage>640</lpage>.<pub-id pub-id-type="pmid">12714745</pub-id></mixed-citation></ref><ref id="ref202"><label>[202]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wills</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Credle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haggerty</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J-H</given-names>
</string-name>, <string-name>
<surname>Oaks</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</string-name> (<year>2011</year>) <article-title>Tauopathic changes in the striatum of A53T <italic>&#x003b1;</italic>-synuclein mutant mouse model of Parkinson&#x02019;s disease</article-title>. <source>PLoS One</source>
<volume>6</volume>, <fpage>e17953</fpage>.<pub-id pub-id-type="pmid">21445308</pub-id></mixed-citation></ref><ref id="ref203"><label>[203]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mallory</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2002</year>) <article-title>Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters</article-title>. <source>J Neurosci Res</source>
<volume>68</volume>, <fpage>568</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">12111846</pub-id></mixed-citation></ref><ref id="ref204"><label>[204]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Farmer</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Henson</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Carretero Murillo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2018</year>) <article-title>Tau oligomers mediate <italic>&#x003b1;</italic>-synuclein toxicity and can be targeted by immunotherapy</article-title>. <source>Mol Neurodegener</source>
<volume>13</volume>, <fpage>13</fpage>.<pub-id pub-id-type="pmid">29544548</pub-id></mixed-citation></ref><ref id="ref205"><label>[205]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Guerrero-Mu&#x000f1;oz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lasagna-Reeves</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Gerson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Estes</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>ADT</given-names>
</string-name>, <string-name>
<surname>Dineley</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2014</year>) <article-title>Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles</article-title>. <source>J Neurosci</source>
<volume>34</volume>, <fpage>4260</fpage>&#x02013;<lpage>4272</lpage>.<pub-id pub-id-type="pmid">24647946</pub-id></mixed-citation></ref><ref id="ref206"><label>[206]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Singh</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Covelo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Martell-Mart&#x000ed;nez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nanclares</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Okematti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Meints</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Teravskis</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Gallardo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Savonenko</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Benneyworth</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Lesn&#x000e9;</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Araque</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MK</given-names>
</string-name> (<year>2019</year>) <article-title>Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of <italic>&#x003b1;</italic>-synucleinopathy</article-title>. <source>Acta Neuropathol</source>
<volume>138</volume>, <fpage>551</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">31168644</pub-id></mixed-citation></ref><ref id="ref207"><label>[207]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chaudhuri</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Prajapati</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Anand</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Dubey</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kar</surname>
<given-names>K</given-names>
</string-name> (<year>2019</year>) <article-title>Amyloid cross-seeding raises new dimensions to understanding of amyloidogenesis mechanism</article-title>. <source>Ageing Res Rev</source>
<volume>56</volume>, <fpage>100937</fpage>.<pub-id pub-id-type="pmid">31430565</pub-id></mixed-citation></ref><ref id="ref208"><label>[208]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Morales</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moreno-Gonzalez</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Soto</surname>
<given-names>C</given-names>
</string-name> (<year>2013</year>) <article-title>Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases</article-title>. <source>PLoS Pathog</source>
<volume>9</volume>, <fpage>e1003537</fpage>.<pub-id pub-id-type="pmid">24068917</pub-id></mixed-citation></ref><ref id="ref209"><label>[209]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lasagna-Reeves</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Castillo-Carranza</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Guerrero-Munoz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2010</year>) <article-title>Preparation and characterization of neurotoxic tau oligomers</article-title>. <source>Biochemistry</source>
<volume>49</volume>, <fpage>10039</fpage>&#x02013;<lpage>10041</lpage>.<pub-id pub-id-type="pmid">21047142</pub-id></mixed-citation></ref><ref id="ref210"><label>[210]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Oddo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Caccamo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Golde</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Metherate</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mattson</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Akbari</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</string-name> (<year>2003</year>) <article-title>Triple-transgenic model of Alzheimer&#x02019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction</article-title>. <source>Neuron</source>
<volume>39</volume>, <fpage>409</fpage>&#x02013;<lpage>421</lpage>.<pub-id pub-id-type="pmid">12895417</pub-id></mixed-citation></ref><ref id="ref211"><label>[211]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Clinton</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Blurton-Jones</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Myczek</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</string-name> (<year>2010</year>) <article-title>Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline</article-title>. <source>J Neurosci</source>
<volume>30</volume>, <fpage>7281</fpage>&#x02013;<lpage>7289</lpage>.<pub-id pub-id-type="pmid">20505094</pub-id></mixed-citation></ref><ref id="ref212"><label>[212]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Corrochano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Renna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chrobot</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kent</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SDM</given-names>
</string-name>, <string-name>
<surname>Rubinsztein</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Acevedo-Arozena</surname>
<given-names>A</given-names>
</string-name> (<year>2012</year>) <article-title><italic>&#x003b1;</italic>-Synuclein levels modulate Huntington&#x02019;s disease in mice</article-title>. <source>Hum Mol Genet</source>
<volume>21</volume>, <fpage>485</fpage>&#x02013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">22010050</pub-id></mixed-citation></ref><ref id="ref213"><label>[213]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bittar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name> (<year>2018</year>) <article-title>Prospects for strain-specific immunotherapy in Alzheimer&#x02019;s disease and tauopathies</article-title>. <source>NPJ Vaccines</source>
<volume>3</volume>, <fpage>9</fpage>.<pub-id pub-id-type="pmid">29507776</pub-id></mixed-citation></ref><ref id="ref214"><label>[214]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Brundin</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dave</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</string-name> (<year>2017</year>) <article-title>Therapeutic approaches to target alpha-synuclein pathology</article-title>. <source>Exp Neurol</source>
<volume>298</volume>, <fpage>225</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">28987463</pub-id></mixed-citation></ref><ref id="ref215"><label>[215]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Barkovits</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kruse</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Linden</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>T&#x000f6;nges</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pfeiffer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mollenhauer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Marcus</surname>
<given-names>K</given-names>
</string-name> (<year>2020</year>) <article-title>Blood contamination in CSF and its impact on quantitative analysis of alpha-synuclein</article-title>. <source>Cells</source>
<volume>9</volume>, <fpage>E370</fpage>.<pub-id pub-id-type="pmid">32033488</pub-id></mixed-citation></ref><ref id="ref216"><label>[216]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wagner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ryazanov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leonov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Prix</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pan-Montojo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bertsch</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Mitteregger-Kretzschmar</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Geissen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eiden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leidel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hirschberger</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Deeg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Krauth</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Zinth</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Tavan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pilger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zweckstetter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>B&#x000e4;hr</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weishaupt</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Uhr</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Urlaub</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Teichmann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Samwer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;tzel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Groschup</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kretzschmar</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name> (<year>2013</year>) <article-title>Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson&#x02019;s disease</article-title>. <source>Acta Neuropathol</source>
<volume>125</volume>, <fpage>795</fpage>&#x02013;<lpage>813</lpage>.<pub-id pub-id-type="pmid">23604588</pub-id></mixed-citation></ref><ref id="ref217"><label>[217]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Neumann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kahle</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Ozmen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Borroni</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Spooren</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Odoy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fujiwara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Kretzschmar</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Haass</surname>
<given-names>C</given-names>
</string-name> (<year>2002</year>) <article-title>Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies</article-title>. <source>J Clin Invest</source>
<volume>110</volume>, <fpage>1429</fpage>&#x02013;<lpage>1439</lpage>.<pub-id pub-id-type="pmid">12438441</pub-id></mixed-citation></ref><ref id="ref218"><label>[218]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Matthes</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gapsys</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>de Groot</surname>
<given-names>BL</given-names>
</string-name> (<year>2017</year>) <article-title>Resolving the atomistic modes of Anle138b inhibitory action on peptide oligomer formation</article-title>. <source>ACS Chem Neurosci</source>
<volume>8</volume>, <fpage>2791</fpage>&#x02013;<lpage>2808</lpage>.<pub-id pub-id-type="pmid">28906103</pub-id></mixed-citation></ref><ref id="ref219"><label>[219]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Martinez Hernandez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Urbanke</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gillman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ryazanov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Agbemenyah</surname>
<given-names>HY</given-names>
</string-name>, <string-name>
<surname>Benito</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jain</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kaurani</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grigorian</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Leonov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rezaei-Ghaleh</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wilken</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Arce</surname>
<given-names>FT</given-names>
</string-name>, <string-name>
<surname>Wagner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fuhrmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caruana</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Camilleri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vassallo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zweckstetter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Benz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Korte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lal</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Eichele</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>A</given-names>
</string-name> (<year>2018</year>) <article-title>The diphenylpyrazole compound anle138b blocks A&#x003b2; channels and rescues disease phenotypes in a mouse model for amyloid pathology</article-title>. <source>EMBO Mol Med</source>
<volume>10</volume>, <fpage>32</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">29208638</pub-id></mixed-citation></ref><ref id="ref220"><label>[220]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Brendel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Deussing</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blume</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kaiser</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Probst</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Overhoff</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>von Ungern-Sternberg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ryazanov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leonov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zwergal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bartenstein</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yakushev</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Cumming</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Boening</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ziegler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Herms</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rominger</surname>
<given-names>A</given-names>
</string-name> (<year>2019</year>) <article-title>Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer&#x02019;s disease tau</article-title>. <source>Alzheimers Res Ther</source>
<volume>11</volume>, <fpage>67</fpage>.<pub-id pub-id-type="pmid">31370885</pub-id></mixed-citation></ref><ref id="ref221"><label>[221]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Wagner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ryazanov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Steffen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Miklitz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Leonov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kleinknecht</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>G&#x000f6;ricke</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Weishaupt</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Weckbecker</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Reiner</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Zinth</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Remy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kretzschmar</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fuhrmann</surname>
<given-names>M</given-names>
</string-name> (<year>2015</year>) <article-title>Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies</article-title>. <source>Acta Neuropathol</source>
<volume>130</volume>, <fpage>619</fpage>&#x02013;<lpage>631</lpage>.<pub-id pub-id-type="pmid">26439832</pub-id></mixed-citation></ref><ref id="ref222"><label>[222]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Price</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Koike</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wrasidlo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bonhaus</surname>
<given-names>D</given-names>
</string-name> (<year>2018</year>) <article-title>The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson&#x02019;s disease</article-title>. <source>Sci Rep</source>
<volume>8</volume>, <fpage>16165</fpage>.<pub-id pub-id-type="pmid">30385782</pub-id></mixed-citation></ref><ref id="ref223"><label>[223]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Fields</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Bengoa-Vergniory</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wade-Martins</surname>
<given-names>R</given-names>
</string-name> (<year>2019</year>) <article-title>Targeting alpha-synuclein as a therapy for Parkinson&#x02019;s disease</article-title>. <source>Front Mol Neurosci</source>
<volume>12</volume>, <fpage>299</fpage>.<pub-id pub-id-type="pmid">31866823</pub-id></mixed-citation></ref><ref id="ref224"><label>[224]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Begum</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Ubeda</surname>
<given-names>OJ</given-names>
</string-name>, <string-name>
<surname>Simmons</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Ambegaokar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Glabe</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Frautschy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>GM</given-names>
</string-name> (<year>2005</year>) <article-title>Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo</article-title>. <source>J Biol Chem</source>
<volume>280</volume>, <fpage>5892</fpage>&#x02013;<lpage>5901</lpage>.<pub-id pub-id-type="pmid">15590663</pub-id></mixed-citation></ref><ref id="ref225"><label>[225]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Begum</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Morihara</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Heath</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Rock</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Pruitt</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hudspeth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Faull</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Teter</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Frautschy</surname>
<given-names>SA</given-names>
</string-name> (<year>2008</year>) <article-title>Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer&#x02019;s disease</article-title>. <source>J Pharmacol Exp Ther</source>
<volume>326</volume>, <fpage>196</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">18417733</pub-id></mixed-citation></ref><ref id="ref226"><label>[226]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maiti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Frautschy</surname>
<given-names>SA</given-names>
</string-name> (<year>2015</year>) <article-title>Clinical development of curcumin in neurodegenerative disease</article-title>. <source>Expert Rev Neurother</source>
<volume>15</volume>, <fpage>629</fpage>&#x02013;<lpage>637</lpage>.<pub-id pub-id-type="pmid">26035622</pub-id></mixed-citation></ref><ref id="ref227"><label>[227]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Singh</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Kotia</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mohite</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maji</surname>
<given-names>SK</given-names>
</string-name> (<year>2013</year>) <article-title>Curcumin modulates alpha-synuclein aggregation and toxicity</article-title>. <source>ACS Chem Neurosci</source>
<volume>4</volume>, <fpage>393</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">23509976</pub-id></mixed-citation></ref><ref id="ref228"><label>[228]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jha</surname>
<given-names>NN</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Anoop</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Ayyagari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Namboothiri</surname>
<given-names>IN</given-names>
</string-name>, <string-name>
<surname>Maji</surname>
<given-names>SK</given-names>
</string-name> (<year>2016</year>) <article-title>Effect of curcumin analogs on alpha-synuclein aggregation and cytotoxicity</article-title>. <source>Sci Rep</source>
<volume>6</volume>, <fpage>28511</fpage>.<pub-id pub-id-type="pmid">27338805</pub-id></mixed-citation></ref><ref id="ref229"><label>[229]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dimant</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ebrahimi-Fakhari</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name> (<year>2012</year>) <article-title>Molecular chaperones and co-chaperones in Parkinson disease</article-title>. <source>Neuroscientist</source>
<volume>18</volume>, <fpage>589</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="pmid">22829394</pub-id></mixed-citation></ref><ref id="ref230"><label>[230]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Lo Bianco</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shorter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>xE</surname>
</string-name>, <string-name>
<surname>gulier</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lashuel</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aebischer</surname>
<given-names>P</given-names>
</string-name> (<year>2008</year>) <article-title>Hsp104 antagonizes <italic>&#x003b1;</italic>-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease</article-title>. <source>J Clin Invest</source>
<volume>118</volume>, <fpage>3087</fpage>&#x02013;<lpage>3097</lpage>.<pub-id pub-id-type="pmid">18704197</pub-id></mixed-citation></ref><ref id="ref231"><label>[231]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Putcha</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Danzer</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Kranich</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Silinski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mabbett</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hicks</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Veal</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Steed</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>PJ</given-names>
</string-name> (<year>2010</year>) <article-title>Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity</article-title>. <source>J Pharmacol Exp Ther</source>
<volume>332</volume>, <fpage>849</fpage>&#x02013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">19934398</pub-id></mixed-citation></ref><ref id="ref232"><label>[232]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Fonseca-Ornelas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Eisbach</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Paulat</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Giller</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez</surname>
<given-names>CO</given-names>
</string-name>, <string-name>
<surname>Outeiro</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zweckstetter</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>) <article-title>Small molecule-mediated stabilization of vesicle-associated helical <italic>&#x003b1;</italic>-synuclein inhibits pathogenic misfolding and aggregation</article-title>. <source>Nat Commun</source>
<volume>5</volume>, <fpage>5857</fpage>.<pub-id pub-id-type="pmid">25524885</pub-id></mixed-citation></ref><ref id="ref233"><label>[233]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Collier</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Srivastava</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Justman</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grammatopoulous</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hutter-Paier</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Prokesch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Havas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rochet</surname>
<given-names>J-C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Jock</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>de Oliveira</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stirtz</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Sortwell</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Feany</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Lansbury</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lapidus</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Paumier</surname>
<given-names>KL</given-names>
</string-name> (<year>2017</year>) <article-title>Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form</article-title>. <source>Neurobiol Dis</source>
<volume>106</volume>, <fpage>191</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">28711409</pub-id></mixed-citation></ref><ref id="ref234"><label>[234]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Fanning</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haque</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Imberdis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Baru</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Barrasa</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Nuber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Termine</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ramalingam</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>GPH</given-names>
</string-name>, <string-name>
<surname>Noble</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sandoe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Landgraf</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Freyzon</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Soldner</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Terry-Kantor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>T-E</given-names>
</string-name>, <string-name>
<surname>Hofbauer</surname>
<given-names>HF</given-names>
</string-name>, <string-name>
<surname>Becuwe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pincus</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Clish</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Walther</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Farese</surname>
<given-names>RV</given-names>
</string-name>, <string-name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Welte</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kohlwein</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name> (<year>2018</year>) <article-title>Lipidomic analysis of <italic>&#x003b1;</italic>-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment</article-title>. <source>Mol Cell</source>
<volume>73</volume>, <fpage>1001</fpage>&#x02013;<lpage>1014</lpage>.<pub-id pub-id-type="pmid">30527540</pub-id></mixed-citation></ref><ref id="ref235"><label>[235]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Imberdis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Negri</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ramalingam</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Terry-Kantor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>GPH</given-names>
</string-name>, <string-name>
<surname>Fanning</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stirtz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>T-E</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Young-Pearse</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Selkoe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dettmer</surname>
<given-names>U</given-names>
</string-name> (<year>2019</year>) <article-title>Cell models of lipid-rich <italic>&#x003b1;</italic>-synuclein aggregation validate known modifiers of <italic>&#x003b1;</italic>-synuclein biology and identify stearoyl-CoA desaturase</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>116</volume>, <fpage>20760</fpage>&#x02013;<lpage>20769</lpage>.<pub-id pub-id-type="pmid">31548371</pub-id></mixed-citation></ref><ref id="ref236"><label>[236]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Vincent</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Tardiff</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Piotrowski</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Aron</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Bacherman</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Pires</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Subramaniam</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Doshi</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Sadlish</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Raja</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Sol&#x000ed;s</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Khurana</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Le Bourdonnec</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Scannevin</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Rhodes</surname>
<given-names>KJ</given-names>
</string-name> (<year>2018</year>) <article-title>Inhibiting stearoyl-CoA desaturase ameliorates <italic>&#x003b1;</italic>-synuclein cytotoxicity</article-title>. <source>Cell Rep</source>
<volume>25</volume>, <fpage>2742</fpage>&#x02013;<lpage>2754</lpage>.<pub-id pub-id-type="pmid">30517862</pub-id></mixed-citation></ref><ref id="ref237"><label>[237]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Shahmoradian</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Genoud</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hench</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Moors</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Navarro</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Casta&#x000f1;o-D&#x000ed;ez</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schweighauser</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Graff-Meyer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goldie</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>S&#x000fc;tterlin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Huisman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ingrassia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gier</surname>
<given-names>Y de</given-names>
</string-name>, <string-name>
<surname>Rozemuller</surname>
<given-names>AJM</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Paepe</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Erny</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Staempfli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hoernschemeyer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gro&#x000df;er&#x000fc;schkamp</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Niedieker</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>El-Mashtoly</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Quadri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Van IJcken</surname>
<given-names>WFJ</given-names>
</string-name>, <string-name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gerwert</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bohrmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Britschgi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stahlberg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Van de Berg</surname>
<given-names>WDJ</given-names>
</string-name>, <string-name>
<surname>Lauer</surname>
<given-names>ME</given-names>
</string-name> (<year>2019</year>) <article-title>Lewy pathology in Parkinson&#x02019;s disease consists of crowded organelles and lipid membranes</article-title>. <source>Nat Neurosci</source>
<volume>22</volume>, <fpage>1099</fpage>&#x02013;<lpage>1109</lpage>.<pub-id pub-id-type="pmid">31235907</pub-id></mixed-citation></ref></ref-list></back></article>